form10q.htm

0001140361-12-024988.txt : 20120514 0001140361-12-024988.hdr.sgml : 20120514 20120514160307 ACCESSION NUMBER: 0001140361-12-024988 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120514 DATE AS OF CHANGE: 20120514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52491 FILM NUMBER: 12838690 BUSINESS ADDRESS: STREET 1: 811 E LIVINGSTON COURT STREET 2: SUITE B CITY: MARIETTA STATE: GA ZIP: 30076 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 811 E LIVINGSTON COURT STREET 2: SUITE B CITY: MARIETTA STATE: GA ZIP: 30076 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 form10q.htm MIMEDX GROUP INC 10-Q 3-31-2012 form10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2012

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________to______________________

Commission file number 0-52491

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)

Florida		26-2792552
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification Number)

60 Chastain Center Blvd., Suite 60 Kennesaw, GA		30144
(Address of principal executive offices)		(Zip Code)

(678) 384-6720

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filero	Accelerated filer o	Non-accelerated filer o	Smaller reporting company x
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes oNo x

As of April 30, 2012, there were 80,746,672 shares outstanding of the registrant’s common stock.

MIMEDX GROUP, INC.

Table of Contents

Part I FINANCIAL INFORMATION

Item 1	Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets (unaudited) March 31, 2012 and December 31, 2011		3
Condensed Consolidated Statements of Operations (unaudited) Three months ended March 31, 2012 and 2011		4
Condensed Consolidated Statement of Stockholders’ Equity (unaudited) Three months ended March 31, 2012		5
Condensed Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, 2012 and 2011		6
Notes to the Unaudited Condensed Consolidated Financial Statements Three months ended March 31, 2012 and 2011		7

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3	Quantitative and Qualitative Disclosures About Market Risk	26

Item 4	Controls and Procedures	26

Part II OTHER INFORMATION

Item 1	Legal Proceedings	27

Item 1A	Risk Factors	27

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 3	Defaults under Senior Securities	28

Item 4	Mine Safety Disclosures	28

Item 5	Other Information	28

Item 6	Exhibits	28

Signatures		29

Table of Contents

Forward-Looking Statements

This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of the Company’s products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future. Our actual results may differ materially from those projected, stated or implied in these forward-looking statements as a result of many factors, including our critical accounting policies and risks and uncertainties related to, but not limited to, overall industry environment, delay in the introduction of products, regulatory delays, negative clinical results, and our financial condition. These and other risks and uncertainties are described in more detail in our most recent Annual Report on Form 10-K, as well as other reports that we file with the SEC.

Forward-looking statements speak only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that we make in this and other reports that we file with the SEC that discuss factors germane to our business.

Table of Contents

Part I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

	March 31,
	2012			December 31,
	(unaudited)			2011
Current assets:
Cash and cash equivalents	$	3,021,266		$	4,112,326
Accounts receivable, net		2,853,552			1,891,919
Inventory, net		795,516			712,602
Prepaid expenses and other current assets		377,495			164,664

Total current assets		7,047,829			6,881,511

Property and equipment, net of accumulated depreciation of $1,924,861 and $1,814,473, respectively		805,817			869,411
Goodwill		4,040,443			4,040,443

Intangible assets, net of accumulated amortization of $3,802,492 and $3,468,515, respectively		14,756,508			15,090,485
Deposits and other long term assets		209,595			214,342
Total assets	$	26,860,192		$	27,096,192

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued expenses	$	1,825,765		$	2,300,638
Deferred rent current		6,620			6,620
Convertible line of credit with related party, net of unamortized discount of $549,779 and $46,746, respectively, plus accrued interest of $58,931 and $42,726, respectively		809,152			1,295,980
Convertible debt related to acquisition, net of unamortized discount of $90,156 and $170,509, respectively, plus accrued interest of $59,836 and $49,315, respectively		969,680			1,128,806
Current portion of earn-out liability payable In MiMedx common stock		3,185,223			3,185,223
Total current liabilities		6,796,440			7,917,267

Earn-out liability payable in MiMedx common stock, net of current portion		4,225,280			4,225,280
Convertible Senior Secured Promissory Notes, net of unamortized discount of $2,049,190 and $2,263,145, respectively, plus accrued interest of $68,518 and $7,732, respectively		3,019,328			2,744,587
Other liabilities		322,464			312,493
Total liabilities		14,363,512			15,199,627

Commitments and contingencies (Note 12)		-			-

Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding		-			-
Common stock; $.001 par value; 100,000,000 shares authorized; 78,139,596 issued and 78,089,596 outstanding for 2012 and 74,306,895 issued and 74,256,895 outstanding for 2011		78,139			74,307
Additional paid-in capital		75,558,539			73,868,604
Treasury stock (50,000 shares at cost)		(25,000	)		(25,000	)
Accumulated deficit		(63,114,998	)		(62,021,346	)
Total stockholders' equity		12,496,680			11,896,565
Total liabilities and stockholders' equity	$	26,860,192		$	27,096,192

See notes to condensed consolidated financial statements

Table of Contents

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended March 31,
	2012			2011

REVENUES:
Net sales	$	3,705,808		$	1,043,487

OPERATING COSTS AND EXPENSES:
Cost of products sold		958,855			710,117
Research and development expenses		407,072			962,224
Selling, general and administrative expenses		2,971,246			2,627,492

LOSS FROM OPERATIONS		(631,365	)		(3,256,346	)

OTHER INCOME (EXPENSE), net
Financing expense associated with the debt discount recognized in connection with the senior secured promissory notes		(218,701	)		-
Interest expense, net		(243,586	)		(91,216	)


LOSS BEFORE INCOME TAXES		(1,093,652	)		(3,347,562	)
Income taxes		-			-

NET LOSS	$	(1,093,652	)	$	(3,347,562	)

Net loss per common share
Basic and diluted	$	(0.01	)	$	(0.05	)

Shares used in computing net loss per common share
Basic and diluted		74,872,122			70,333,476

See notes to condensed consolidated financial statements

Table of Contents

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(unaudited)

	Convertible
	Preferred Stock								Additional
	Series A				Common Stock				Paid-in			Treasury			Accumulated
	Shares		Amount		Shares		Amount		Capital			Stock			Deficit			Total

Balances, December 31, 2011		-		-		74,306,895		74,307		73,868,604			(25,000	)		(62,021,346	)		11,896,565

Employee share-based compensation expense		-		-		-		-		400,049			-			-			400,049

Other share-based compensation expense		-		-		-		-		100,936			-			-			100,936

Exercise of stock options		-		-		172,000		172		170,828			-			-			171,000

Exercise of warrants		-		-		3,357,369		3,357		319,316			-			-			322,673

Cashless exercise of warrants		-		-		136,246		136		(136	)		-			-			-

Common stock issued for accrued Director fees		-		-		167,086		167		184,486			-			-			184,653

Discount on benefical conversion feature recognized on line of credit with related party		-		-		-		-		514,456			-			-			514,456

Net loss for the peiod		-		-		-		-		-			-			(1,093,652	)		(1,093,652	)

Balances, March 31, 2012		-	$	-		78,139,596	$	78,139	$	75,558,539		$	(25,000	)	$	(63,114,998	)	$	12,496,680

See notes to condensed consolidated financial statements

Table of Contents

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended March 31,
	2012			2011
Cash flows from operating activities:
Net loss	$	(1,093,652	)	$	(3,347,562	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation		110,388			116,180
Amortization of intangible assets		333,977			333,977
Amortization of debt discount and deferred financing costs		310,478			72,918
Employee share-based compensation expense		400,049			380,373
Other share-based compensation expense		100,936			107,560
Increase (decrease) in cash resulting from changes in (net of effects of acquisition):
Accounts receivable		(961,633	)		150,365
Inventory		(82,914	)		(111,983	)
Prepaid expenses and other current assets		(212,831	)		(155,025	)
Accounts payable and accrued expenses		(352,720	)		641,882
Accrued interest		150,012			15,383
Other liabilities		9,971			6,088
Net cash flows from operating activities		(1,287,939	)		(1,789,844	)

Cash flows from investing activities:
Purchases of equipment		(46,794	)		(111,927	)
Cash paid for acquisition, net of cash aquired of $33,583		-			(316,417	)
Net cash flows from investing activities		(46,794	)		(428,344	)

Cash flows from financing activities:
Proceeds from exercise of warrants		322,673			-
Proceeds from exercise of stock options		171,000			-
Repayment of Convertible Debt related to acquisition		(250,000	)		-
Proceeds from Line of Credit with related party		-			800,000
Repayment of Line of Credit		-			(99,000	)
Repayment of Note Payable		-			(15,376	)
Proceeds from sale of common stock and warrants and common stock with registration rights, net		-			1,212,175
Net cash flows from financing activities		243,673			1,897,799
Net change in cash		(1,091,060	)		(320,389	)
Cash, beginning of period		4,112,326			1,340,922
Cash, end of period	$	3,021,266		$	1,020,533

Supplemental disclosure of cash flow information:
Cash paid for interest	$	2,435		$	3,239
Cash paid for income taxes	$	-		$	-

Supplemental disclosure of non-cash financing activity:

During the three months ended March 31, 2012:

the Company issued 167,086 shares of stock valued at $184,653 for accrued Director's fees

the Company issued 136,246 shares of stock for cashless exercise of warrants

the Company recognized $4,747 in deferred financing costs related to placement agent warrants issued in conjunction with the convertible Senior Promissory Notes; the deferred financing costs are recorded in other long term assets

the Company recognized a beneficial conversion feature valued at $514,456 related to the vested contingent warrants on the line of credit with related party

During the three months ended March 31, 2011:

the Company converted its outstanding convertible debt and accrued interest to equity by issuing 406,664 shares of common stock

the Company issued 5,250,000 shares of stock valued at $7,087,500 in conjunction with its acquisition of Surgical Biologics, LLC

the Company recognized a beneficial conversion feature valued at $437,500 related to the convertible debt of $1,250,000 issued with regard to its acquisition of Surgical Biologics See notes to condensed consolidated financial statements

See notes to condensed consolidated financial statements

Table of Contents

MIMEDX GROUP, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

1.	Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included. Operating results for the three months ended March 31, 2012 and 2011, are not necessarily indicative of the results that may be expected for the fiscal year. The balance sheet at December 31, 2011, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2011 included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2012.

The Company operates in one business segment, Biomaterials, which includes the design, manufacture, and marketing of products and amnion tissue processing for a variety of surgical applications using the Company’s proprietary biomaterials—CollaFix™, HydroFix®, EpiFix® and AmnioFix®.

2.	Significant accounting policies

Please see Note 2 to our Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2011, for a description of all significant accounting policies.

Reclassifications

Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer’s current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect the customer’s ability to pay. The Company has $24,000 and $20,000 in the allowance for doubtful accounts as of March 31, 2012, and December 31, 2011, respectively. Actual customer collections could differ from estimates. The approximate provision during the three months ended March 31, 2012 was $4,000, and there were no charge-offs during the same period.

Table of Contents

Inventories

Inventories are valued at the lower of actual cost or market, using the first-in, first-out (FIFO) method. Work in process is calculated by estimating the number of units that will be successfully converted to finished goods, based upon a build-up in the stage of completion using estimated labor inputs for each stage and historical yields reduced by estimated usage for quality control testing. Idle facility expense, excessive spoilage, extra freight, and handling costs are expensed, as necessary, in cost of sales and are not capitalized into inventories. Allocation of fixed production overheads is based on the normal capacity of production facilities.

Goodwill and intangible assets

Goodwill is tested at least annually for impairment, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets with finite useful lives are amortized into Selling, General and Administrative Expenses in the condensed consolidated statements of operations using the straight-line method over various periods depending upon the specific asset.

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

According to ASC-470 Debt Instruments with Detachable Warrants, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.

Revenue Recognition

The Company sells its products primarily through a combination of independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The Company recorded approximately $39,000 and $3,000 for net sales returns provisions for the three months ended March 31, 2012 and 2011, respectively.

Fair value of financial instruments

The carrying value of accounts payable and accrued expenses approximate their fair value due to the short-term nature of these liabilities. The fair value of our short term and long term convertible debt approximates $4,798,000 which represents the face value less the unamortized discount of any beneficial conversion feature plus accrued but unpaid interest at March 31, 2012. The fair value of warrants issued in conjunction with placement fees approximates $13,000 which represents the face value less the unamortized discount of any beneficial conversion feature at March 31, 2012.

Net loss per share

Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method. For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.

Table of Contents

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended March 31,
	2012			2011
Net loss	$	(1,093,652	)	$	(3,347,562	)
Denominator for basic earnings per share - weighted average shares		74,872,122			70,333,476
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)		—			—

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities		74,872,122			70,333,476

Loss per common share - basic and diluted	$	(0.01	)	$	(0.05	)

(a)

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive are as follows:

	Three months ended March 31,
	2012		2011
Outstanding Stock Options		12,517,000		9,778,000
Outstanding Warrants		7,891,567		6,813,644
Convertible Debt, promissory notes		5,131,018		—
Convertible Line of Credit with Related Party		1,358,931		800,000
Convertible Debt, Acquisition		1,059,836		1,261,644
		27,958,352		18,653,288

The table above excludes all securities with contingencies including the earnout liability and contingent warrants.

Recent Accounting Pronouncements

Changes to accounting principles generally accepted in the United States of America (U.S. GAAP) are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASU’s) to the FASB’s Accounting Standards Codification.

The Company considers the applicability and impact of all ASU’s. ASU’s not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

Goodwill

The Financial Accounting Standards Board (“FASB”) issued updated authoritative guidance in September 2011 to amend previous guidance on the annual and interim testing of goodwill for impairment; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. The guidance provides entities with the option of first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not less than the carrying amount, the two-step impairment test would still be required. Annual impairment tests are performed by the company in the second quarter of each year. The adoption of this updated authoritative guidance did not have a significant impact on the Company’s condensed consolidated financial statements.

Table of Contents

Fair Value Measurements

The FASB issued updated authoritative guidance in May 2011 to amend fair value measurements and related disclosures; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. This guidance relates to a major convergence project of the FASB and the International Accounting Standards Board to improve International Financial Reporting Standards (“IFRS”) and GAAP. This guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between IFRS and GAAP. The guidance also changes some fair value measurement principles and enhances disclosure requirements related to activities in Level 3 of the fair value hierarchy. The adoption of this updated authoritative guidance had no impact on the Company’s condensed consolidated financial statements.

Recently issued accounting pronouncements not yet adopted:

In December 2011, the FASB issued new accounting guidance that will require entities to disclose information about instruments (including derivatives) and transactions eligible for offset in the statement of financial position or subject to an agreement similar to a master netting arrangement. These new provisions are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, and should be applied retrospectively for all comparative periods presented. We do not expect this accounting standard to have an impact on our condensed consolidated financial statements.

3.	Liquidity and management’s plans

As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents. The Company reported total current assets of approximately $7,048,000 and current liabilities payable in cash of approximately $3,611,000 after adjusting for the short term earn-out liability payable in MiMedx common stock in the second quarter of 2012. The Company believes that its anticipated cash from operations and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities and pay its debt when due for the next twelve months.

4.	Acquisition of Surgical Biologics, LLC

On December 21, 2010, we entered into an Agreement and Plan of Merger (“the Merger Agreement”) with Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC, the owners of Surgical Biologics, LLC (“Surgical Biologics”), a privately held company headquartered in Kennesaw, Georgia. This transaction closed on January 5, 2011 and as a result we acquired all of the outstanding shares of Surgical Biologics in exchange for $500,000 cash, a total of $1,250,000 in 4% Convertible Secured Promissory Notes, and $7,087,500 in stock, represented by 5,250,000 shares of our common stock (525,000 of which were held in escrow for the purpose of securing the indemnification obligations outlined in the Merger Agreement). Contingent consideration may be payable in a formula determined by sales and certain expenses for the years 2011 and 2012. The contingent consideration was initially valued at $7,404,700 and is shown in the schedule below as fair value of earn-out. We completed the acquisition of Surgical Biologics in an effort to extend our biomaterials product lines. As of December 31, 2011, the Company evaluated the contingent liability based on operating results for the year, and adjusted the earn-out liability to $7,410,503. No additional adjustment was required as of March 31, 2012.

In total, the 4% Convertible Promissory Notes are convertible into up to 1,250,000 shares of the Company’s common stock at $1.00 per share (a) at any time upon the election of the holder of the Convertible Notes; or (b) at the election of the Company, at any such time as the closing price per share of the Company’s common stock (as reported by the OTCBB or on any national securities exchange on which the Company’s shares may be listed, as the case may be) closes at no less than $1.75 per share for not less than 20 consecutive trading days in any period prior to the maturity date. If converted, the Common Stock will be available to be sold following satisfaction of the applicable conditions as set forth in Rule 144. The 4% Convertible Promissory Notes mature in eighteen (18) months and earn interest at 4% per annum on the outstanding principal amount payable in cash on the maturity date or convertible into shares of common stock of the Company as provided for above. The 4% Convertible Promissory Notes are secured by a security interest in the Intellectual Property, including the Patents and know-how and trade secrets related thereto, owned by, or exclusively licensed to, Surgical Biologics, LLC.

Table of Contents

The Company has evaluated the 4% Convertible Promissory Notes for accounting purposes under GAAP and has determined that the conversion feature meets the conventional-convertible exemption and, accordingly, bifurcation and fair-value measurement of the conversion feature is not required. We are required to re-evaluate this conclusion upon each financial statement closing date while the 4% Convertible Promissory Notes are outstanding. Notwithstanding, the 4% Convertible Promissory Notes were issued with a beneficial conversion feature having an intrinsic value of $437,500. The intrinsic value of the beneficial conversion feature was determined by comparing the contracted conversion price to the fair value of the common on the date the respective 4% Convertible Promissory Notes were issued. A beneficial conversion feature only exists when the embedded conversion feature is “in-the-money” at the commitment date.

As a result of the beneficial conversion feature, the 4% Convertible Promissory Notes were recorded net of a discount of $437,500 related to the beneficial conversion feature, the offset of which is recorded in paid-in capital, and the discount will be amortized through periodic charges to interest expense over the tem of the 4% Convertible Notes using the effective interest method.

The contingent consideration which was initially valued at $7,404,700 was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the Surgical Biologics acquisition, and direct costs associated with the combination. The actual purchase price was allocated as follows:

Value of 5,250,000 shares issued at $1.35 per share	$	7,087,500
Cash paid at closing		350,000
Cash retained for working capital		150,000
Assumed Debt		182,777
Convertible Secured Promissory Note		1,250,000
Fair value of earn-out		7,404,700
Total fair value of purchase price	$	16,424,977

Assets purchased:
Tangible assets:
Debt-free working capital	$	671,880
Other assets, net		385
Property, plant and equipment		72,866
		745,131
Intangible assets:
Customer relationships		3,520,000
Supplier relationships		241,000
Patents and know-how		5,530,000
Trade names and trademarks		1,008,000
In-process research and development – liquid		2,160,000
In-process research and development – other		25,000
Licenses and permits		13,000
		12,497,000

Goodwill		3,182,846
Total Assets Purchased	$	16,424,977

Table of Contents

Working capital and other assets were composed of the following:

Working capital:
Cash	$	33,583
Prepaid Expenses		2,738
Accounts Receivable		181,087
License Receivable		340,000
Inventory		347,106
Accounts payable and accrued expenses		(196,101	)
Deferred rent and customer deposits		(36,533	)
Debt-free working capital		671,880

Current portion of debt		(62,590	)
Long-term debt		(21,187	)
Line of credit		(99,000	)
Net working capital	$	489,103

Deposits	$	16,582
Deferred rent (non-current)		(16,197	)
	$	385

The combination was accounted for as a purchase business combination as defined by FASB Topic 805 – Business Combinations. The allocation of the purchase price to the assets acquired and liabilities assumed was based on an independent valuation report obtained by us.

The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:

	Estimated useful
Intangible asset:	life (in years)
Customer relationships	14
Supplier relationships	14
Patents and know-how	14
Trade names and trademarks	indefinite
In-process research and development – liquid	indefinite
In-process research and development – other	indefinite
Licenses and permits	3

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction. Goodwill is tested for impairment as defined by FASB Topic 350 – Intangibles – Goodwill and Other.

5.	Inventories

Inventories consisted of the following items as of March 31, 2012, and December 31, 2011:

	March 31, 2012			December 31, 2011
Raw materials	$	82,703		$	95,288
Work in process		443,072			308,763
Finished goods		323,165			361,007
	$	848,940		$	765,058
Reserve for obsolescence		(53,424	)		(52,456	)
Inventory, net	$	795,516		$	712,602

Table of Contents

6.	Property and equipment

Property and equipment consist of the following as of March 31, 2012, and December 31, 2011:

	March 31, 2012			December 31, 2011
Leasehold improvements	$	925,086		$	925,086
Lab and clean room equipment (a)		1,470,852			1,463,144
Furniture and office equipment (a)		334,740			295,654
		2,730,678			2,683,884
Less accumulated depreciation		(1,924,861	)		(1,814,473	)
	$	805,817		$	869,411

(a)

The table above includes reclassifications of production equipment previously included in the furniture and office equipment category.

7.	Intangible assets and royalty agreement

Intangible assets activity is summarized as follows:

		March 31, 2012							December 31, 2011
	Weighted
	Average	Gross					Net		Gross					Net
	Amortization	Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
	Lives	Value		Amortization			Value		Value		Amortization			Value
Intangible assets subject to amortization:
License-Shriners Hsp for Children & USF Research (a)	10 years	$	996,000	$	(512,933	)	$	483,067	$	996,000	$	(488,033	)	$	507,967
License - SaluMedica LLC Spine Repair (b)	10 years		2,399,000		(1,387,577	)		1,011,423		2,399,000		(1,313,573	)		1,085,427
License - Polyvinyl Alcohol Cryogel (c)	10 years		2,667,000		(1,067,011	)		1,599,989		2,667,000		(998,932	)		1,668,068
Customer Relationships (d)	14 years		3,520,000		(314,286	)		3,205,714		3,520,000		(251,429	)		3,268,571
Supplier Relationships (d)	14 years		241,000		(21,518	)		219,482		241,000		(17,215	)		223,785
Patents & Know-How (d)	14 years		5,530,000		(493,750	)		5,036,250		5,530,000		(395,000	)		5,135,000
Licenses/Permits (d)	3 years		13,000		(5,417	)		7,583		13,000		(4,333	)		8,667
			15,366,000		(3,802,492	)		11,563,508		15,366,000		(3,468,515	)		11,897,485
Intangible assets not subject to amortization:
Trade Names/Trademarks (d)	indefinite		1,008,000		—			1,008,000		1,008,000		—			1,008,000
In-process Research & Development-Liquid (d)	indefinite		2,160,000		—			2,160,000		2,160,000		—			2,160,000
In-process Research & Development-Other (d)	indefinite		25,000		—			25,000		25,000		—			25,000
		$	18,559,000	$	(3,802,492	)	$	14,756,508	$	18,559,000	$	(3,468,515	)	$	15,090,485

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.

(b)

License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp.

(c)

On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. At March 31, 2012 and 2011, there are no additional amounts accrued for this obligation due to its contingent nature.

(d)

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.

Table of Contents

Estimated future amortization expense related to the March 31, 2012 net carrying amount of $11,563,508 for intangible assets subject to amortization is as follows:

	Estimated
	Amortization
Year ending December 31,	Expense
2012 (a)	$	1,001,932
2013		1,335,909
2014		1,331,575
2015		1,225,337
2016		1,024,843
Thereafter		5,643,912
	$	11,563,508

(a)

Estimated amortization expense for the year ending December 31, 2012 includes only amortization to be recorded after March 31, 2012.

Debt

The following disclosures reflect a summary of our outstanding convertible securities, as well as activity related to financing transactions. The table below summarizes the Company’s financing, and further details regarding each transaction are provided following the table:

	Convertible Line of Credit with Related Party			Convertible Senior Secured Promissory Note			Total
Face Value of Note	$	1,300,000		$	5,000,000		$	6,300,000
Due date	(a)	12/31/2012		(b)	12/31/2013
Annual Interest rate		5	%		5	%

Contingent warrants issued at inception (c):
First Contingent Warrants	(d)	325,000		(e)	1,250,000			1,575,000
Second Contingent Warrants	(f)	325,000		(f)	1,250,000			1,575,000
Total Contingent Warrants		650,000			2,500,000			3,150,000

Vested Warrants as of March 31, 2012:
First Contingent Warrants	(d)	(325,000	)	(e)	(1,250,000	)		(1,575,000	)
Second Contingent Warrants		—			—			—

Contingent Warrants Outstanding as of March 31, 2012 (g)
First Contingent Warrants		—			—			—
Second Contingent Warrants		325,000			1,250,000			1,575,000
Total Contingent Warrants Outstanding as of March 31, 2012		325,000			1,250,000			1,575,000
Weighted average exercise price of warrants	$	0.01		$	0.01

(a)

The initial termination date of the Credit Agreement is December 31, 2012 and the Company may elect to extend the termination date until December 31, 2013 upon payment of an extension fee of 5% of the outstanding principle balance or $65,000.

(b)

Unless the Company has repaid the applicable lender’s Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012.

(c)

The Contingent Warrants have a term of five years from the date of issuance; however each is subject to automatic terminations as defined in the First Contingent Warrant and Second Contingent Warrant terms. The shares of Common Stock issuable upon exercise of the Contingent Warrants do not carry registration rights and may be exercised on a “cashless” basis. In the event of a change in control transaction on or prior to the First Measurement Date, then the Contingent Warrants shall be exercisable immediately prior to the closing of such change in control transaction. In the event (i) of a change in control transaction after the First Measurement Date and on or prior to the Second Measurement Date and (ii) the per share value of the consideration received by the holders of Common Stock in such change in control transaction is at least $1.75, the Second Contingent Warrant shall be null and void. If the value of the per share consideration received by the holders of Common Stock in such transaction is less than $1.75, the Second Contingent Warrant shall be exercisable immediately prior to the closing of such change in control transaction.

(d)

The First Contingent Warrant, (the “First Contingent Warrant”) is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company’s Gross Revenue as reported in the Company’s Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the “First Measurement Date”) the closing trading price of the Stock is at least $1.50 per share for ten or more consecutive trading days. During the three months ended March 31, 2012, the First Contingent Warrants vested due to the Company’s Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.

(e)

(f)

The Second Contingent Warrant, (the “Second Contingent Warrant”) is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company’s Gross Revenue as reported in the Company’s Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the “Second Measurement Date”) the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days.

(g)

The contingent warrants have not been included in our earnings per share calculation per the guidance in ASC 260-10-45-13 Earnings per share: Treatment of Contingently Issuable Shares in Weighted-Average Shares Outstanding which states that shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) shall be considered outstanding common shares and included in the computation of basic EPS as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).

Table of Contents

Convertible Line of Credit with related party

On March 31, 2011, the Company and its Chairman of the Board and CEO (“the Lender”) entered into a Subscription Agreement for a 5% Convertible Senior Secured Promissory Note (“Subscription Agreement”) and, in connection therewith, agreed to issue a 5% Convertible Senior Secured Promissory Note (“Note”) in the amount borrowed by the Company, and a First Contingent Warrant (“First Contingent Warrant”) and a Second Contingent Warrant (“Second Contingent Warrant”) to Purchase Common Stock.

The Lender agreed to issue a Revolving Secured Line of Credit Agreement (“Credit Agreement”) to the Company of $1,300,000, after reductions for funds raised through other financing activities, to fund its working capital needs. The first borrowing in the amount of $800,000 was on March 31, 2011, resulting in the issuance of 400,000 contingent warrants at an exercise price of $0.01 per warrant. Additional borrowings in the amount of $500,000 were drawn during the three months ended June 30, 2011, resulting in the issuance of 250,000 contingent warrants at an exercise price of $0.01 per warrant.

The Company may repay and reborrow, provided there is no event of default, as needed. Collateral for the Credit Agreement includes (i) all of the Company’s intellectual property with the exception of intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, as more particularly set forth in the Security and Intercreditor Agreement.

At the option of the Lender, the Note is convertible into the number of shares of common stock of the Company equal to the quotient of the outstanding principal amount and accrued interest of the Note as of the date of such election divided by $1.00 per share.

On February 28, 2012, 325,000 First Contingent Warrants vested to the Lender at an exercise price of $0.01 per share. The vesting of the shares resulted in an additional beneficial conversion feature which requires recognition. According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The amount of the warrants and beneficial conversion feature totaled approximately $550,000 net of previously recognized interest expense which has been recorded as a debt discount that will be charged to interest expense over the life of the convertible note.

The issuance of the aforementioned securities was not registered in reliance on Section 4(2) of the Securities Act of 1933, as amended.

Senior Secured Promissory Notes

From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000 and issued a First Contingent Warrant (“First Contingent Warrant”) and a Second Contingent Warrant (“Second Contingent Warrant”) to Purchase Common Stock.

The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO, who had committed to lend the Company up to $1,500,000, to the extent other lenders did not subscribe to the Company’s debt offering. The terms of those advances were subject to amendment as authorized by the Company’s Board of Directors to be consistent with the final terms of the Company’s debt offering.

Table of Contents

In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) at $1.00 per share at any time upon the election of the holder of the note. The Notes mature on December 31, 2013, and bear interest at 5% per annum on the outstanding principal amount payable in cash on a quarterly basis, with all unpaid interest being due and payable on maturity. Unless the Company has repaid the applicable lender’s Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012. At the election of the holder, unpaid interest is convertible into shares of Common Stock at $1.00 per share. Common Stock issued upon conversion of the Notes is available to be sold following satisfaction of the applicable conditions set forth in Rule 144.

The Notes are secured by a first priority lien in all of the patents and other intellectual property owned by the Company and its subsidiaries, provided that until the Convertible Secured Promissory Notes in the principal sum of $1,250,000 issued January 5, 2011, in connection with the acquisition of Surgical Biologics, LLC, are paid in full, (i) the patents and other intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, are excluded from the collateral. The maturity of the Notes may be accelerated upon the occurrence of certain Events of Default as set forth in the Notes. The lien is at an equal rate for all note holders in payment and lien priority with the notes outstanding under the Company’s Line of Credit with Related Party Agreement dated March 31, 2011, (the “Prior Notes”), all of which are held by the Company’s Chairman & CEO. In order to effectuate that, to conform the description of the collateral and Events of Default in the Prior Notes to the description of the collateral and Events of Default in the Notes, and to clarify certain adjustments that would be applicable in the event of a stock split, stock dividend or similar event, the Amended and Restated Security and Intercreditor Agreement executed by the Company’s Chairman & CEO in connection with the Notes on December 27, 2011, superseded the Security and Intercreditor Agreement that was originally executed in connection with the Prior Notes and, on January 3, 2012, the parties also executed an amendment to certain of the other documents executed in connection with the Prior Notes.

Under the terms of the sale of the Convertible Senior Secured Promissory notes, each lender received a warrant (the “Conversion Warrant”) to purchase that number of shares of Common Stock equal to the number of shares of Common Stock that would be issuable upon conversion of the principal of such lender’s Note, at an exercise price of $1.00 per share, provided that such Conversion Warrant shall only be exercisable for the number of shares of Common Stock that would have been issued upon conversion of any portion of the principal of the lender’s Note that is, in fact, prepaid prior to maturity of the Notes. The maximum number of shares of Common Stock issuable upon exercise of the Conversion Warrants is 5,000,000 shares. The Conversion Warrant expires on December 31, 2013. The shares of Common Stock issuable upon exercise of the Conversion Warrant do not carry registration rights. The Conversion Warrant must be exercised for cash.

According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The amount of the warrants (i.e. the exercisable First Contingent Warrants) and beneficial conversion feature totaled $2,278,052 which has been recorded as a debt discount that will be charged to interest expense using the effective interest rate over the life of the convertible note.

In conjunction with the sale of the Convertible Senior Secured Promissory notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. The warrants expire in five years. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 are recorded as deferred financing costs and are being amortized over the term of the Senior Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.

Table of Contents

9.	Common Stock Placements

October 2010 Private Placement

In October 2010, the Company commenced a private placement to sell common stock and warrants. From October 30, 2010, through December 31, 2010, the Company sold 2,405,000 shares of common stock at a price of $1.00 per share and received proceeds of $2,337,020 net of $67,980 in offering costs. For the nine months ended September 30, 2011, the Company sold an additional 3,778,321 shares of Common Stock and issued an additional 1,889,161 warrants and received net cash proceeds of $3,730,587 net of $47,733 in offering costs. Under the terms of the offering, for each share purchased, the investor received one 5-year warrant to purchase the common stock of the Company at an exercise price of $1.50 per share. The terms of the warrant, (the “Callable Warrant”) are that for every two shares of common stock purchased, the holder is issued a 5-year warrant to purchase one share of the Company’s Common Stock at an exercise price of $1.50 per share. The Callable Warrant does not carry registration rights and is callable by the Company at any time after the issuance if the closing sale price of the Stock exceeds $1.75 for fifteen (15) or more consecutive trading days. Upon written notice, the Company may redeem the Callable Warrant at a price of $0.01 per share. Additionally, the Company issued a First Contingent Warrant (“First Contingent Warrant”) and a Second Contingent Warrant (“Second Contingent Warrant”) to Purchase Common Stock.

The First Contingent Warrant, (the “First Contingent Warrant”) vested during the period resulting in the issuance of 1,672,742 warrants at an exercise price of $0.01 per share.

The warrants met all the requirements for equity classification under GAAP and are recorded in stockholders’ equity.

The Company’s Chairman and CEO invested $1,006,664 in the October 2010 Private Placement including the investment of principal and accrued interest from the October 2010 Bridge note converted under the same terms as the Private Placement, receiving 503,332 warrants with an exercise price of $1.50, 251,666 First Contingent warrants at an exercise price of $0.01 and 251,666 Second Contingent warrants at an exercise price of $0.01 as per the aforementioned terms of the offering.

In connection with the October 2010 Private Placement, the Company entered into a registration rights agreement that provides “Piggy-Back” registration rights to each investor.

10.

Equity

Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2012 totaled 375,000 and the maximum number of shares of common stock which can be issued under the 2006 Plan is 12,500,000 at March 31, 2012.

Table of Contents

Activity with respect to the stock options is summarized as follows:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2012		10,333,583		$	1.17
Granted		2,593,000		$	1.25
Exercised		(172,000	)	$	0.99
Forfeited or cancelled/expired		(237,583	)	$	1.17
Outstanding at March 31, 2012		12,517,000		$	1.19		7.6	$	1,533,000

Vested or expected to vest at March 31, 2012		6,372,990		$	1.16		5.9	$	1,351,000

The intrinsic value of the options exercised during the three months ended March 31, 2012, was approximately $26,800.

Following is a summary of stock options outstanding and exercisable at March 31, 2012:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price		Number Exercisable		Weighted- Average Exercise Price
$	0.50		585,000		2.6	$	0.50		543,023	$	0.50
$	0.65 - $1.00		2,797,500		5.8	$	0.78		2,615,918	$	0.78
$	1.04 - $1.80		8,584,500		8.9	$	1.29		2,664,049	$	1.42
$	2.40		550,000		0.5	$	2.40		550,000	$	2.40
			12,517,000		7.6	$	1.19		6,372,990	$	1.16

A summary of the status of the Company’s unvested stock options follows:

Unvested Stock Options	Number of Shares			Weighted- Average Grant Date Fair Value
Unvested at January 1, 2012		4,333,086		$	0.72
Granted		2,593,000		$	0.67
Cancelled/expired		(237,583	)	$	0.65
Vested		(544,493	)	$	0.78
Unvested at March 31, 2012		6,144,010		$	0.70

Total unrecognized compensation expense related to granted stock options at March 31, 2012, was approximately $4,448,000 and will be charged to expense through July 2015.

The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

Table of Contents

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

	Three months ended March 31,
	2012			2011
Expected volatility		58.3	%		57.6 - 57.8	%
Expected life (in years)		6			6
Expected dividend yield		—			—
Risk-free interest rate		0.88	%		1.96% - 2.14	%

The weighted-average grant date fair value for options granted during the three months ended March 31, 2012 was approximately $0.67.

Warrants

The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors. The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants have been issued for terms of five years.

Following is a summary of warrants outstanding at March 31, 2012:

	Number of Warrants			Weighted- Average Exercise Price per Warrant		Number of Contingent Warrants			Weighted- Average Exercise Price per Contingent Warrant
Warrants outstanding at January 1, 2012		9,388,817		$	1.00		5,245,484		$	0.01
Issued in connection with private placement of common stock		1,672,743		$	0.01		(1,672,743	)	$	0.01
Issued in connection with line of credit with related party		325,000		$	0.01		(325,000	)	$	0.01
Warrants exercised		(3,494,993	)	$	0.09		—			—
Warrants outstanding at March 31, 2012		7,891,567		$	1.15		3,247,741		$	0.01

Warrants may be exercised in whole or in part by:

notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or

election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.

These warrants are not mandatorily redeemable, do not obligate the Company to repurchase its equity shares by transferring assets or issue a variable number of shares.

The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.

All of our warrants are classified as equity as of March 31, 2012 and December 31, 2011.

Table of Contents

11.	Income taxes

The Company has incurred net losses since its inception and, therefore, no current income tax liabilities have been incurred for the periods presented. Due to the Company’s losses, management has established a valuation allowance equal to the amount of net deferred tax assets since management cannot determine that realization of these benefits is more likely than not.

12.	Contractual Commitments

The Company has entered into operating lease agreements for facility space and equipment, and employment agreements with some key employees acquired with Surgical Biologics. In addition, the Company has minimum royalty payments due in conjunction with one of its licenses. The estimated annual lease, royalty, and employment agreement expense are as follows:

12-month period ended March 31,
2013	$	848,000
2014		231,000
Thereafter		93,000
	$	1,172,000

13.	Subsequent Events

On April 30, 2012, the Company issued 2,632,576 shares of common stock valued at approximately $3,185,000 for earn-out consideration related to the acquisition of Surgical Biologics. The consideration paid in the Company’s common stock was based on a formula determined by sales and certain expenses for the year ended December 31, 2011. For further discussion of the contingent consideration, see Note 4 – Acquisition of Surgical Biologics.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

MiMedx Group, Inc. ("MiMedx Group") is an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

"Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant.

Recent Events

On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC, for an aggregate of $16.4 million in cash, stock and assumed debt. Certain additional considerations are contingent pending certain earn-out provisions. This strategic acquisition brings together market leading know-how in amnion tissue processing technology with a global distribution network uniquely positioned to rapidly exploit significant market opportunities across multiple surgical indications.

Surgical Biologics, (“SB”), is located in Kennesaw, Georgia. Surgical Biologics develops bioimplants processed from human amniotic membrane that can be used for a wide range of surgical indications including ocular surface repair, gum repair, wound care, burns, and many other types of surgery that require the repair of a patient's integumental (native) tissue. SB is focused on developing technologically innovative bioimplants that offer the surgeon a variety of clinical options; allowing for greater flexibility in treatment, as well as improved surgical results.

Table of Contents

Surgical Biologics currently distributes tissue in several different membrane subsegments, such as ocular, dental, spine and wound care. The wound care and tissue management market in the U.S. is currently valued at approximately $7.4B, in which our products could play a strong role. The regenerative dental market is estimated at approximately $232M. The Millennium Research Group has projected the anti‐adhesion market to reach an estimated $500M in 2012, and the ocular market is valued at approximately $100M. Each market’s sub‐segment has unique competitors, products and distribution methods. Amniotic membrane, as processed by SB, has unique “bio‐active” properties that offer benefits that most competitive products cannot offer. SB’s tissues provide anti-inflammatory, anti-angiogenesis, anti-scarring and barrier properties as well as enhanced healing at the surgical site.

Surgical Biologics has developed a specialized method for the processing of amniotic membrane. This patent pending process, named Purion®, consists of unique methods which maximize yield, while minimizing manufacturing costs. The Purion® process was engineered to create an implant that is optimized for ease of use while providing the patient with the maximum assurance of safety. Surgical Biologics currently has seven patents pending that have been filed with the United States Patent Office. The patent filings consist of the intellectual property used to process tissues and/or apply the tissues in a unique manner in surgery.

The Company received the CE Mark for CollaFix® Surgical Mesh CD during the first quarter of 2012. CollaFix® Surgical Mesh CD is intended for use in general surgical procedures for reinforcement of soft tissue where weakness exists. This is the first product in the CollaFix® technology platform to receive the CE mark.

Results of Operations comparison for the Three Months Ended March 31, 2012 to the Three Months Ended March 31, 2011

Revenue

Total revenue increased approximately $2,663,000 to $3,706,000 for the three months ended March 31, 2012, as compared to $1,043,000 for the three months ended March 31, 2011. The increase in revenue as compared to the prior year is due primarily to sales of our amniotic membrane tissue. The Company experienced strong demand in the Spine, Wound Care, Ophthalmology, and Orthopedics markets.

Tissue Processing Costs and Cost of Products Sold

Cost of products as a percentage of revenue improved to 25.9% from 68.1% as compared to prior year. The improvement was due primarily to the increase in revenue. Beginning in 2012, the company decided to allocate both depreciation expense and stock compensation to each functional area. These expenses were reclassified in the prior year to maintain comparability. The amount of depreciation expense was approximately $35,000 and $27,000, and the amount of share-based compensation was $24,000 and $25,000 for the three months ended March 31, 2012 and 2011, respectively.

Personnel costs represent approximately $468,000 or 48.8% of total manufacturing, quality assurance and regulatory spending for the three months ended March 31, 2012.

Research and Development Expenses

Our research and development expenses (“R&D expenses”) decreased approximately $555,000 or 57.7% to $407,000 during the three months ended March 31, 2012, compared to approximately $962,000 in the prior year. The decrease is primarily related to the closure of our Tampa research facility in mid-2011, along with decreased spending on animal studies for our CollaFix™ and HydroFix® products. Approximately $136,000, or 33.4%, of R&D expenses for the three months ended March 31, 2012 were attributable to personnel costs, compared to approximately $357,500 or 37.2% for the three months ended March 31, 2011. Development and testing costs were approximately $39,000 and $224,000 for the three months ended March 31, 2012 and 2011, respectively. This decrease of approximately $185,000 is a result of lower costs in animal studies related to our CollaFix™ and HydroFix® products. Additionally, as described above in Cost of Products Sold, beginning in 2012, we decided to allocate both depreciation expense and share-based compensation expense to other functional areas, and have reclassified prior year amounts to maintain comparability. During the three months ended March 31, 2012 and 2011, we recorded approximately $31,000 and $28,000 for depreciation expense and approximately $72,000 and $86,000 for share-based compensation expense, respectively, to research and development during the most recent quarter.

Table of Contents

Our research and development expenses consist primarily of internal personnel costs, fees paid to external consultants, and supplies and instruments used in our laboratories. During the quarter, the Company filed 3 international patent applications for the amniotic tissue technology and 1 international patent application for the collagen technology.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses for the three months ended March 31, 2012, increased approximately $344,000 to $2,971,000 compared to $2,627,000 for the three months ended March 31, 2011. Selling expense increases were driven by costs associated with our regional account management organization as we continue to build our distribution network for our amniotic tissue platform as well as increased commissions due to higher revenue. Increased spending on support costs related to medical reimbursement including our 24-hour reimbursement hotline and scientific and clinical studies in support of both reimbursement and ongoing marketing activities were somewhat offset by reduced expense in legal and professional expenses incurred in 2011 related to the acquisition of Surgical Biologics and the aforementioned allocation of depreciation and share-based compensation expense to other functional areas. General and administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation. Personnel costs represent approximately $1,042,000 or 35.1% of total Selling, General and Administrative expenses in the first quarter of 2012.

Historically, the Company has reported depreciation and share-based compensation expense as part of selling, general and administrative expense. The Company decided to report these expenses in each functional area in order to more accurately present all of the costs attributable to each functional area. During the three months ended March 31, 2012 and 2011, we recorded a total of approximately $110,000 and $116,000 in depreciation expense allocated to each functional area per the table below. The overall $6,000 decrease in depreciation was attributable to the retirement of leasehold improvements for the Marietta facility when the lease was terminated in August 2011. We depreciate our assets on a straight-line basis, principally over five to seven years.

The following table shows the allocation of depreciation for the three months ended March 31, 2012 and 2011, to operating departments:

	Three Months Ended March 31,
	2012		2011
Cost of products sold		35,000		27,000
Research and development		31,000		28,000
Selling, General and administrative		44,000		61,000
		110,000		116,000

Share-based compensation for the three months ended March 31, 2012 and 2011, was approximately $501,000 and $488,000, respectively, an increase of approximately $13,000 or 3%. Increased employee stock option grants reflecting management’s philosophy of aligning employee compensation with investor objectives was the primary reason for the increase in expense. The following table shows the allocation of share-based compensation for the three months ended March 31, 2012 and 2011, to operating departments:

	Three Months Ended March 31,
	2012		2011
Cost of products sold		24,000		25,000
Research and development		72,000		86,000
Selling, General and administrative		405,000		377,000
		501,000		488,000

We recorded approximately $334,000 in amortization expense related to intangible assets in each of the three months ending March 31, 2012 and 2011. We amortize our intangible assets over a period of three to fourteen years, which we believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill but we test at least annually our goodwill for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.

Table of Contents

Net Interest Expense

We recorded other expense of approximately $462,000 during the three months ended March 31, 2012, compared with approximately $91,000 of other expense during the three months ended March 31, 2011. The increase of approximately $371,000 is primarily due to interest related to our Convertible Senior Secured Promissory Notes, which were issued during the last quarter of 2011. The following table summarizes the interest charges for each of the three months ended March 31, 2012 and 2012:

	Three Months Ended March 31,
	2012								2011
	Debt Discount		Accrued Interest		Interest Expense		Total		Debt Discount		Accrued Interest		Interest Expense		Total
Convertible Line of Credit with Related Party	$	11,000	$	16,000	$	—	$	27,000	$	—	$	—	$	—	$	—
Convertible Debt related to acquisition		80,000		11,000		—		91,000		73,000		12,000		—		85,000
Convertible Senior Secured Promissory Notes		214,000		123,000		—		337,000		—		—		—		—
Deferred financing related to Senior Secured Promissory Notes		5,000		—		—		5,000		—		—		—		—
Other		—		—		2,000		2,000		—		—		6,000		6,000
	$	310,000	$	150,000	$	2,000	$	462,000	$	73,000	$	12,000	$	6,000	$	91,000

Contractual Obligations

Contractual obligations associated with our ongoing business activities are expected to result in cash payments in future periods. The table below summarizes the amounts and estimated timing of these future cash payments as of March 31, 2012:

Table of Contents

	Payments due by period
Contractual Obligations	TOTAL		Less than 1 year		1-3 years		3-5 years		More than 5 years
Convertible senior secured promissory notes	$	5,000,000		—	$	5,000,000		—		—
Convertible debt, line of credit with related party		1,300,000		1,300,000		—		—		—
Convertible debt, note related to acquisition of SB		1,000,000		1,000,000		—		—		—
Employment agreements		294,000		294,000		—		—		—
Operating lease obligations		783,000		459,000		324,000		—		—
Royalty payments		95,000		95,000		—		—		—
	$	8,472,000	$	3,148,000	$	5,324,000		—		—

Liquidity and Capital Resources

Revenue continue to increase quarter over quarter while management maintains tight controls over spending. As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents. The Company reported total current assets of approximately $7,048,000 as compared to $6,882,000 as of December 31, 2011 and total current liabilities payable in cash of approximately $3,611,000, after adjusting for the short term earn-out liability payable in MiMedx common stock in the second quarter of 2012, as compared to approximately $4,732,000 in current liabilities net of the earn-out liability as of December 31, 2011. Additionally, the current liabilities include a Convertible line of credit of approximately $809,000 which is due to be paid in December 2012 but can be extended for an additional 12 months with a one-time payment of 5% of the principal balance due or $65,000 in December 2012. Therefore the current liabilities after adjustment for the earnout and the convertible line of credit are approximately $2,802,000 which results in a current ratio of 2.52. The Company believes that its anticipated cash from operations and existing cash and cash equivalents, and the line of credit will enable the Company to meet its operational liquidity needs, fund its planned investing activities and pay its debt when due for the next twelve months.

Discussion of cash flows

Net cash used in operations during the three months ended March 31, 2012, decreased approximately $502,000 to $1,288,000 compared to $1,790,000 used in operating activities for the three month period ended March 31, 2011, primarily attributable to our increased sales activity, improved gross margins and reduced spending in research and development.

Net cash used in investing activities during the three months ended March 31, 2012, decreased approximately $381,000 to $47,000 compared to $428,000 used in investing activities for the three month period ended March 31, 2011. The decrease was due to a reduction in purchased equipment.

Net cash flows from financing activities during the three months ended March 31, 2012 decreased approximately $1,654,000 to $244,000 compared to $1,898,000 during the three months ended March 31, 2011. Cash flows from financing activities during the current quarter include approximately $323,000 related to the exercise of warrants, $171,000 from the exercise of stock options, and $250,000 in payments related to the acquisition of Surgical Biologics.

Due to the material amount of non-cash related items included in the Company results of operations, the Company has developed an Adjusted EBITDA metric which provides management with a clearer view of operational cash burn (see the table below). The Adjusted EBITDA for the quarter was approximately $314,000 which is an improvement of approximately $2,632,000 as compared to the prior year quarter. This improvement was the result of increased revenue, improved gross margins and reduced spending in research and development.

We use various numerical measures in conference calls, investor meetings and other forums which are or may be considered “Non-GAAP financial measures” under Regulation G. We have provided below for your reference, supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation. The following table provides reconciliation of reported Net Loss on a GAAP basis to Adjusted EBITDA defined as Earnings before Interest, Taxes, Depreciation, Amortization and Share-Based Compensation:

Table of Contents

	Three Months Ended March 31,
	2012			2011
Net Loss (Per GAAP)	$	(1,093,652	)	$	(3,347,562	)

Add back:
Income Taxes		-			-

Financing expense associated with beneficial conversion of note payable issued in conjunction with acquisition		80,353			72,918

Financing expense associated with beneficial conversion of Line of Credit with Related Party		11,423			-

Financing expense associated with beneficial conversion of Senior Secured Promissory Notes		213,954			-

Other interest expense, net		156,557			18,298

Depreciation Expense		110,388			116,180
Amortization Expense		333,977			333,978
Employee Share Based Compensation		400,049			380,373
Other Share Based Compensation		100,936			107,560

Earnings/(Loss) Before Interest, Taxes, Depreciation, Amortization and Share-Based Compensation	$	313,985		$	(2,318,255	)

Critical Accounting Policies

In preparing our financial statements we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We continually review our accounting policies and financial information disclosures. A summary of our significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in our Annual Report on Form 10-K for the year ended December 31, 2011. During the first three months of fiscal 2012, there were no material changes to the accounting policies and assumptions previously disclosed.

Recent Accounting Pronouncements

For a description of recent accounting pronouncements, see Item 1 Financial Statements – Note 2.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

There have been no significant changes from the disclosures presented in the Company’s Form 10-K for the year ended December 31, 2011. For an in-depth discussion of the Company’s market risks, see Item 7A - “Quantitative and Qualitative Disclosures About Market Risk” of the Company’s Form 10-K for the year ended December 31, 2011.

Item 4.

Controls and Procedures

Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our controls and procedures were effective as of the end of the period covered by this report.

Table of Contents

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding disclosures.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the three months ended March 31, 2012, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

We have confidence in our internal controls and procedures. Nevertheless, our management, including our Chief Executive Officer and Principal Financial Officer, does not expect that our disclosure procedures and controls or our internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all our control issues and instances of fraud, if any, have been detected.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

None.

Item 1A.

Risk Factors

As of the date of this report, there have been no material changes to the risk factors included in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2011, except for the following:

Market Concentrations and Credit Risk

Distribution – The Company’s principal concentration of risk is related to its limited distribution channels. Three customers accounted for approximately 46% of revenue for the three months ended March 31, 2012, including one customer who represented 19%, a second customer who represented 16%, and another customer who represented 11% of total revenue.

The Company’s accounts receivable are derived from customers primarily located in the United States of America. Two customers accounted for 31% of the total accounts receivable as of March 31, 2012. One customer represented approximately 21% of total receivables, and a second customer represented approximately 10% of total receivables as of the end of the most recent quarter.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2012, the Company issued 167,086 shares of Common Stock valued at $184,653 for accrued Director’s fees, and issued 136,246 shares of Common Stock for cashless exercises of warrants. Additionally, the Company issued 3,357,369 shares of Common Stock and received cash proceeds of approximately $322,673 for the exercise of warrants during the most recent quarter.

Table of Contents

The Company relied on Section 4(2) of the Securities Act of 1933 (the “Securities Act”) and Rule 506 of Regulation D under the Securities Act, as amended, to issue the securities described above because they were offered to accredited investors and a limited number of unaccredited investors who purchased for investment in transactions that did not involve a general solicitation.

Form 10-K for the twelve months ended December 31, 2011 filed March 30, 2012, provides information related to unregistered sales of equity securities during the twelve months ended December 31, 2011.

We did not repurchase any shares during the three months ended March 31, 2012, and currently have no share repurchase plans or programs.

Item 3.

Default Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit Number	Reference	Description

10.14	*	MiMedx Group, Inc. 2012 Management Incentive Plan dated February 23, 2012 (1)

31.1	#	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2	#	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1	#	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	#	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

#	Filed herewith

* Indicates a management contract or compensatory plan or arrangement

(1) Incorporated herein by reference to the Company’s Form 8-K dated as of February 29, 2012

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 14, 2012
	By:	/s/ Michael J. Senken
		Michael J. Senken
		Chief Financial Officer

EX-31.1 2 ex31_1.htm EXHIBIT 31.1 ex31_1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14(A) AND 15d-14(A)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Parker H. Petit, certify that:

1. I have reviewed this Form 10-Q for the quarter ended March 31, 2012, of MiMedx Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 14, 2012	/s/ Parker H. Petit
	Parker H. Petit
	Chief Executive Officer

EX-32.2 3 ex31_2.htm EXHIBIT 31.2 ex31_2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(A) AND 15d-14(A)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Michael J. Senken, certify that:

1. I have reviewed this Form 10-Q for the quarter ended March 31, 2012, of MiMedx Group, Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 14, 2012	/s/ Michael J. Senken
	Michael J. Senken
	Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1 Unassociated Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Parker H. Petit, Chief Executive Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2012	/s/ Parker H. Petit
	Parker H. Petit
	Chief Executive Officer

EX-32.2 5 ex32_2.htm EXHIBIT 32.2 Unassociated Document

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Senken, Chief Financial Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2012	/s/ Michael J. Senken
	Michael J. Senken
	Chief Financial Officer

EX-101.INS 6 mdxg-20120331.xml INSTANCE DOCUMENT 0001376339 2012-01-01 2012-03-31 0001376339 2012-04-30 0001376339 2012-03-31 0001376339 2011-12-31 0001376339 2011-01-01 2011-03-31 0001376339 2011-03-31 0001376339 us-gaap:CommonStockMember 2011-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001376339 us-gaap:TreasuryStockMember 2011-12-31 0001376339 us-gaap:RetainedEarningsMember 2011-12-31 0001376339 us-gaap:SeriesAPreferredStockMember 2011-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0001376339 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-03-31 0001376339 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0001376339 us-gaap:TreasuryStockMember 2012-01-01 2012-03-31 0001376339 us-gaap:RetainedEarningsMember 2012-01-01 2012-03-31 0001376339 us-gaap:CommonStockMember 2012-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001376339 us-gaap:TreasuryStockMember 2012-03-31 0001376339 us-gaap:RetainedEarningsMember 2012-03-31 0001376339 us-gaap:SeriesAPreferredStockMember 2012-03-31 0001376339 2010-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

2853552

1891919

3802492

3468515

1924861

1814473

316417

75558539

73868604

310478

72918

110388

116180

333977

809152

1295980

33583

3021266

4112326

1340922

1020533

2435

3239

-352720

641882

961633

-150365

150012

15383

82914

111983

212831

155025

100000000

78139596

74306895

78089596

74256895

78139

74307

969680

1128806

3019328

2744587

958855

710117

6796440

7917267

<div><div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold;">8</font>.</div></td><td><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Debt</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The following disclosures reflect a summary of our outstanding convertible securities, as well as activity related to financing transactions.  The table below summarizes the Company's financing, and further details regarding each transaction are provided following the table:</div></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div><div style="text-align: right; width: 100%; font-family: Times New Roman; font-size: 8pt;"></div></div></div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Convertible Line </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">of Credit with </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Related Party</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Convertible </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Senior Secured </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Promissory Note</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Face Value of Note</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,300,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,000,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">6,300,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Due date</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(a)</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">12/31/2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(b)</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">12/31/2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Annual Interest rate</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 64%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Contingent warrants issued at inception (c):</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">First Contingent Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(d)</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(e)</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,575,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Second Contingent Warrants</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(f)</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(f)</div></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,575,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Total Contingent Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">650,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,500,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,150,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 64%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Vested Warrants as of March 31, 2012:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">First Contingent Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">(d)</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(e)</div></td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,575,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Second Contingent Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 64%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Contingent Warrants Outstanding as of March 31, 2012 (g)</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">First Contingent Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Second Contingent Warrants</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,575,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Total Contingent Warrants Outstanding as of March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,575,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 64%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Weighted average exercise price of warrants</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> 0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(a)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The initial termination date of the Credit Agreement is December 31, 2012 and the Company may elect to extend the termination date until December 31, 2013 upon payment of an extension fee of 5% of the outstanding principle balance or $65,000.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(b)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unless the Company has repaid the applicable lender's Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender's Notes as of December 31, 2012.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(c)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Contingent Warrants have a term of five years from the date of issuance; however each is subject to automatic terminations as defined in the First Contingent Warrant and Second Contingent Warrant terms. The shares of Common Stock issuable upon exercise of the Contingent Warrants do not carry registration rights and may be exercised on a "cashless" basis. In the event of a change in control transaction on or prior to the First Measurement Date, then the Contingent Warrants shall be exercisable immediately prior to the closing of such change in control transaction. In the event (i) of a change in control transaction after the First Measurement Date and on or prior to the Second Measurement Date and (ii) the per share value of the consideration received by the holders of Common Stock in such change in control transaction is at least $1.75, the Second Contingent Warrant shall be null and void. If the value of the per share consideration received by the holders of Common Stock in such transaction is less than $1.75, the Second Contingent Warrant shall be exercisable immediately prior to the closing of such change in control transaction.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(d)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The First Contingent Warrant, (the "First Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "First Measurement Date") the closing trading price of the Stock is at least $1.50 per share for ten or more consecutive trading days.  During the three months ended March 31, 2012, the First Contingent Warrants vested due to the Company's Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(e)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The First Contingent Warrant, (the "First Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000. During the three months ended December 31, 2011, the First Contingent warrants vested due to the Company's Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(f)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Second Contingent Warrant, (the "Second Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "Second Measurement Date") the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days.</div></td></tr></table></div><div style="font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"> </td><td style="text-align: left; width: 18pt;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(g)  </div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The contingent warrants have not been included in our earnings per share calculation per the guidance in ASC 260-10-45-13 Earnings per share: Treatment of Contingently Issuable Shares in Weighted-Average Shares Outstanding which states that shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) shall be considered outstanding common shares and included in the computation of basic EPS as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).</div></td></tr></table></div></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Convertible Line of Credit with related party</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">On March 31, 2011, the Company and its Chairman of the Board and CEO ("the Lender") entered into a Subscription Agreement for a 5% Convertible Senior Secured Promissory Note ("Subscription Agreement") and, in connection therewith, agreed to issue a 5% Convertible Senior Secured Promissory Note ("Note") in the amount borrowed by the Company, and a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Lender agreed to issue a Revolving Secured Line of Credit Agreement ("Credit Agreement") to the Company of $1,300,000, after reductions for funds raised through other financing activities, to fund its working capital needs.  The first borrowing in the amount of $800,000 was on March 31, 2011, resulting in the issuance of 400,000 contingent warrants at an exercise price of $0.01 per warrant.  Additional borrowings in the amount of $500,000 were drawn during the three months ended June 30, 2011, resulting in the issuance of 250,000 contingent warrants at an exercise price of $0.01 per warrant.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company may repay and reborrow, provided there is no event of default, as needed. Collateral for the Credit Agreement includes (i) all of the Company's intellectual property with the exception of intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, as more particularly set forth in the Security and Intercreditor Agreement.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">At the option of the Lender, the Note is convertible into the number of shares of common stock of the Company equal to the quotient of the outstanding principal amount and accrued interest of the Note as of the date of such election divided by $1.00 per share.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">On February 28, 2012, 325,000 First Contingent Warrants vested to the Lender at an exercise price of $0.01 per share. The vesting of the shares resulted in an additional beneficial conversion feature which requires recognition. According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The amount of the warrants and beneficial conversion feature totaled approximately $550,000  net of previously recognized interest expense which has been recorded as a debt discount that will be charged to interest expense over the life of the convertible note.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The issuance of the aforementioned securities was not registered in reliance on Section 4(2) of the Securities Act of 1933, as amended.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Senior Secured Promissory Notes</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the "Notes") to individual accredited investors for aggregate proceeds of $5,000,000 and issued a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The aggregate proceeds included $500,000 of Notes sold to the Company's Chairman of the Board and CEO, who had committed to lend the Company up to $1,500,000, to the extent other lenders did not subscribe to the Company's debt offering.  The terms of those advances were subject to amendment as authorized by the Company's Board of Directors to be consistent with the final terms of the Company's debt offering.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company ("Common Stock") at $1.00 per share at any time upon the election of the holder of the note. The Notes mature on December 31, 2013, and bear interest at 5% per annum on the outstanding principal amount payable in cash on a quarterly basis, with all unpaid interest being due and payable on maturity.  Unless the Company has repaid the applicable lender's Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender's Notes as of December 31, 2012.  At the election of the holder, unpaid interest is convertible into shares of Common Stock at $1.00 per share.  Common Stock issued upon conversion of the Notes is available to be sold following satisfaction of the applicable conditions set forth in Rule 144.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Notes are secured by a first priority lien in all of the patents and other intellectual property owned by the Company and its subsidiaries, provided that until the Convertible Secured Promissory Notes in the principal sum of $1,250,000 issued January 5, 2011, in connection with the acquisition of Surgical Biologics, LLC, are paid in full, (i) the patents and other intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, are excluded from the collateral.  The maturity of the Notes may be accelerated upon the occurrence of certain Events of Default as set forth in the Notes. The lien is at an equal rate for all note holders in payment and lien priority with the notes outstanding under the Company's Line of Credit with Related Party Agreement dated March 31, 2011, (the "Prior Notes"), all of which are held by the Company's Chairman & CEO.  In order to effectuate that, to conform the description of the collateral and Events of Default in the Prior Notes to the description of the collateral and Events of Default in the Notes, and to clarify certain adjustments that would be applicable in the event of a stock split, stock dividend or similar event,  the Amended and Restated Security and Intercreditor Agreement executed  by the Company's Chairman & CEO in connection with the Notes on December 27, 2011,  superseded  the Security and Intercreditor Agreement that was originally executed in connection with the Prior Notes and, on January 3, 2012, the parties also executed an amendment to certain of the other documents executed in connection with the Prior Notes.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Under the terms of the sale of the Convertible Senior Secured Promissory notes, each lender received a warrant (the "Conversion Warrant") to purchase that number of shares of Common Stock equal to the number of shares of Common Stock that would be issuable upon conversion of the principal of such lender's Note, at an exercise price of $1.00 per share, provided that such Conversion Warrant shall only be exercisable for the number of shares of Common Stock that would have been issued upon conversion of any portion of the principal of the lender's Note that is, in fact, prepaid prior to maturity of the Notes. The maximum number of shares of Common Stock issuable upon exercise of the Conversion Warrants is 5,000,000 shares. The Conversion Warrant expires on December 31, 2013. The shares of Common Stock issuable upon exercise of the Conversion Warrant do not carry registration rights.  The Conversion Warrant must be exercised for cash.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.  The amount of the warrants (i.e. the exercisable First Contingent Warrants) and beneficial conversion feature totaled $2,278,052 which has been recorded as a debt discount that will be charged to interest expense using the effective interest rate over the life of the convertible note.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In conjunction with the sale of the Convertible Senior Secured Promissory notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share.  The warrants expire in five years.  The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique.  The total direct costs of approximately $47,800 are recorded as deferred financing costs and are being amortized over the term of the Senior Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders' equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.</div></div></div></div>

400049

380373

218701

<div><div style="text-align: center;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="text-indent: 0pt; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote11_income_taxes"></a>11.</div></td><td><div style="text-align: justify; font-family: times new roman; font-size: 10pt; font-weight: bold;">Income taxes</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: center;"></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company has incurred net losses since its inception and, therefore, no current income tax liabilities have been incurred for the periods presented.  Due to the Company's losses, management has established a valuation allowance equal to the amount of net deferred tax assets since management cannot determine that realization of these benefits is more likely than not.</div></div></div>

14756508

15090485

4040443

243586

91216

795516

712602

14363512

15199627

26860192

27096192

243673

1897799

-46794

-428344

-1287939

-1789844

-1093652

-3347562

-1093652

-1091060

-320389

-631365

-3256346

5000000

0.001

1212175

800000

171000

805817

869411

99000

15376

250000

-63114998

-62021346

3705808

1043487

2971246

2627492

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote2_significant_accounting_policy"></a>2.           Significant accounting policies</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Please see Note 2 to our Consolidated Financial Statements included in the Company's Form 10-K for the fiscal year ended December 31, 2011, for a description of all significant accounting policies.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Reclassifications</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Use of estimates</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Accounts Receivable</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect the customer's ability to pay.  The Company has $24,000 and $20,000 in the allowance for doubtful accounts as of March 31, 2012, and December 31, 2011, respectively.  Actual customer collections could differ from estimates.  The approximate provision during the three months ended March 31, 2012 was $4,000, and there were no charge-offs during the same period.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Inventories</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Inventories are valued at the lower of actual cost or market, using the first-in, first-out (FIFO) method.  Work in process is calculated by estimating the number of units that will be successfully converted to finished goods, based upon a build-up in the stage of completion using estimated labor inputs for each stage and historical yields reduced by estimated usage for quality control testing.  Idle facility expense, excessive spoilage, extra freight, and handling costs are expensed, as necessary, in cost of sales and are not capitalized into inventories.  Allocation of fixed production overheads is based on the normal capacity of production facilities.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Goodwill and intangible assets</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Goodwill is tested at least annually for impairment, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  Intangible assets with finite useful lives are amortized into Selling, General and Administrative Expenses in the condensed consolidated statements of operations using the straight-line method over various periods depending upon the specific asset.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Debt Instruments with Detachable Warrants and Beneficial Conversion Features</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">According to ASC-470 Debt Instruments with Detachable Warrants, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Revenue Recognition</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company sells its products primarily through a combination of independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  The Company recorded approximately $39,000 and $3,000 for net sales returns provisions for the three months ended March 31, 2012 and 2011, respectively.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair value of financial instruments</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The carrying value of accounts payable and accrued expenses approximate their fair value due to the short-term nature of these liabilities. The fair value of our short term and long term convertible debt approximates $4,798,000 which represents the face value less the unamortized discount of any beneficial conversion feature plus accrued but unpaid interest at March 31, 2012.  The fair value of warrants issued in conjunction with placement fees approximates $13,000 which represents the face value less the unamortized discount of any beneficial conversion feature at March 31, 2012.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Net loss per share</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method.  For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The following table sets forth the computation of basic and diluted net loss per share:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="border-left: medium none; width: 56%; font-family: times new roman; font-size: 10pt; border-top: medium none;">  </td><td valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="width: 22%; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none; border-right: medium none;"> </td></tr><tr><td valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 56%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,093,652</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,347,562</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Denominator for basic earnings per share - weighted average shares</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">74,872,122</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">70,333,476</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Effect of dilutive securities: Stock options and warrants outstanding and convertible debt <font style="display: inline; font-size: 70%; vertical-align: text-top;">(a)</font></div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; font-weight: bold;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; font-weight: bold;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold; border-right: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="border-left: medium none; width: 56%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">74,872,122</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">70,333,476</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="border-left: medium none; width: 56%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Loss per common share - basic and diluted</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.05</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;">)</td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(a)</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">Securities outstanding that were excluded from the computation, because they would have been anti-dilutive are as follows:</div></td></tr></table></div><div> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding Stock Options</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,517,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,778,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,891,567</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,813,644</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Convertible Debt, promissory notes</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,131,018</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; font-weight: bold;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Convertible Line of Credit with Related Party</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,358,931</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Convertible Debt, Acquisition</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059,836</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,261,644</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 66%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">27,958,352</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,653,288</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 72pt; font-size: 10pt; margin-right: 0pt;">The table above excludes all securities with contingencies including the earnout liability and contingent warrants.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Recent Accounting Pronouncements</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Changes to accounting principles generally accepted in the United States of America (U.S. GAAP) are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASU's) to the FASB's Accounting Standards Codification.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company considers the applicability and impact of all ASU's. ASU's not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Financial Accounting Standards Board ("FASB") issued updated authoritative guidance in September 2011 to amend previous guidance on the annual and interim testing of goodwill for impairment; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year.  The guidance provides entities with the option of first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.  If it is determined, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not less than the carrying amount, the two-step impairment test would still be required.  Annual impairment tests are performed by the company in the second quarter of each year.  The adoption of this updated authoritative guidance did not have a significant impact on the Company's condensed consolidated financial statements.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Fair Value Measurements</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The FASB issued updated authoritative guidance in May 2011 to amend fair value measurements and related disclosures; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year.  This guidance relates to a major convergence project of the FASB and the International Accounting Standards Board to improve International Financial Reporting Standards ("IFRS") and GAAP.  This guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between IFRS and GAAP.  The guidance also changes some fair value measurement principles and enhances disclosure requirements related to activities in Level 3 of the fair value hierarchy.  The adoption of this updated authoritative guidance had no impact on the Company's condensed consolidated financial statements.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Recently issued accounting pronouncements not yet adopted:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In December 2011, the FASB issued new accounting guidance that will require entities to disclose information about instruments (including derivatives) and transactions eligible for offset in the statement of financial position or subject to an agreement similar to a master netting arrangement.  These new provisions are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, and should be applied retrospectively for all comparative periods presented.  We do not expect this accounting standard to have an impact on our condensed consolidated financial statements.</div></div></div>

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote9_common_stock_placements"></a><div style="text-align: center; text-indent: 0pt; display: block;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">9.</div></td><td><div style="text-align: justify; font-style: normal; font-family: times new roman; font-size: 10pt; font-weight: bold;">Common Stock Placements</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote9_common_stock_placements"></a> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">October 2010 Private Placement</div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In October 2010, the Company commenced a private placement to sell common stock and warrants. From October 30, 2010, through December 31, 2010, the Company sold 2,405,000 shares of common stock at a price of $1.00 per share and received proceeds of $2,337,020 net of $67,980 in offering costs.  For the nine months ended September 30, 2011, the Company sold an additional 3,778,321 shares of Common Stock and issued an additional 1,889,161 warrants and received net cash proceeds of $3,730,587 net of $47,733 in offering costs.  Under the terms of the offering, for each share purchased, the investor received one 5-year warrant to purchase the common stock of the Company at an exercise price of $1.50 per share. The terms of the warrant, (the "Callable Warrant") are that for every two shares of common stock purchased, the holder is issued a 5-year warrant to purchase one share of the Company's Common Stock at an exercise price of $1.50 per share. The Callable Warrant does not carry registration rights and is callable by the Company at any time after the issuance if the closing sale price of the Stock exceeds $1.75 for fifteen (15) or more consecutive trading days. Upon written notice, the Company may redeem the Callable Warrant at a price of $0.01 per share.  Additionally, the Company issued a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The First Contingent Warrant, (the "First Contingent Warrant") vested during the period resulting in the issuance of 1,672,742 warrants at an exercise price of $0.01 per share.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Second Contingent Warrant, (the "Second Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "Second Measurement Date") the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The contingent warrants have not been included in our earnings per share calculation per the guidance in ASC 260-10-45-13 Earnings per share: Treatment of Contingently Issuable Shares in Weighted-Average Shares Outstanding which states that shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) shall be considered outstanding common shares and included in the computation of basic EPS as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The warrants met all the requirements for equity classification under GAAP and are recorded in stockholders' equity.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company's Chairman and CEO invested $1,006,664 in the October 2010 Private Placement including  the investment of principal and accrued interest from the October 2010 Bridge note converted under the same terms as the Private Placement, receiving 503,332 warrants with an exercise price of $1.50, 251,666 First Contingent warrants at an exercise price of $0.01 and 251,666 Second Contingent warrants at an exercise price of $0.01 as per the aforementioned terms of the offering.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In connection with the October 2010 Private Placement, the Company entered into a registration rights agreement that provides "Piggy-Back" registration rights to each investor.</div></div></div>

7047829

6881511

407072

962224

26860192

27096192

<div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 27pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote7_intangibles"></a>7.</div></td><td><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Intangible assets and royalty agreement</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Intangible assets activity is summarized as follows:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Weighted</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Average</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Gross</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Gross</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Amortization</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Lives</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Amortization</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Amortization</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"> </td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Intangible assets subject to amortization:</div></td><td valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div></td><td align="left" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="left" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td align="right" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td align="right" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;"> </td><td align="right" colspan="2" nowrap="nowrap" valign="bottom"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">License-Shriners Hsp for Children & USF Research <font style="display: inline; font-size: 70%; vertical-align: text-top;">(a)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">10 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">996,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(512,933</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">483,067</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">996,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(488,033</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">507,967</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">License - SaluMedica LLC Spine Repair <font style="display: inline; font-size: 70%; vertical-align: text-top;">(b)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">10 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,399,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,387,577</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,011,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,399,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,313,573</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,085,427</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">License - Polyvinyl Alcohol Cryogel <font style="display: inline; font-size: 70%; vertical-align: text-top;">(c)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">10 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,667,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,067,011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,599,989</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,667,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(998,932</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,668,068</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Customer Relationships <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,520,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(314,286</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,205,714</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,520,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(251,429</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,268,571</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Supplier Relationships <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">241,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(21,518</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">219,482</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">241,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(17,215</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">223,785</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Patents & Know-How <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,530,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(493,750</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,036,250</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,530,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(395,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,135,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Licenses/Permits <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="padding-bottom: 2px; width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">3 years</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(5,417</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,583</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(4,333</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,667</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 21%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"> </div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,366,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,802,492</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,563,508</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,366,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,468,515</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,897,485</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Intangible assets not subject to amortization:</div></td><td valign="bottom" style="width: 7%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Trade Names/Trademarks <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">indefinite</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,008,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,008,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,008,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,008,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In-process Research & Development-Liquid <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">indefinite</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,160,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,160,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,160,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,160,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 21%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In-process Research & Development-Other <font style="display: inline; font-size: 70%; vertical-align: text-top;">(d)</font></div></td><td valign="bottom" style="padding-bottom: 2px; width: 7%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">indefinite</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 21%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 4px; width: 7%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,559,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,802,492</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,756,508</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,559,000</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,468,515</td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,090,485</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(a)</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.  The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date).  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(b)</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair.  This license was acquired through the acquisition of SpineMedica Corp.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(c)</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel.  The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date).  The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales.  On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement.  As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000.  At March 31, 2012 and 2011, there are no additional amounts accrued for this obligation due to its contingent nature.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(d)</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Estimated future amortization expense related to the March 31, 2012 net carrying amount of $11,563,508 for intangible assets subject to amortization is as follows:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Estimated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Amortization</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Year ending  December 31,</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Expense</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">2012 (a)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,001,932</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,335,909</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">2014</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,331,575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">2015</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,225,337</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">2016</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,024,843</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Thereafter</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,643,912</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,563,508</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-indent: 0pt; display: block;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 45pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(a)</div></td><td><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;">Estimated amortization expense for the year ending December 31, 2012 includes only amortization to be recorded after March 31, 2012.</div></td></tr></table></div></div></div>

322464

312493

46794

111927

25000

209595

214342

9971

6088

-1093652

-3347562

6620

0.001

50000

12496680

11896565

74307

73868604

-25000

-62021346

78139

75558539

-25000

-63114998

172

170828

171000

172000

1825765

2300638

400049

377495

164664

514456

322673

74306895

78139596

<div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote4_acquisition_of_SB"></a>4.           Acquisition of Surgical Biologics, LLC</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">  </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">On December 21, 2010, we entered into an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC, the owners of Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia.  This transaction closed on January 5, 2011 and as a result we acquired all of the outstanding shares of Surgical Biologics in exchange for $500,000 cash, a total of $1,250,000 in 4% Convertible Secured Promissory Notes, and $7,087,500 in stock, represented by 5,250,000 shares of our common stock (525,000 of which were held in escrow for the purpose of securing the indemnification obligations outlined in the Merger Agreement).  Contingent consideration may be payable in a formula determined by sales and certain expenses for the years 2011 and 2012.  The contingent consideration was initially valued at $7,404,700 and is shown in the schedule below as fair value of earn-out.  We completed the acquisition of Surgical Biologics in an effort to extend our biomaterials product lines.  As of December 31, 2011, the Company evaluated the contingent liability based on operating results for the year, and adjusted the earn-out liability to $7,410,503.  No additional adjustment was required as of March 31, 2012.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">In total, the 4% Convertible Promissory Notes are convertible into up to 1,250,000 shares of the Company's common stock at $1.00 per share (a) at any time upon the election of the holder of the Convertible Notes; or (b) at the election of the Company, at any such time as the closing price per share of the Company's common stock (as reported by the OTCBB or on any national securities exchange on which the Company's shares may be listed, as the case may be) closes at no less than $1.75 per share for not less than 20 consecutive trading days in any period prior to the maturity date. If converted, the Common Stock will be available to be sold following satisfaction of the applicable conditions as set forth in Rule 144. The 4% Convertible Promissory Notes mature in eighteen (18) months and earn interest at 4% per annum on the outstanding principal amount payable in cash on the maturity date or convertible into shares of common stock of the Company as provided for above. The 4% Convertible Promissory Notes are secured by a security interest in the Intellectual Property, including the Patents and know-how and trade secrets related thereto, owned by, or exclusively licensed to, Surgical Biologics, LLC.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company has evaluated the 4% Convertible Promissory Notes for accounting purposes under GAAP and has determined that the conversion feature meets the conventional-convertible exemption and, accordingly, bifurcation and fair-value measurement of the conversion feature is not required. We are required to re-evaluate this conclusion upon each financial statement closing date while the 4% Convertible Promissory Notes are outstanding. Notwithstanding, the 4% Convertible Promissory Notes were issued with a beneficial conversion feature having an intrinsic value of $437,500. The intrinsic value of the beneficial conversion feature was determined by comparing the contracted conversion price to the fair value of the common on the date the respective 4% Convertible Promissory Notes were issued. A beneficial conversion feature only exists when the embedded conversion feature is "in-the-money" at the commitment date.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">As a result of the beneficial conversion feature, the 4% Convertible Promissory Notes were recorded net of a discount of $437,500 related to the beneficial conversion feature, the offset of which is recorded in paid-in capital, and the discount will be amortized through periodic charges to interest expense over the tem of the 4% Convertible Notes using the effective interest method.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The contingent consideration which was initially valued at $7,404,700 was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer's equity shares.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The actual purchase price was based on cash paid, the fair value of our stock on the date of the Surgical Biologics acquisition, and direct costs associated with the combination. The actual purchase price was allocated as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%; border-top: medium none;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Value of 5,250,000 shares issued at $1.35 per share</div></td><td align="right" valign="bottom" style="width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; border-top: medium none;">7,087,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-top: medium none; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cash paid at closing</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">350,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cash retained for working capital</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">150,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Assumed Debt</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">182,777</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Convertible Secured Promissory Note</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,250,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Fair value of earn-out</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,404,700</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Total fair value of purchase price</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">16,424,977</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="border-left: medium none; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Assets purchased:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Tangible assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Debt-free working capital</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">671,880</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Other assets, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">385</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Property, plant and equipment</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">72,866</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="border-left: medium none; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">745,131</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Intangible assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Customer relationships</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,520,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Supplier relationships</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">241,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Patents and know-how</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,530,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Trade names and trademarks</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,008,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">In-process research and development - liquid</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,160,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">In-process research and development - other</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Licenses and permits</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="border-left: medium none; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,497,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="border-left: medium none; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,182,846</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="border-left: medium none; padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Total Assets Purchased</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">16,424,977</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt; border-right: medium none;"> </td></tr></table></div><div style="text-indent: 0pt; display: block;"> </div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Working capital and other assets were composed of the following:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Working capital:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Cash</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">33,583</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Prepaid Expenses</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,738</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Accounts Receivable</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">181,087</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">License Receivable</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">340,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Inventory</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">347,106</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and accrued expenses</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(196,101</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Deferred rent and customer deposits</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(36,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Debt-free working capital</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">671,880</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Current portion of debt</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(62,590</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Long-term debt</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(21,187</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Line of credit</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(99,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Net working capital</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">489,103</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Deposits</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">16,582</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Deferred rent (non-current)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(16,197</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 68%; font-family: times new roman; font-size: 10pt;">  </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">385</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The combination was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.  The allocation of the purchase price to the assets acquired and liabilities assumed was based on an independent valuation report obtained by us.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The values assigned to intangible assets are subject to amortization.  The intangible assets were assigned the following lives for amortization purposes:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="top" style="width: 60%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Estimated useful</div></td></tr><tr><td align="left" valign="top" style="padding-bottom: 2px; width: 60%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Intangible asset:</div></td><td valign="top" style="border-bottom: black 2px solid; width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">     life (in years)</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Customer relationships</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14</div></td></tr><tr bgcolor="white"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Supplier relationships</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Patents and know-how</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">14</div></td></tr><tr bgcolor="white"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Trade names and trademarks</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">    indefinite</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In-process research and development - liquid</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">    indefinite</div></td></tr><tr bgcolor="white"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In-process research and development - other</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">    indefinite</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="top" style="padding-left: 0pt; width: 60%; margin-left: 9pt;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Licenses and permits</div></td><td valign="top" style="width: 20%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">3</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.  Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction.  Goodwill is tested for impairment as defined by FASB Topic 350 - Intangibles - Goodwill and Other.</div><br /></div></div>

406664

7087500

-0.01

-0.05

74872122

70333476

false --12-31 2012-03-31 No No Yes Smaller Reporting Company MIMEDX GROUP, INC. 0001376339 80746672 2012 Q1 10-Q

3185223

4225280

549779

46746

58931

42726

90156 170509 59836 49315 2049190 2263145 68518 7732

100936

107560

3357 319316 322673 0 0 0 3357369 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote3_liquidity"></a>3.           Liquidity and management's plans</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">       </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents.  The Company reported total current assets of approximately $7,048,000 and current liabilities payable in cash of approximately $3,611,000 after adjusting for the short term earn-out liability payable in MiMedx common stock in the second quarter of 2012.  The Company believes that its anticipated cash from operations and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities and pay its debt when due for the next twelve months.</div></div></div> <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><a name="footnote10_equity"></a>10.         Equity</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 27pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">   Stock Incentive Plans</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the "2006 Plan"), the MiMedx Inc. 2007 Assumed Stock Plan (the "Assumed 2007 Plan") and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the "Assumed 2005 Plan") which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2012 totaled 375,000 and the maximum number of shares of common stock which can be issued under the 2006 Plan is 12,500,000 at March 31, 2012.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Activity with respect to the stock options is summarized as follows:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt;"> </div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Price</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Remaining</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contractual</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Term</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Aggregate</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Intrinsic</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding at January 1, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,333,583</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.17</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Granted</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,593,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Exercised</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(172,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.99</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Forfeited or cancelled/expired</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(237,583</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">1.17</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,517,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">1.19</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">7.6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">1,533,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Vested or expected to vest at March 31, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,372,990</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.16</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5.9</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,351,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The intrinsic value of the options exercised during the three months ended March 31, 2012, was approximately $26,800.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Following is a summary of stock options outstanding and exercisable at March 31, 2012:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 14%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="10" valign="bottom" style="border-bottom: black 2px solid; width: 43%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Options Outstanding</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 28%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Options Exercisable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 14%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Range of Exercise Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 13%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">outstanding</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 13%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Remaining</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contractual</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Term</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 13%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 13%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercisable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 13%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 13%; font-family: times new roman; font-size: 10pt;">0.50</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">585,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">2.6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">0.50</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">543,023</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">0.50</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 13%; font-family: times new roman; font-size: 10pt;">0.65 - $1.00</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">2,797,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">5.8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">0.78</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">2,615,918</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">0.78</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 13%; font-family: times new roman; font-size: 10pt;">1.04 - $1.80</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">8,584,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">8.9</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">1.29</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">2,664,049</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">1.42</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 13%; font-family: times new roman; font-size: 10pt;">2.40</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">550,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 12%; font-family: times new roman; font-size: 10pt;">0.5</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 12%; font-family: times new roman; font-size: 10pt;">2.40</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">550,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 12%; font-family: times new roman; font-size: 10pt;">2.40</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 13%; font-family: times new roman; font-size: 10pt;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">12,517,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 12%; font-family: times new roman; font-size: 10pt;">7.6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 12%; font-family: times new roman; font-size: 10pt;">1.19</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 12%; font-family: times new roman; font-size: 10pt;">6,372,990</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 12%; font-family: times new roman; font-size: 10pt;">1.16</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">A summary of the status of the Company's unvested stock options follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Unvested Stock Options</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Grant Date Fair </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Unvested at January 1, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,333,086</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.72</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Granted</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,593,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.67</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cancelled/expired</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(237,583</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.65</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Vested</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(544,493</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">0.78</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Unvested at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,144,010</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">0.70</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-indent: 0pt; display: block;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Total unrecognized compensation expense related to granted stock options at March 31, 2012, was approximately $4,448,000 and will be charged to expense through July 2015.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the "simplified method" which computes expected term as the average of the sum of the vesting term plus the contract term.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="6" valign="bottom" style="width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three months ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">58.3</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">57.6 - 57.8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected life (in years)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected dividend yield</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; font-weight: bold;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt; font-weight: bold;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Risk-free interest rate</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.88</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.96% - 2.14</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The weighted-average grant date fair value for options granted during the three months ended March 31, 2012 was approximately $0.67.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrants</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors.  The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants have been issued for terms of five years.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Following is a summary of warrants outstanding at March 31, 2012:</font><br /></div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">  </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrants</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Price per </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contingent </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrants</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Price per </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contingent</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrants outstanding at January 1, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,388,817</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.00</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,245,484</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Issued in connection with private placement of common stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,672,743</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,672,743</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Issued in connection with line of credit with related party</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(325,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrants exercised</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,494,993</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">0.09</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrants outstanding at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,891,567</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">1.15</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,247,741</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">0.01</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"> </td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;"> </div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">Warrants may be exercised in whole or in part by:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 9pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">·</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"></div></td><td style="width: 9pt;"><div style="text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">·</div></td><td><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">These warrants are not mandatorily redeemable, do not obligate the Company to repurchase its equity shares by transferring assets or issue a variable number of shares.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;"> </div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 36pt; font-size: 10pt; margin-right: 0pt;">All of our warrants are classified as equity as of March 31, 2012 and December 31, 2011.</div></div></div> 5250000 437500 1250000 4747 136 -136 0 0 0 0 136246 136246 167 184486 184653 0 0 0 167086 167086

EX-101.SCH 7 mdxg-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 040100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Significant accounting policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Liquidity and management's plans link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Acquisition of Surgical Biologics, LLC link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Property and equipment link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Intangible assets and royalty agreement link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Common Stock Placements link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Contractual Commitments link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mdxg-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mdxg-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mdxg-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounts receivable, net Intangible assets, accumulated amortization Property and equipment, accumulated depreciation Cash paid for acquisition, net of cash aquired of $33,583 Payments to Acquire Businesses, Net of Cash Acquired Additional paid-in capital Amortization of debt discount and deferred financing costs Depreciation Amortization of intangible assets Convertible line of credit with related party, net of unamortized discount of $549,779 and $46,746, respectively, plus accrued interest of $58,931 and $42,726, respectively CONSOLIDATED BALANCE SHEETS [Abstract] Acquisition, cash acquired Cash and cash equivalents Cash, beginning of period Cash, end of period Cash paid for interest Accounts payable and accrued expenses Accounts receivable Increase (Decrease) in Accounts Receivable Accrued interest Inventory Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (decrease) in cash resulting from changes in (net of effects of acquisition): Contractual Commitments Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Common stock; $.001 par value; 100,000,000 shares authorized; 78,139,596 issued and 78,089,596 outstanding for 2012 and 74,306,895 issued and 74,256,895 outstanding for 2011 Convertible debt related to acquisition, net of unamortized discount of $90,156 and $170,509, respectively, plus accrued interest of $59,836 and $49,315, respectively Convertible Senior Secured Promissory Notes, net of unamortized discount of $2,049,190 and $2,263,145, respectively, plus accrued interest of $68,518 and $7,732, respectively Cost of products sold Total current liabilities Liabilities, Current Current liabilities: Current liabilities: Debt Debt Disclosure [Text Block] Employee share-based compensation expense Financing expense associated with the debt discount recognized in connection with the senior secured promissory notes Financing Interest Expense CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income taxes Income Tax Disclosure [Text Block] Intangible assets, net of accumulated amortization of $3,802,492 and $3,468,515, respectively Goodwill Interest expense, net Interest Expense Inventory, net Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net loss NET LOSS Net loss for the period Net change in cash Cash and Cash Equivalents, Period Increase (Decrease) OTHER INCOME (EXPENSE), net LOSS FROM OPERATIONS Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Proceeds from sale of common stock and warrants and common stock with registration rights, net Proceeds from Line of Credit with related party Proceeds from Lines of Credit Proceeds from exercise of stock options Property and equipment, net of accumulated depreciation of $1,924,861 and $1,814,473, respectively Property and equipment [Abstract] Repayment of Line of Credit Repayments of Lines of Credit Repayment of Notes Payable Repayments of Notes Payable Repayment of Convertible Debt related to acquisition Repayments of Convertible Debt Accumulated deficit Retained Earnings (Accumulated Deficit) REVENUES: Net sales Inventories Inventory Disclosure [Text Block] Selling, general and administrative expenses Series A Preferred Stock [Member] Significant accounting policies Significant Accounting Policies [Text Block] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] Stockholders' equity: Stockholders' equity: Common Stock Placements Stockholders' Equity Note Disclosure [Text Block] Supplemental disclosure of cash flow information: Cash paid for income taxes Total current assets Assets, Current Current assets: Treasury Stock [Member] Common Stock [Member] Property and equipment Property, Plant and Equipment Disclosure [Text Block] Research and development expenses Total assets Assets Intangible assets and royalty agreement Intangible Assets Disclosure [Text Block] Other liabilities Other Liabilities, Noncurrent Statement [Table] ASSETS Statement [Line Items] Equity [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Treasury stock (50,000 shares at cost) Treasury Stock, Value Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Deposits and other long term assets Net loss per common share Other liabilities LOSS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Deferred rent current Common stock, par value (in dollars per share) Treasury stock, shares (in shares) Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Income taxes Income Tax Expense (Benefit) Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Statement, Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Equity Component [Domain] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period OPERATING COSTS AND EXPENSES: Commitments and contingencies (Note 12) Adjustments to reconcile net loss to net cash flows from operating activities: Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Employee share-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Discount on beneficial conversion feature recognized on vested contingent warrants on the line of credit with related party Adjustments to Additional Paid in Capital, Other Proceeds from exercise of warrants Balance (in shares) Balance (in shares) Shares, Outstanding Acquisition of Surgical Biologics, LLC Mergers, Acquisitions and Dispositions Disclosures [Text Block] Subsequent Events Subsequent Events [Text Block] Inventories [Abstract] Significant accounting policies [Abstract] Subsequent Events [Abstract] Outstanding convertible debt and accrued interest to equity (in shares) Stock valued in conjunction with the acquisition of Surgical Biologics, LLC Basic and diluted (in dollars per share) Basic and diluted (in shares) Supplemental disclosure of non-cash financing activity: Shares used in computing net loss per common share Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Current liabilities related to business acquisition, payable in common stock. Short-term earn-out liability Current portion of earn-out liability payable In MiMedx common stock Noncurrent liabilities related to business acquisition, payable in common stock. Earn-out liability, payable in MiMedx stock Earn-out liability payable in MiMedx common stock, net of current portion Carrying value as of the balance sheet date of [accrued] interest payable to related party on long-term convertible debt that has been incurred and is unpaid. Long-term line of credit with related party, accrued interest Convertible line of credit with related party, unamortized discount The portion of amortized discount on related party line of credit. Long-term line of credit with related party, amortized discount Convertible line of credit with related party, accrued interest Carrying value as of the balance sheet date of amortized discount on the current portion of convertible debt. Current portion of convertible debt, amortized discount Convertible debt, unamortized discount Carrying value as of the balance sheet date of [accrued] interest payable on the current portion of convertible debt that has been incurred and is unpaid. Current portion of convertible debt, accrued interest Convertible debt, accrued interest Carrying value as of the balance sheet date of amortized discount on the noncurrent portion of convertible senior secured promissory notes. Non Current Portion Of Convertible Senior Secured Promissory Notes Unamortized Discount Convertible Senior Secured Promissory Notes, unamortized discount Carrying value as of the balance sheet date of [accrued] interest payable on noncurrent portion of convertible senior secured promissory notes that has been incurred and is unpaid. Noncurrent Portion Of Convertible Senior Secured Promissory Notes Accrued Interest Convertible Senior Secured Promissory Notes, accrued interest This element represents the amount of recognized non-employee equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "non-employee stock-based compensation". Other share-based compensation expense Other share-based compensation expense Value of stock issued during the period upon the exercise of warrants. Stock Issued During Period, Value, Exercise of Warrants Exercise of warrants The number of shares issued during the period upon the exercise of warrants. Stock Issued During Period, Shares, Exercise of Warrants Exercise of warrants (in shares) EX-101.PRE 11 mdxg-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Significant accounting policies

3 Months Ended

Mar. 31, 2012

Significant accounting policies [Abstract]

Significant accounting policies

2. Significant accounting policies

Please see Note 2 to our Consolidated Financial Statements included in the Company's Form 10-K for the fiscal year ended December 31, 2011, for a description of all significant accounting policies.

Reclassifications

Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation.

Use of estimates

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect the customer's ability to pay. The Company has $24,000 and $20,000 in the allowance for doubtful accounts as of March 31, 2012, and December 31, 2011, respectively. Actual customer collections could differ from estimates. The approximate provision during the three months ended March 31, 2012 was $4,000, and there were no charge-offs during the same period.

Inventories

Goodwill and intangible assets

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

Revenue Recognition

The Company sells its products primarily through a combination of independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The Company recorded approximately $39,000 and $3,000 for net sales returns provisions for the three months ended March 31, 2012 and 2011, respectively.

Fair value of financial instruments

Net loss per share

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended March 31,
	2012			2011
Net loss	$	(1,093,652	)	$	(3,347,562	)
Denominator for basic earnings per share - weighted average shares		74,872,122			70,333,476
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)		-			-

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities		74,872,122			70,333,476

Loss per common share - basic and diluted	$	(0.01	)	$	(0.05	)

(a)

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive are as follows:

	Three months ended March 31,
	2012		2011
Outstanding Stock Options		12,517,000		9,778,000
Outstanding Warrants		7,891,567		6,813,644
Convertible Debt, promissory notes		5,131,018		-
Convertible Line of Credit with Related Party		1,358,931		800,000
Convertible Debt, Acquisition		1,059,836		1,261,644
		27,958,352		18,653,288

The table above excludes all securities with contingencies including the earnout liability and contingent warrants.

Recent Accounting Pronouncements

Changes to accounting principles generally accepted in the United States of America (U.S. GAAP) are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASU's) to the FASB's Accounting Standards Codification.

The Company considers the applicability and impact of all ASU's. ASU's not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

Goodwill

The Financial Accounting Standards Board ("FASB") issued updated authoritative guidance in September 2011 to amend previous guidance on the annual and interim testing of goodwill for impairment; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. The guidance provides entities with the option of first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not less than the carrying amount, the two-step impairment test would still be required. Annual impairment tests are performed by the company in the second quarter of each year. The adoption of this updated authoritative guidance did not have a significant impact on the Company's condensed consolidated financial statements.

Fair Value Measurements

The FASB issued updated authoritative guidance in May 2011 to amend fair value measurements and related disclosures; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. This guidance relates to a major convergence project of the FASB and the International Accounting Standards Board to improve International Financial Reporting Standards ("IFRS") and GAAP. This guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between IFRS and GAAP. The guidance also changes some fair value measurement principles and enhances disclosure requirements related to activities in Level 3 of the fair value hierarchy. The adoption of this updated authoritative guidance had no impact on the Company's condensed consolidated financial statements.

Recently issued accounting pronouncements not yet adopted:

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A9&8V,3,S,E]B8SAC7S0W.#1?8C%C95]C9C0P M,C1D9#,P9F8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7V%C8V]U;G1I;F=?<&]L:6-I M93PO>#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%C<75I#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=F5N=&]R:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?87-S971S7V%N9%]R;WEA M;'1Y7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E M8G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5Q=6ET>3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]T87AE#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D-O;G1R86-T=6%L7T-O;6UI=&UE;G1S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A9&8V,3,S,E]B8SAC7S0W M.#1?8C%C95]C9C0P,C1D9#,P9F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO861F-C$S,S)?8F,X8U\T-S@T7V(Q8V5?8V8T,#(T9&0S,&9F+U=O M'0O:'1M M;#L@8VAA2!);F9O2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^3F\\2!#=7)R96YT(%)E<&]R=&EN M9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2P@ M<&QU3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@<&QU3PO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@:6X@36E-961X(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&-U3H\+W-T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M+#@P,BPT.3(\F5D(&1IF5D(&1I3H\+W-T2!S=&]C M:RP@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E(&%SF5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@2!N;W1E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A9&8V,3,S M,E]B8SAC7S0W.#1?8C%C95]C9C0P,C1D9#,P9F8-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO861F-C$S,S)?8F,X8U\T-S@T7V(Q8V5?8V8T,#(T M9&0S,&9F+U=O'0O:'1M;#L@8VAA2!3=&]C:R!;365M8F5R73QB M65E M('-H87)E+6)A'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5R8VES92!O9B!S=&]C M:R!O<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65E('-H87)E+6)A'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT,#`L,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R8VES92!O9B!W87)R86YT6UE;G0@;V8@3&EN92!O9B!#6UE;G0@ M;V8@3F]T97,@4&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!W87)R86YT M2!.;W1E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,S9P=#L@9F]N="US:7IE.B`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`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M M87)G:6XM3L@=&5X="UI;F1E;G0Z M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM65A6QE/3-$)W1E>'0M86QI M9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM65A65A6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3L@9F]N="US='EL93H@:71A;&EC.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#,V<'0[(&9O;G0M3L@=&5X="UI M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA'!E;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'0[(&1I3L@9F]N="US='EL93H@:71A;&EC.R!T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#,V<'0[(&9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM&ES=&EN M9R!R96-E:79A8FQE&EM871E('!R;W9I3H@8FQO8VL[(&UA M3L@9F]N="US M='EL93H@:71A;&EC.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z M(#,V<'0[(&9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I M3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&UA6EE;&1S(')E9'5C960@8GD@97-T:6UA M=&5D('5S86=E(&9O'!E M;G-E9"P@87,@;F5C97-S87)Y+"!I;B!C;W-T(&]F('-A;&5S(&%N9"!AF5D(&EN=&\@:6YV96YT;W)I97,N)B,Q-C`[)B,Q-C`[ M06QL;V-A=&EO;B!O9B!F:7AE9"!P6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!F;W(@:6UP M86ER;65N="P@;W(@;6]R92!FF5D('-E<&%R871E;'D@870@:7-S=6%N8V4@8GD@86QL M;V-A=&EN9R!A('!O3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO M8VL[(&UA6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SY2979E;G5E(%)E8V]G;FET:6]N/"]D:78^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R M9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F M=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!R96-O9VYI>F5S(')E=F5N=64@=VAE;B!T M:71L92!T;R!T:&4@9V]O9',@86YD(')I2!M871T97)S(&]F(&-UF5D(&1I MF5D(&%T('1H92!T M:6UE('1H92!P2!R96-O2`D,SDL,#`P(&%N9"`D,RPP,#`@9F]R(&YE="!S86QE2X\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R!M87)G:6XMF5D(&1I2!B96YE9FEC:6%L(&-O;G9EF5D(&1I2!B96YE9FEC:6%L M(&-O;G9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM3H@8FQO8VL[(&UA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&UA3H@8FQO8VL[(&UA M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`R,B4[ M(&)O'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O#L@=VED=&@Z M(#4V)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D M97(M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PP.3,L-C4R/"]T M9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RPS-#6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R M9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE M9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XMF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R<'@@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N M="US:7IE.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`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`S-G!T.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY396-U&-L=61E9"!FF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C8E.R!D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@-C8E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M.7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!N;W1E6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@ M8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXQ M+#,U."PY,S$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXX,#`L,#`P/"]T9#X\=&0@;F]W#L@=VED=&@Z(#8V)3LG/CQD:78@3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@.7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W!A M9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXQ+#(V,2PV-#0\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`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`P<'0[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M65A M6EN9R!A;6]U;G0L('1H92!T=V\M2!T M:&4@8V]M<&%N>2!I;B!T:&4@3H@ M8FQO8VL[(&UA3H@8FQO8VL[(&UA3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UEF4Z(#$P<'0[(&UA"!A="!T:&4@8F5G:6YN:6YG(&]F(&ET6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G M:6XM6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,S9P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM2`Q+"`R,#$S+"!A;F0@:6YT M97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!A;FYU86P@<&5R:6]D7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!A;F0@;6%N86=E;65N="=S('!L86YS(%M!8G-T3X\+V$^,RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M,:7%U:61I='D@86YD(&UA M;F%G96UE;G0G3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[ M(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!H860@ M87!P2`D,RPP,C$L,#`P(&]F(&-A2`D-RPP-#@L,#`P M(&%N9"!C=7)R96YT(&QI86)I;&ET:65S('!A>6%B;&4@:6X@8V%S:"!O9B!A M<'!R;WAI;6%T96QY("0S+#8Q,2PP,#`@869T97(@861J=7-T:6YG(&9O&ES=&EN M9R!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S('=I;&P@96YA8FQE('1H92!# M;VUP86YY('1O(&UE970@:71S(&]P97)A=&EO;F%L(&QI<75I9&ET>2!N965D M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&UA2`U+"`R,#$Q(&%N9"!A2`U+#(U,"PP,#`@2!B92!P87EA8FQE(&EN(&$@9F]R;75L82!D971E65A2!E=F%L M=6%T960@=&AE(&-O;G1I;F=E;G0@;&EA8FEL:71Y(&)A65A3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA M2=S(&-O;6UO;B!S M=&]C:R!A="`D,2XP,"!P97(@2!T:6UE('5P;VX@ M=&AE(&5L96-T:6]N(&]F('1H92!H;VQD97(@;V8@=&AE($-O;G9E2=S(&-O;6UO;B!S=&]C:R`H87,@2!N871I;VYA;"!S96-U2!B M92!L:7-T960L(&%S('1H92!C87-E(&UA>2!B92D@8VQO2!P97)I;V0@<')I;W(@ M=&\@=&AE(&UA='5R:71Y(&1A=&4N($EF(&-O;G9E2!D871E(&]R(&-O;G9E2!A2P@:6YC;'5D:6YG('1H92!0871E;G1S(&%N M9"!K;F]W+6AO=R!A;F0@=')A9&4@&-L=7-I=F5L>2!L:6-E;G-E9"!T;RP@4W5R9VEC M86P@0FEO;&]G:6-S+"!,3$,N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@ M;6%R9VEN+6QE9G0Z(#,V<'0[(&UA2!H87,@979A;'5A M=&5D('1H92`T)2!#;VYV97)T:6)L92!02!E>&ES=',@=VAE;B!T:&4@96UB961D960@8V]N=F5R6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,S9P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[ M(&1I3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UEF4Z(#$P<'0[(&UA2!W:&5R96)Y M(&$@9FEN86YC:6%L(&EN2!S971T;&4@8GD@:7-S=6EN9R!A M('9A2!I9BP@870@:6YC97!T:6]N M+"!T:&4@;6]N971A6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\='(@8F=C;VQO3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B0\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE M/3-$)V)O3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXQ-3`L,#`P/"]T9#X\=&0@;F]W6QE/3-$)V)O3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ.#(L-S3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`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`\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(MF4Z(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,C=P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-S$L.#@P/"]T9#X\=&0@;F]W M6QE/3-$)V)O3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,C=P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS.#4\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#(W<'0[(&9O;G0M2P@<&QA;G0@ M86YD(&5Q=6EP;65N=#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ XML 16 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 3,021,266	$ 4,112,326
Accounts receivable, net	2,853,552	1,891,919
Inventory, net	795,516	712,602
Prepaid expenses and other current assets	377,495	164,664
Total current assets	7,047,829	6,881,511
Property and equipment, net of accumulated depreciation of $1,924,861 and $1,814,473, respectively	805,817	869,411
Goodwill	4,040,443	4,040,443
Intangible assets, net of accumulated amortization of $3,802,492 and $3,468,515, respectively	14,756,508	15,090,485
Deposits and other long term assets	209,595	214,342
Total assets	26,860,192	27,096,192
Current liabilities:
Accounts payable and accrued expenses	1,825,765	2,300,638
Deferred rent current	6,620	6,620
Convertible line of credit with related party, net of unamortized discount of $549,779 and $46,746, respectively, plus accrued interest of $58,931 and $42,726, respectively	809,152	1,295,980
Convertible debt related to acquisition, net of unamortized discount of $90,156 and $170,509, respectively, plus accrued interest of $59,836 and $49,315, respectively	969,680	1,128,806
Current portion of earn-out liability payable In MiMedx common stock	3,185,223	3,185,223
Total current liabilities	6,796,440	7,917,267
Earn-out liability payable in MiMedx common stock, net of current portion	4,225,280	4,225,280
Convertible Senior Secured Promissory Notes, net of unamortized discount of $2,049,190 and $2,263,145, respectively, plus accrued interest of $68,518 and $7,732, respectively	3,019,328	2,744,587
Other liabilities	322,464	312,493
Total liabilities	14,363,512	15,199,627
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 100,000,000 shares authorized; 78,139,596 issued and 78,089,596 outstanding for 2012 and 74,306,895 issued and 74,256,895 outstanding for 2011	78,139	74,307
Additional paid-in capital	75,558,539	73,868,604
Treasury stock (50,000 shares at cost)	(25,000)	(25,000)
Accumulated deficit	(63,114,998)	(62,021,346)
Total stockholders' equity	12,496,680	11,896,565
Total liabilities and stockholders' equity	$ 26,860,192	$ 27,096,192

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net loss	$ (1,093,652)	$ (3,347,562)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation	110,388	116,180
Amortization of intangible assets	333,977	333,977
Amortization of debt discount and deferred financing costs	310,478	72,918
Employee share-based compensation expense	400,049	380,373
Other share-based compensation expense	100,936	107,560
Increase (decrease) in cash resulting from changes in (net of effects of acquisition):
Accounts receivable	(961,633)	150,365
Inventory	(82,914)	(111,983)
Prepaid expenses and other current assets	(212,831)	(155,025)
Accounts payable and accrued expenses	(352,720)	641,882
Accrued interest	150,012	15,383
Other liabilities	9,971	6,088
Net cash flows from operating activities	(1,287,939)	(1,789,844)
Cash flows from investing activities:
Purchases of equipment	(46,794)	(111,927)
Cash paid for acquisition, net of cash aquired of $33,583	0	(316,417)
Net cash flows from investing activities	(46,794)	(428,344)
Cash flows from financing activities:
Proceeds from exercise of warrants	322,673	0
Proceeds from exercise of stock options	171,000	0
Repayment of Convertible Debt related to acquisition	(250,000)	0
Proceeds from Line of Credit with related party	0	800,000
Repayment of Line of Credit	0	(99,000)
Repayment of Notes Payable	0	(15,376)
Proceeds from sale of common stock and warrants and common stock with registration rights, net	0	1,212,175
Net cash flows from financing activities	243,673	1,897,799
Net change in cash	(1,091,060)	(320,389)
Cash, beginning of period	4,112,326	1,340,922
Cash, end of period	3,021,266	1,020,533
Supplemental disclosure of cash flow information:
Cash paid for interest	2,435	3,239
Cash paid for income taxes	$ 0	$ 0

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } ZIP 19 0001140361-12-024988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-12-024988-xbrl.zip M4$L#!!0````(`&V`KD"^++HIYX8``)D6!P`1`!P`;61X9RTR,#$R,#,S,2YX M;6Q55`D``PYEL4\.9;%/=7@+``$$)0X```0Y`0``[%UY;^,XEO]_@?T.'$]5 M3PJP8\FW4\<@G50U"EO=%532,PLL%@-:HFUVRZ*'I))X/_T^4H=E6Y;E,W;, MGNZ)+?%X[_'W+O))_O#WYY&''@D7E/D?2_:E54+$=YA+_<''4B`J6#B4EO[^ MZ3__X\-?*I5?B$\XEL1%O0EZ&+*18#[Z00()`Z!KQR$>=*FHQL\][B$8VQ=7 MZB/]6!I*.;ZJ5I^>GB[5E4O&!]6:9=6KU!<2^PXI1>T]ZO^9TUS=[F&1-']> M:/]4UZWM;K=;U7>3IH)F-81A[>I___KMWAF2$:[,TZ.F=Z<=T]2TJN'-N"D5 MK%&SVWG,ABV2#OXC$7)V;$& M(;J1T<4E-'L2N)'1W`]&V3RXDE?E9$RJT()PZB0=F%^@#_,K<_T<%OB23[)I MBVYFT.<$G"_I`W<`P%F=?$P=D=U+W\KH(JB3W0%N9#67XR5DJ3L9'5T(#_P?I(ZTN5VJU M/I8$'8T]I07ZVI"3_L>2FK\23W;Y+-P2JH8#:2V']?0E>9:(NA]+CFYG6[9D M"7FZ;=*:^)+*270MN4I==;U/"4>:,#+#32R@FZ__5?ID@>;6VZUZO?NA.M\Y MGJJ:,5 M=@5$LB=Y).;'/AFDS)@?>WWS8^_/_)R.$&?@M5]U^]>]!/F.@+;/_PZ`O!LV M&C,?OHKK9RK^!5]'S+^7S/GS5S+J$?X"\IMBBPP4HI0&=*( M7`@M_#`GB(+*JUPV2Y_B9@O\?JAF3C$EK9I%V]%:E`)+?NVZ5(+LL'>'J?O5 MO\%C*K%W%LN?R_OY0>&!$RP"/CD?_<_@^/R6_0>1F/K$_8RY3_V!.(N5SV;Z M_!;_'D8FXOH.$F;".7'/1_=S.']=,)C;UC#QP'''`T>]H[,.DHQI>4'3\FI0 M9%)2@YCU$&/2&(.:]5%CLJ"#9T%'C1WCF8[&,QWF.,HD1R>0'!T/%$R4<9;+ M;L*$E]PL?>'%-SL:Q[%9ND<86*=8E&+M;O,X\&DHC-^!YCDYC+3])Y^B]1QB M3D0\5'PO/;P::]G8M25C1R6G5[_?WVXZ='UN:)<^@KCGQ:=Z_*;J.[%D?%YU M"M.3%G#VB*GI;HG/1M3/GW"5<.=G7!PTOIOB>U%L?ZE4KAU=LRH0)PZAC[CG MD3+RB=0UT=`D"?RB=C^29K\1>:-+5R6*(/1#U5M.B]R0FDA?TTN-7.+0$?;$ MQY)5^E3K-.O-9NU#M<@$^Z4V+$'+I=;N=&WXWYK4?O5!`P<4;B(L!)&BC+#C M!*/`TP7I>,2XI/^'53P]S\`7"M20;_21N--1KO4@U],AKE,C;+((]8Y5:W13 MB[#^M$?";($UK#=:G:;=W`FS=YR!)943A'T7$7":8^759CEVR1A02C,Y3HU_ MFVH&GSVB/ES[,_/&T]UY8-'AWN=XQDT6W>[6&IV6/8/EG1!S_-(II.EVH]&N M[U,Z>**^"R09NG;@-B?HYT!`:`W0`ZT!0X)8']U@,8SON_,2BL=X8%&+Z0#0 M_7M?=8[[9F!DML(]5Q[65!+K3'H\W,X7U.;;"+O5L-M;LCS=(T%C3-T*!7,5 M;I,L`#U[-V43K6XWFTUPJ6D7E3WX'LDLH%[M>J?5:5F--AN-*;93F+IM-=J= M%'\%9STFAM?2F7:M:V_#[VV.)TC?VVY9%">=%)GID;SZ@V1+3D+2VV\O6>'ZN@_&PGFG?C(<;YC^"/]=$>V#Z%1\.Z!YD MFD]4#B$1">.9,0:GKW,1U2+PHWA713JQZL+U-\U&M]QN=[4:OVFTRFWX#\80 M8^)("$0]&&+L!4*%2CR`SB`R`K>CSIURMVY'?6OE=FVN[P)D`_+`?H0$W@%] M%+P6\YW-D[:.U;73.5ON!&$BRE M0Y(OG(U2/;=5H&8G%1?GS#-=>4THR%I3K#*!1^RI>"J3:-]5?SY/6UW+&\SY M!+S'/[`7D(TR7*MFUUJM.;)7S70H!@K@I:':U(Z5`:L`X.L-JUNK'2D#1=RU M5;.:]7GDK\>`"K!1G_'$&,U3_S6ZKF+@[7QUK5%/[7&DQ]TE2>M9CEHZ+\DD M*=G8&^,)U@$"+'ELP[J]:B,`MWG&AO^CDTU]J$?Y=#PM%U9IJ[.%DTPFVTL1,-!!94#[.+ M%!["X$[=SF.X"`U'*HDUM;!IU7)MX%J24`615(9[W(I=R'8E!('$=Q1(U7:7 MQ]2Y+?J?!U5B\+/'G#__=R%XG0ZB(LOT$-,15'_=?242/OWDR?S1@7^%_@B$I/W)>Z0O4E^5(UPA:RS?JXQ[[.')%>JI"=]# MH.C+2A^/J`?7'N@(6/N-/*$?;(3]]VB$^8#Z%8_TX_ZZO8#D_0K9TPM/A`Z& MT*3'/#?IQ<-KJE4I)A@CR/Z!VCYCTF>2V+5_*9XY=F2`/?BL][OY=#.=&*762<^Y4QDO2C%'0H><;BJ48CRK(7<,JGHK$U5+ M*'X8$K548^Q/T!`+1+1?U:Z?(74^AY5^`9W*@N$!)R347Y4.];&C8M4)$F/L MD(4C3/5U-/:8/A=*]]5;68*-"/J33*(VA(ADGR9L MO_H(1^)L@CT@=!P?L;F0X%*]R_-'X#MZQT=/RL(]-PI- M/.KHC")S5B4VB#[`5.H3>]]7D-="*L>3+9=`G*P@S-7V+LC2\]B3N%J%F3R$ M)&CO<51-%'TU`!V]X-/N,@R=B>>-E5C5BP*MDOZN%CG^'@WT1%TYO$(=Z^T< M0J5&J`\(Y2%"Y^$XG8\GGT".BJ:/)87C$GJ,OO68E&PT/V>K\W:EAF(C"\C+0-Q<`]"OFSA#5[?+\JE6EFY)/ODCLMRG. MJ*_VCS=;EEDC-D.!PQ0.@(3:J@6RK0.0X[,GKMZ5&/Y=2M(B*%(BVR5)U12< M.>H-0%R,?RS]U7$(Z?=+KP'J2W`-`54]'[P1C[KC2O`<`#L'PLJ;C6;64DJF M[FXV=:?1*5N6=;)J\S2DDKQRI6D8I=D]"3O1GAJXXU/6G@V=3A3V5<++5Z@V M?DXH/PFE@M"<$]R'J'8'JI4GC<-AN\>X2WA"1,_#SI^*%$BB/.I&TGY9]5N' MQ)VH9[>^8^T\Y%(7=7@%4=F8T]'M:$4[TI7&\>@*D()<%D!JNWME*1[@K47: M3I3$+MOMVI[U9)_+G-*3JMZ9R-K9R/J<*D%8:[]X9J^:^2`%N%A&X>-%"`=R MR+BNL[J@?G3U7=8.=?3<_[UN<3WM5J`NQUXHJHC^F>5IR0R'9B"C+F>?#%`A M@C6)_QIVV4#R[8Y=[S:[K1RZP\$/17,!8;<;=:O5Z3:WI)D%4CT3J11]+<*_ MI_IM)'&KLT+BJ1D.ST*A!:@U5RS`*A;>HS>7,+"J\E1F.0#/`#JDS+CZ;U&7 MWZ-VIPQ0+8/D8K2IO6>X"N+45]/"4%OW:CG"-HTR`*8,!,_T;)2!"WTUHZ>= M(\.-RP^ULF4*;:Y([%4+JLAS(:#A[4*"FM82ZP=&MURWF_E5Q"FJ;X'H+1Z;[;:ZKMAO-XH)K=3% M87=-51%WVH44N=4N1)6R@T7KE%3;'14D97P,C^FCE#T\PR^A<'\A.;`O?H`/ M0=,V)_C)WH%DX_3NU>PDNBYEZ>[Q3&W#UB54.=5`JFT\<_9IRJ]#UP MB@@C$8R@]T39=Q;PF43`2?EVH9QZ9-*P0$^@DNHO5HY555&E`L[IT\J28U]@ M7:&TO!(IM`8]`E1&Q`!C(ET-]3;NNI=99YB9X"YIIE@9YB> M5Y-2;\=Q4\*0\XKBO(/U=> M*WA(IVG?U+/9ZU58OB#EZJ4QJ8?(3X;NZ%%OI)[UGN0?YN_VU/O MJ">#];F-GY.A>VZ'RFBIT=*"B163V#M5N.RWY&ZFG*=Q`B5W7]3C/^&!%L0: MJ^V`*2GBT>J+E1`9Z)PN]9GRJ;Z#W(O7\>Z!KJR=C\NC9$&*M$[=N MNWR*YN1#DEN(15R\*A`Y:B4\N/V_P.\.Y`%6P2?J\'+9B5VKUNVJ.I0]4(KR M,A`[#BH.#_2>`?H\T%<\O6N`?BIAU6Z>G=Q#?+67!_F/(,#:\NG^4XBFKL,7 MG,0O74-\T\CJN!]5/IIGCYL[U)#ME.&M65JSM,>]M"_G)(_0'Q[G`\LI7[=C M!!6OBS$@/G<0&VP8;!AL&&R8O&^-4JKP=0D2/6'.L7IU9OSTJP0M<,A85XA? M..\6B\"-:I_$&R3/&!WE!?-CE6G/7!4<&(:_0+]OE9OM$3,D!7T9["M[Z MGC@L_4LW.W77Y_ERVHO^EL4[^WPK[>Y=_H$7^4R`MX'A.&A95@SR=??3#@[X M?<0P!O+'8FOW3.+1!D?'^"[PU[:1H1\`/LY]D]AH--@PV##;,F?!.7G*2G`M_3_V&9]89,;H8;+81 M9M3LW-7,8,-@PV##8&-_V>EK<]#FF/C4].H$-GL,0`Q`#$`,0(XC7S8O.C$/ MWY_BP_?F?2?'N;CG@C_S^I%C7=[S0>"K?/W(N?Z4^=*WDJP\$MA#G',F/\>X M;QI/)-(Q/S]M$/C2L8[!H,'@2T<[YC?2#Q3K_).H"^JW7!X)QP."R#/A#A4$ MC3EUB`IQGO:WB7,F:OWFB+79NK3L$U5D@[J31=U4?J>-OZ-&W+%*)P--YJ?& M<^.4JL2@A\FWE!->$E?\$0A)^Y-X2M7@"E$)=YVU'QU^T&S\!FS\R(@VZJW, M<$-?>")AM-%CGKLT`IGC?S5O19]_7GS">1D%X5P)/I2LD4,\+UKMCR6KI+^+ M,7;B[W,GOY:UX>J'46@,0,G&Z1!T;I).$6RO/`+MS/&]O$<^##+YN<#O4L0M M7=H9DHMB>7')U\#I6H^X/PP)HCZ5%'LP*Q]1'^O?.'2QU"&QA/LWG+A4HNL! M)V2D=@FI0+?$(:,>X=,:8>R[86LV&F-_`A-.$/&((Y%D$&M+$MU?F"7P)?46 M!JRC8`PMQGBBIP12L!\.(U3//M'D-=_&1++4AB4$]+Y#QX#M'O:PKX)[CMZT M="IWF;-`Z]JA?9B<`O8E@72/H^H2$HV*[T+%>Z]!Q7_W/2+$C&X.L4"E^>57I@3^FLUGGL#*/Q ME.XJ^"FE!T-#?3`")&P9&A0_I&/$@E#7^_01\G+(S]7=B^;;=[&:XP%8H8$V M3HL*#T-/AQ!!,GW"3GB2L<"#L0G&)A2V"0!?[Z3=OM9# ME_2I3]Q8]9=5/>NP8FFYE1Y57"+%CAABL"F*,C!&(P@1[B6H5DBFPKL.)Y(] MOSBTR9"!RR!KDLB![Q.PD@,J)`_#%2U%H4E2T4UONH?H(KB-4R"?*(A!SA##A(IO8$IR!G$7S"NPHZ=0__*IN9V*YE>"1<##^.L6 MED#;77\I$R`-,-M3"K4(Z&@$D1QT]B:S4S@>$\J.QF8SE\8YIB[HNR*,X3ZL M50X_6JH9W$=KG]G\@L+WMB7[68Y36X&5),5\95#5>0_,NJ",$-:9PB?\K,= M"W,$1W$`../U*-X#AHS'-1ZWJ,=U7XO'7>;DRNA":5!IV?W2.Z6]RI.!ZL>1 M-?4?(80.]6\<<%`W<&NU:4+L!SK&5>J8>,;0.L2MW;(R8=C/.`E[HS:KIV:H M#'?8(]@AE2]`GUR/'9H-YGN3!=O13R<+$)7_PAE8I!_*D8#Q"Y,2QN4T+)@V MO0X@?8`;7R"(@%@?0OU["59(.00(3ECH6E2H@E3([RX$^?#_D6,G_PZ@-_0@ MSPZ!EF_@7O23+]HL]P,.8_$YEK5-R[?E,=&A7]2]$@L91TN)><]7 M>C=C;L&HQBF0D_B/./29<5%-*^57M,2(=KB,LLU;L- MN)Y:[>8,.2$PA"^'(I+\;*%8.1PQR'&XQB/#+VU-C3H[6G_==B3Y@3TAOJ.%[BAI6*!.L'@/O00Z0U8[#F!%VZ_CJ,=[$%`76T'H-OU M_0VJM:R*;54:S8I=1Y\7Q@#&.,$RKF.86ELPKE_CXXG[T,##B'&A;]:-Q M('%,@CH_<=#GN_OHT#8Y>M+"2I]#S;FOS>>9U;"?$&R@G:)VD"MO?J*\1$M4_ M/5$YA-@&;`%@:HRYG*S+_BXK^?952[B]L)=0_-V?W1FT9RM'M$D``WTSQ)3# M7+%J_LPP=_7=F\_?T45)7?NFJSH@A"*ZD$29$'76C.Z#GG`X'6L;,BU74Z80 MJU*Q].+>$U]%=1">!6J$.W#Q8!486!-5*@(390\&DP(MY>A8"TR0OJU"3:+P M`=&X:NG&T2+98&+U1V4+,S4Q/<8Y>YJ>_$5B*VO)X.5;(Q=Y6SQAW^5)P$5N M.@,LWL4Y2_KT<<%:&K58$:A\BXJD%J`#217S'I7_C.$R9Y.F(+\HS5\*ERBM M8RHIM,OU<)>G'!W)0Z_`"9VG4I1^X+N0PF%=U"#_O[VW;VX;.1*'_[^J^PXX M/4Y%K@)E`GS?;+9*ENT]Y>RUSO)F?U>IE`L$AB*R(,#%BV3FTS_=/8,W$B1! M$B0!:9++F2*!F9Z>?I^>[JGO10]3Q2-?:L*]'+P1#B\\@L9E@8ISX#O$O$^> M_SMI>V..XAU4-+.*CQ!PV1.B3$[9^-9*%MBKH0A(/:$-L"H_0&='3IAY-:O7 MN^+=(BMPN\LL'BV$_3K-9$N`#PJ@C\-I3R`<%,LWGES%VACL^UL$F]MIEUJ> MN!U[Z/(DJ^Z:-)5F-V,&)5=OB9[TGEZN7^PA6#VZ/\M;V'`\^`I-__'BCIBDW"(%AHO5-8B/T5,SY`A() MHU20<+S`SI@\'D*X05'#S7_X`P,W`4>4-R&<4!`#32L;?2X?'(V`D?X.IS$/ MD""T0X[W6]3_)F$+9DSP)X&N4!]JITO+18: M\!W%*$F8$^=E@RCPCV<:&62%3Q[2,1]]C''_-'A#+BE&?"?@.?$\PI01\I`1 M8,!D]%MJ+F#FY23_'?PQ"YCSR,B:(!"`@K)YOWQ',-*?$1L)C@)O=1%/*\FI MP,[(VO`(:8Q`P2L)+?2MN`')Y_#9S+")6%9F68NPY84OP9E+9[UV`H]+.CQL ML$A$;"2<.9!+YMI"7BXF4R;`"<+Z-XP;@,G@\^1)(TSM.9!(8@5D7:_%:DYX M@@P$$8E1LDSN*(P:0XDN<\26]ZHF2 M+05&L\MH'D#=H^U%@;/(HB41Y^S[G+E!S)IX385B>?BHC_L"7QA\;T':$>WP M-3_9(OH($N%!^%#+8WJ/(GSKV)-LBG"R=RXH$:D)=KX]N!1+-8"525`!O1#% MD[T&KB)Y<1AZYSGU(G"#XLOF[[MHW!'==R_UY,;/?3K`M4DTI(TZ'3(7C1GY M30W'J59*I-0?Y6=DDP]H,"1GV?J@Z"+=4C@T@+W9+7(8'SC39Q[[ M@=6BR8LZ`PUGQ@^KXZ0#X:8E%^H2+4.Q"PH1Q:?I(FU!QAF;2X-?8EB\>KY2"!V$23\'K\2EH$,8F-[V&X5,G M"\.&!51+5`5D\VSH&N^BH3&J"DLY#AID`@-!8?""TV`JY\J%+RXOLB((95NX M'$S@+NV".TR)EY9$(<2`_.I6DNB%IB>9Y!S@&3>SX?&5N@BJ,,\-/S5Q84;0 M%7.Z:.U&,T7,N3&<,C<6/)_+Y:D!=($1_`L?QL2L+[R_J'+J13\F#+E MF%%R4<1OXL6#P2`$NATN"KE0WD7??A>]Z,0AW$!#ZLK>%)'[FNNQJ^1;",#* ME=HX`)'Q#9((GB:(L4NE`9B\V4Q:?3(&[T)9%,,SF$6FL\Q7(] MS^?B'CS"Z6!:638PZ9FP@3X3L8$XI^S](R&*9!^=AJ$D7#GFH=&Y1N04F9QJ M4@@,9^+KQT0P#/['5Z'MM&80(H!>3H@[V7"7@,^*[8AT0]XH*TH`^B(2@.XP M`2AS1&?1M\LGU-PENR.-)1PS-68M'N/"_9@RI\"X3"QMV@?\'YK8A?MSBRG` M!#^H.C`BD>A$JAR9UD#S@"Q1OX&E:2U)$"PY@D2Z0V)3,.M(XZ]ZCT3B< MWA%$!T3#9)&0B6&AY.8!;Q[B\R+$4DY)V"O5%;C1!E+5AI7S/_BQ#_(E:#@; M9"NFE^,;:A$J<;QK'EMLM2"..K15@&5@@X,F(;Q(M=!FB432I:"'V-)W,E::G32 MBP\Y@9>.BO99XH`A90B*B,\(2;I:GBG.6G:`1MH,N]@,OR82,>>SQH=>J^IZ M773*Y8R>M<&30A9&?.H@1.5-:D_F(D#),1H19-&A<\Y$S1V4;'TZ+U_R%6-6 M#=RM(!IJ=?T;KN+$^2*[+#!-D%YOQJ/=MG($M>18Y];, M)T!_$0TCL.EQ;=RG2[RU0ON!:_B9\=V>@0VW=1U;B_DLX8[\D&47G\]9@&CV M?4X'P45>]V$UAI9GVE9B:*T15C`6N;FY4D1(%NC22W&W4QJ,//&7)_[/^<1_ MG4Q9DP1P:5_!CO.@?*IRUF;WO-XA:^"5KNJ#H=KNZ46^T+(*V]S,1M$`ML#(PEH+B:ACK@$\*N.K@[SYY1=7>U2 M:G0FCI_*./1KEG&X&4&64%(^<7T.?"+!5QCPB:HD M\KJ)G-*Y\YM-N-%XSEU*\6^QHT'KWIQZ#@M:GP#;@`$!1@,N.N^-&UWP%'NLQS'6FS":)O2FP)\!#H`]IDX-`"!`T2`PC'A MP[C@)/=+W=1_W,C+,P:ZS;I2/O#+WFK1QF:4'M[F=(P@L.E6H"TH0P2._HRB M%LW3,3.-B!P-!C+:G-J,_)0T'$H)@X$=YF+4J,W$`/$<)DF"Z:OL7';[)/XQ4#F.0+F_SUPD3O MO:VUM="C3YV.=J%$KLU__;7=UB^`#$R@%"?`6]8_`2.VNZ,4^.(Y3@:[EL"N M;8>],VQW!IW2L'](J/XVIM#WQ<`F3\8/BN<.0[6N#0=M+05WW2S'!'@G_+9W M@/76!2I@RE?CNY+2OO(/I'Z%R/^?RS#S-^"%`E[9BNB?EDH*K%&[)MU`S!0" M(".)=YE)B@[4K`@!Z?6UY0/6W\[?W(NK^';^#I>*`19#<8T9E9CP0K0"-.V; M39OX+32^LR!Y[HV!GS;7("I?E&`W=*\K32'HDP"ML-K&T0W-FMNURPS6!%/X MZU)V0V*]8@XT"*(`DZMLJA\1TJ_B:A;%RNF@#E-H52K:0`=H=`%,4!>X+,;8 M=GA";":8%\\1QP3!8+4]<""%YXI9LH65'`N2J3B(*BS/!1.*3"E-$LX@>#PKI-X'W5`5L9')(1;Y$"?W;[0[4'ECM>7)ESF]99K&JO>+)KFNL7 M!BH1CVU!<_SL>18YPJM:;*O.U;J#7K_7'F;7OGVF!N%`T_2M..BU1^WNL+ M/_/3?G*KT^_TM`P`F0$/G;^4S-!&H[X^*#T_3WZ@D,`&4*Y=ZSX3A7@O0@B[ MXT?O#_MM;52,G\)9C@UT":3J@_:HOQ_02,4WF+=Z%Q^BCA?*Y:\!179>*ZEK M>YW4JEA>$0R!(\0#O%W@V[=N\FKZYL%BK9\-(Y2?MR:KW4E>:L/18#`:'7.Y MMVY\$7CGY2:O5K6YK6Y_,.IN76W!O#59[4Z;V^KJPT[WJ,O]/*?R=/LL-WFU MLLW5].%@U-E.S`4SUV2]NVVO-AB.AB7V=]MZT84L6`1WLSYBO=@#]Z4]ZO1[ M>@[.=/`#0=D-99T.>E3E0;G.^$GOZ+`T5/[QB;)-5D*8.Z'L6U)[EJM*=.@] M%\^VKK_;P;^;315V@]=CAYRDRIU@AG_PZF9IF+K/, M=NGUY=)^3K$F/N$15I(I8G4G$@5N1-6N4ZPKG1YGOW7%W-6N$OWRX:-;:_40L`:H:C`Q?]\?/]O?+AR^=/RN>[]U^NO]Y^ M_N5^>4V)YJU,E_8[&LCX%/2"&2J'<%?D]OJ=;K\HOS(R%D-ZR>)W)[W??>=:XSE_%OR@$?YO30 M@1F_/&:(3A"8$H1Q8?HDY$&:$(5W%5,ADY[>4;*\J(>SG"PD,F9S?>T#Y8&Y M>,,*LTI-/#],ZZC_ZA(@][PV/-#U]0RTCFDHEQ>8=W3QFHX(*8?*GF4`L^F* M6"HGDPP^GN`J2L2&GO(!;Y)I[=;_TF/76*P1K^12Y8@O[$$4RP^4^];_*[[, M'"=:.PN59UF)='A1BR*;:[4,5"PV@KAL&SG3N"Z>]0Y;XK"0%>)[W5U>7-1HS]8?Z";/_VE"YV%2TP##/$$\9!;F_<1SOE-1LR> MPTV*5V-C%P#7HBRW1[:\!#JX37HDXP%?YFAZ`HH/T(:)D6O3$,>&0RP03!FC M^@8%]7*2K&'`,UTF2M+T,]RXA0<-D5=L44OE<81W,UAP&G*4Z<7E1>[_>1'0 M`MU@`IO9$ED`NTC;T'M@='4P$6Q3&\L@T27L[:\OU0$ITR)MI;W(M>MB@L07 MZH^$UXQB4?H_)?O)36Q,GT\6D"F-1NV7TL-E,Z]#`)X_"(W`=K&J2<`>N-IX:V/3>Q!*H`I4<<4A*>$L;DW# MNBC#)L+K<3""OQR71!7 M%A`7I;D:21.ITT0?K$J`KZ%N&F=@;E%-Z@_V=[Y1P^Y0_XNJ_/?"\KWD2VW0 MA>_>S^W<-]PD0%!S7^^8C5.U6Y7XAFE4DE*_U:0?35KC"9O%B*8VR]Y>/K#( MN_)ZQUR'N<>RXAEO^UA[[L`5R/O!I MH2Z!]6J@SA;!V!'TS[D&3U5C/3/ZN19Q^":46@3X?N(.$,)NH?#U,_W#MBSC MSO`_^R3_K+_C('?,O^>MR[9O22>[FMM?/L!ZKMK9.P3EICK[T@HVJOJE92\# MQ]?:T0]TZ"J<[_7KVO8>UTU)X23-D M":.M*[ZK"O\71P31UJ7;4[Z&Q.!X]GO'-`N(`K M\#Z>=,^DVF&[-]0&N;6O';\IRRZ1=#GLC[J:MN.ROS!158VDQA;QD3[\>7(< M>;=VAF,#O%OJ^"@G)G8%FM^`ON.E53>!3`^*YXZ"XNP$1P5V-_W=ZPSZ>P.< M+4:`-ZHWP9QY%A\],!VXUUY+%DL3G0#T?15%.:AYREG:$_FR(/MMQ0=8SE3+ MO!,GS.TA[3'/0>N.1L/L&K9-=(:EE)#@K;[>UK5<1L0.2T&U@:;[BI6!AF[P M!4LC1@PO`@7%>G4'4N\,0,5F[YH535$18+N)CG:WTQT.2@*67'4I?_5KFXY,VOQEX\T]OFIT]%Z7VSQ;;9*W?->T>X:KYW^L1M"J:\:?Y\SI@R MVYKTCTC*M*5UT^V0S>+J\?G3>GZ$M')L^,,V!&Q:[M9\G9T*8^PFGX8'B:>, M1(H%U=@+0V^63",@:?&O?U#T^?>_*&+N7G_/N1.R4U:DQ#YP:(>"L0J%Z2'. M`0Q0BJ[WY!OSOU[P?R_60-U01B[,MH^Q4?6 M\%F>:3;*];+X694C)]Y325EUH*P5T?L,B"MC1H#)-WZ`/?;`V/S_3).QR21K M]PGH$<2U:\E(USV275NC`W=SM,MN?C&>E"0E8O-.BL72"-O6CAN4+,%V'?#: M3B4.5M%[&-&\VFMFPE(R]6B_J8>Z.FAW*N2IXTE%21RG)HY13]6'P_H3QQK9 M^C0%&_\Y2];?//]W:M3"L]BD;*T>A$KXJ-OMJ.V!7G]&DF1R3C+IM(?JH-\` M95RM+;LM?%![,?S!=GDUOP<,>%<@A>OA]&YS*6O`@KN`6`V+ZAU5Z_<:ZH-* M^FL\_?4UM=T>-)3^RMKIVTWSBLV.@ACS"[6#SAF*Z`[54;==?_-'4L<9J&/0 M[ZGM7G.#$2_5./["`N8_\AY[WCC`=BHFMK*59G(]0:R$62][';6K=^MMIKR6 M9%Y5"+JMO8LZ_.I MDRSM>^:`C_J@QK6Q>-D,:X91;KIM^LCBYG&K&>;\W9_YF]>N=9U[KYKN%B/8 MQVS.?KE)S[F^G7+J];X^Z&9K^>^Z/J!/:IOHALIU6O3L#HPN$W-B-R7<9]Y- M7XW??,'E%?5O08J9;VDIN6]SQ,UB*5O[""3WP@X+UM6WS-(107FI]8?E^N6?E^L9Q MU@WS\=Z?:+87Q%PR][&#,C'"ELJC/LNT1`:N!`V))0[C)GYQ_\%U0^7J6$H6 M.0Z+_,HK1&!#%X7]:B(J?\MKOII4G=.R8=5^7(K5"S)8DO+A./)!>#R!`KJ4V8_D8C<(TV<7 M$0G^_`1_2.U1YE7]XR9)RE)#$-Y8$_^FP&?_!S7 MZE9S)6230L-"Q.#U*;RPCZX]&JE8:I0*U@:\S.L"Y4X0S:EXK)T#MUFL=?8- MI_KM2==BW$4,W863R(DM?^HKG/8'7@+1)/G`\]$-/`]KR2MIJI>SVQ_0#7H(I/ M7A0JEQ]N/WQ^K7BJT+61W-L-*",(]NQ6M$\%G!@T3_$E3>Q MP0`*"+[.6+R`>V",J*N&A;H!M!27*H+;T*%#U2T_!%6,/=L!T;&[T#/@&PD M#N+B:@K_S^'E>(.0[[D8PE)1>"<--53NM06D@*ER$'?$1*L*D_>4HZ+6-E"0 MDJGO4BS*07&8&3?Q.[PHBK#3=[!=4V981`2),J9-YXU`8$)8,Z_"GGE/(*)I M043.^/67JW'/>MI[V&?#?:#*:-Q7;A[&SRAJ$U2B]@Q]$S2L< MWOK"!D/,]GGE2Q2VGH_.$?@Q\`TVAIDHZ!!A8,%7>%,*'F&Q?3.:84%LD[Z@ M]C&,RTBRW'#+E!E"A>*2S[*FKI/V<.4_/GD\K[.`HBQ.Z:;B/Y)B&9SCVIZL$A<5$M3*(6VH;$"?5M\*(@ MZ>YC,9B3:I&3[*>7P?[$\#A?IA0A1Q`A5!GQEOI<\8TD4GK'0M"9Y.?\EJUH M_19(!DOJ`=7PRH=DH7]@!O;QD`)GU]`+]0)#&^CZ_J;5';25TKNAE-S"0>SE07B5Y7D$[A*>2":%RB^M='23&C[Q0.YK+%//;3>#&P?<7",_ M[,E3F",X/V.O\6"IPV4(-?LBBS5I(;0$&0&&MBC^EJN<+IY/OH,_9@%S'M.` M+V;FX&.V*%;.`PD4ITW;BB4X"KS5122#I^OD;K+HUP7FUERT!Q;F%)_#9S,# M2<9?G64MPI87O@0GR$@W,,ADNE*NG<#CX3)TR"WJFIZRG9FRW82S77P0E9'5 M28G4S)0)<&E\3@GXX0##7GIA@DHT@\4*J+/;6JPR-(SC)8)N`8BAREP"GBE8]M-_"B$&XT:XC^4O\A/%II9]CBB."8*NR3@3G(S ML;E^O;J_$H9].DKN9=OES2SYA,!5W/-?"JHF_!XDL?JG*<-^6J'#8NXEWYM# M8P>_(^P8Q>6":8(!?SP@CZ/_*H_.H63B\37N=B8EHX2(%`=FU#<0Q8HWAHT5 M!F+2-'"IN9R(_L-((3=/KFLOT7)@?;I$\V?'2$*;>[WYE#E8=<5 M>YYL'_P*>$H``\(N6LP^.=5B$,M)O.(0X^Q?K1YD:/^*G?*:8ODVXR.0; M@.T+PGU9F*;A\7@8.VYQ&L9]'>VD""^B551C!M$Z]0*2GK0\X0(P9X6@KC!A M2+0-C*E7S4Z7T0A9[2ID/:$K.=V)R/MRX*'(2_$GCM,7@;PV?<_!PG6FH&6C@56>4 M1M0[]!$M@!0``7X:E=ZODV@^HMZ82'-3%-Z'Q.+,YSID;.&F(?W,ZL\$&YG: M/"=838Z2YJ*/`;$Q-O]EF>2)[$D.,`EL2^H-T'&RD+K!%*1A"P_]%)>;B5PL M@J3*)'EP$3/)[2[F4-+;"KU-:2$>.E/X5]8$)M,[`P^=#PU&0^+R^`A;R$M^ M[#@Q3!%JATT(^'>1FT918A%&Z'`7VZQS)PH2!&&7W`XG_(IKO\32>?T4N%Z"D#X!23)ZX,V'Y;0$T:)U3X:!@B0WCP_H+/VP, M0#9;TF&N:3@^HZQ[:Z#CZF91&#=OHZ9[>/0%)D3$SX7BV";?%V:UP,;S\;`H M/0'+OIWOT9@Y=XZ/G`O8_9WMT&35@\23[&!TC-&([]`8!V8780*$F'>YRS;F M4I=[VRV)V!2&T&=&$(&URM_?<,*(=BE:T"L-WE4.XC("DI4GUJ!!\:?EO:/G MZ,",1R9,D,'"J%RS5"_7"C/3MJ_DZI\HW0%#/VYHMV+\-D[,G=G<2$O]\Z+Y M=+8QP3P=$=E">D^\:[[Q"3T7$LO6#@#UV8$F]`T0%T#Y\F?,LB,PW#RLCK-_ M\P#1Q:45>O/\F'MW%=C[-F=94%8A2>J_]TO7?Q=0ZOJ?MLV[E6;.6/C]ZP;W M=W,M@--7`5J+YO@'L;CR.Y^K!'$(^SS/AAP%YJOLI+"[:=^89AW[[+Q2MJ1(9?W!UN%(6U%$N8E>H].-8PV9:D!47=YBYFFI:FMH>==1^KSZ% MZ_,7"/T?#J'Y)$0 M%O?G34-EK20@J,0!01[UDI*[>A"J*7C558<#7=7T6K"JK*I<8TIIJYU.1^T. MJBS+=S2A?G;SNO%EF=_S^Z.8X!L?WXCKT38+?E#NL\<5%!5/3BRRAQN%IQ>X M;`0C7GU+%+BZ1B2<7GC8&5;0-SC&/#*DX'I35:F36Z"88:^BV2-EXL M;4A/Y=3AJ3@]9Y<`E6)8>`M)W,4K\'AJYU0TP/9J@J%UO"B8[-LH2?#,X;6* M+7QISDN3[268;-*^ONM1?2=#-KW1S!/,4Y`NQ\.3V4?G;2%K[H.M( MR4Z'WCRKCO.3T"6L(AVZV>);N;JV%I#U*FUIM<,U@*QNXF9(]E?5\<'[.HA+ M61I[H.D^B MT!`O!>)-P6#E>M\>#+B5.8YU66]TY,MZ8II^OW+WIY;>^6%7\&IT'^,9W+2K M]-;<)CW>EW?C7OR5)'DW3A)B+0BQL7?C3ADHRPCNVA]D?\X8LSR_]O.\L%.C M3(JO26Q:T]6>-L"Z5O4W@R2EG)-21NI@,&P&H51Y`:ZIXC:*&#:EH)+?,SL(L`JUZQ6T M8I;\51/^ZJE:1U/;VK#^_'5Z0JDP"E//.U%-N_-T]C#&L[>BLZ+\(S;A\B;* M#>_42S6BOS#>T/'.\,.%E.HUE>J:VND-U5&GRF2<9R/5):&D,`S;[49'-?8T MKK<=$C9*3'.+^]K\([*#PKY-,MVM'B!6)-K;O9$Z[-3WHHF\ZU1;$"NB0+VO M51R2.>5N'WB?:1G4[K$33/9BEVY]V`5`42PO`E557WY9!V,E#*,/U!&8XYU* M"VV>>,,E$3:<"+6AVN]U5'U89:3OE!O>J!3YRJYF;<[W'NB[Y80RT2K%&'N/ M29YU0%UUTEH)/-!CPJ"PMC&E3;GFO?5P3^Y\#_;#Y6]7!EM?44)9WSJ.&NZZ-?]V'U![/FRC7,^;;IJ%<4BO>GZ^O[U[3_0,6 M(,_9P10[^BWHW0])L\G,)MYC\H*![5#?>O"/X\:S[(EMTI4*V7AJ-QD:]X<%@1?8%O4[ MAF^-^1R$158@VO`8K\&)`I;VYHK_@X>B(#VI8LV8.=X3O_AB!`$+L&4NW9-E MV)V2NO?"?HZ!D&SLGTROQG.!*,>F:'1G!GO%\F?I-@R\:<^PG:D`PJ4FF`@R MNH6\77!"AG./1XYP-)\%D1,227MS;"R,*8R-(Y%SB?$UJ_C9\ZPGVW&:AL8S M(WVT=%_!?> M*ST>"J^MS8!1J3`O0H1/?[(_,>M[W$A[S``1KA@5V\=31^B)'9@P^0*LKK7- M7I-91*]QO/,39JPY')U7^^7-CGUL)4O2!F?[`Q87XVD"TL+C+=P3"82-TTGV MV"'V4YQY/G;<_9U1-WO#)9%$U_?"E;ZSV*6;FIC#-)'+WQ<]8N%%7&/2-=B8 MX0X7+O%V(J9.A:(:[PU6%B!I5;`*=1U8^,TJ8(4+2Z$-LSV..;0J[V'YY(&L M8?/,YA-]B-N)0"A`'&.6]+$O7.,UI[&E(0*2[B"'T0!(+0A3J*"XUSD#P6XA M!OR0]^]DACG=3#*&E1)$.+6#;7QCV1;A@[2+H00@)"=!Z(J-5*IC#I"5U,_\[D?7GDDFX62?#V"`4?(PRY-])-?J71/RF+U]>W'[X<@^J'"=$%ZK4\ M=8Y0;X,YL]&&$WB**7S/P)NQ-823]41Q=.9.\?T@"U-N"3&-D3\+),0M`,#, M1_;('*43;VIFNJD--KYO3A>5*8JI@8I"*H4:!X_`OA%2+A?VR$:12-/1(.=LC\H' MS4'>VYH+)=L-0C_B.W>91FLM\%4>B3\#+E1#WW`#E`W8]X,!OBB%!$6?-YD$ M+$PLRI@)N;]0%"@(HC$I"A0V`,:#S_@+@0T8-?Q8OP1HD;HLI(527/B!GELG M;V!YB!UR9`+>GL1?5HK"'TLM^+@G?$8_$HS&!&?_FP&/^PL%-@*VHZ/F'+GX M5?23:/&(8#&!^(V_$$R3MNT8?F&HTD/?"^8<,."IB>A03]:YS\7B2K?ZPG7_ M!O:U1RS'`SE5JT>FG__P/1?GQOUHMNOLZ!2'$_.#/RGL@XW"A_.*%3'F7JJU_X'L* MO?C/5HN_F\R7&8"_CF^G+R=3TI$#_/&%3?YZ8:(IU-;:6NC1ITY'N_A)2(GJ MCA]VD!F'WA%'@`W%!9/PKQ<3SPOQ(L7H&[=L)1`GMEBU^_BN4ZEZVVV9HE#S3INY#%C?`!MSV`6S3_(PAA\ZD(.\K[0H>3=M'\"B,R<`LPUB_9S)FT1BO=+73 M&:AMO8V&*GW3'ZBC81NM8;"+P80#$\ST`C2="JRW#V#W(;`NQLIS-;?2DP:Q M8JU@66@]@S(5$9(.E1KHZ%IFD3EA3L:K\-YR;VKJ<#A2M;Z6-O/++1G79AK! M-+]VF`]@ZPT'R=J[`_BJ4W+MO\(Z^>HQ,A_$$8;X396,8HI&\TV81[XY-0(, MX.-SM@NN24C'C@)*#W#8:V$L*UX&4E?\6AS]3O=<3!AC%$G`!2N:^:8=L!PQ M]#+$<*5\7099S*8JE_C7Q0U8\F3XB&("%_PXGSPT6M,C`Y/22KE! MB\<,\>9M6B9B@2,LO[X_!TO$L,MREY<$/@?CCCX=:\`>/-C@1G*_DJ1#(*@- M'A"OB@.('+H79*8(9XMV%5;(HZ0<>#3(GWP[#!F=VL`,>4:;&;@\ M"UQ4_O4R)I8D!Q8RSF"O\+PF83QGD9\KV=\/=,YVD^9%Q;-=7JS[2<0^#9`< M=*13^/+:WRXH]^,N)J(LI30NEG;NHX`U&Q2+APT;B!(-`_V1'R?,\2"`"%7C MER+*DO`)T)RF]@>Z.NCJ&>F]CKF7R5-N[2Y;NY9]XKW=Q%^I_`9.([V6J+"L M_-9[?XI%G!N1`0!_I8KB?EE#E-QJ-3[@M]*3[?62`EX!F\QSG07E#_'!2>S9 MRTKE9Q\+]W\!I>9&5#.7Q];2?+?TT>O(HM2W]"CG/HDLD>S&QTFQ<1MHV;+3 MU236A4?V*-VY_`=;1%.U'MU()"DXB7Q*.\BO.8@`Z?DECA'+#D_0>/3L!&A< MCDA-`(SR+>@428^*1?,X.:=Q#*$6M)P#N\>,'&X1S85UDST#OKZ_ M4?1^NZ6U6]U>2^LH[U?&@)7YS`CC8'K*I\"6MTB,R)#W7#3`B+^)%G>M:]'B M3OR4K6_U-+71H.:YIYPIQ/OQ>$A4#IA#/$/0];CA'V(2\79CO(3;9HQO%<^V6CIJ9_Q@P'2,($A2D96(W$D\ M1N=V,)UPFQAZ)DH)^;3V0^&8B M8P5!C9(`1(#9,]RE-WA.]@J-:XS%6K;:R@P2)(C*`CVA9P#EH'14%8"1W[!0`A4UQ&5>$2>+L9M+/ M^_YTN,9)V:/DUX*(2G)2+@Q3D;%[<6<_/"Q:;PWS]XO"%Y<=CEV/<JR8G MN3<4+#1LWE87.!93E4+C.PN6CVQOZ;>O^-,=/K_M8)92;NG77]MM_4*QF(FW M%0(\/ORIG<*\-.X1(-,2R+1*(+L&2R,,5.4F\GW8XV5P^,_BQP(T;05AT.X. MAOHH!20W8C5@:)J^#8S^<*CU-&T;&'<^WB$)%RKR"X;90.0A[ MA(:X=JUD@(I2`O+GW.*TN>']C%:EZ)G/7?O?YF(;O[%X_Y:.7/L5GJFO76C9 M\_.8Z'CB90SQ^8_/#SIIW)[NT3B=7;Q/<2)PDO!*':`H`XTLI*07C@A(XR9L:^\V8$4FM`KZGGVV#E''Y-RB5F9;B>59!J'P2V6H`T&HJ*AG=]!6 MAY66*)22]WD22K^C:B^O(4_C:X9_B'S7#B.1".]-)GBL6+5TKH?/+R MG9HDE"V$TA]VU.%0FM%-,Z,_8CU`PS2C620*>K&YSTS;D*UWZ@MB)3Q[J:DC MO:L.^U6V53O"=K^6E%^YR^NGI;6.SQ=VO<:-VC;<4$I-VX/-"TW,1+W2/'">OXJ8<#OF7E6Q*_SI"<= M<9E_O,BZ=`MULOF,!$9F#YZ_>N5P5Z;:?%-GEPL/R56++RQ@E%7)FX<\,L?C M0&-%23=8O1D3OP`3O$L??\^?/NP&3[<]:`_T=$$;ISK5"G:ZZ3/JZ[K>W74% M_!),\66;?2[[Z/UAOZV-].5K-OM-6.):CSYHC_J;)KQU0\/E16/%+"4O\:0O M\O?DW1U]G3:IW=V=P3<[V;WE.HF#.EW:R5"GP:F3"J!Y"\/!&R+QQ6>_LKFPYKWR/52J4()K!>S"*A1=_^"V@H&PI\_H@^*#;0`<*L]W# M-!1(JCHT\R+F7ITZNU2Y'J%D24X-O\=SM)/8[;1U M]$23I7EK3PAQ::W-^W\2;&Y@S?(7]XX-TMZ<SQ3;>PC^8Q2PCUG"=>(':D]__W"-IW8R+U^3GLM M9:V4M<]X1VK/?\V0M=)S.-!SF&'?Y'^7N+(D6>I@9-]@;S6LC%]_OI(;7@EW MI9<#Y9Z_D#V73"XW7&[X<]YP*=5?WIXWB,EW=(G.F3?9^(2RC_8CVQ*DJD/* M:&45P.N_(W\WG&C+09A,%)5$5%541-*2I"4ID"0122*21%1W(I):3=)2_012 MC6[/"``+JQ9NV9&S%R-F3@7YN&$Z^=5AUZ^H6@7#. MKJFCOMIN5]GY2[:D>3[4<=G3='74J;*SP'G:5TBJJ)`JNL..VNY765%?RHSG M0QU2HTCJV*!1NL.AVI8:15)%=NI>>Z".FJ!1RC8M>JZ.L])2[@TG^L0L\&V5 MCQ]OE/LYD#SXR7/#]BOWDL?22Y9:JR(0*FK-V1F-I'DC"66KG:.IG>%`[0WJ MH]2DI5,G`M'4MJ:I7;T^EK"4)+4D%*ER)*&45CE:!U1.?42*5#EU(A!0.<,> MJ)SZF"3RB'J3IWWG.8M'VUTXRK5C>E//46[\A??`G,K];%/ZV5*7U4E4Z6J_ M/Y!&CR24$D9/&RFETC[+TNAY/@2BJ3UPGT;#46WH0TJ26A**5#F24,JIG-%H MJ(XZ>FWH1"J<.I&'!G)D"$;)L#;T(4^S5VJW10'`SGSE"W/H"G0PM>=!Y6ZU M]=+1QX:2$(I44QF!'JL5Q\ZD59.GLD[38`%H985"_0*W64SM] MV:9&4DJ)$Q]UV-;5[J@^B=GRS*=.!*)I:J_?47OM^MSKD**DGI0BE8ZDE+)* MIXO7G67^OB20=4IG.!JHW0:G\#?S/OQH%T?PU@T-]\$>.TPQ@H"%,*P7*D$T M_A&0&I7WQNUUQR>*4OA#&5871+*-AA:DD`D@4A)(@E%$HHD%*ER)('4@$`:)$F>U4'N M;L[UK=N:^Y[)@D#YP@)F^.8T4YGM'7MDCC>?`62MC_8?D6U)MUNZW<]=^C%NEWKFLY%;7F@?Z8;4LZX324I0H"W$T@"CW-^WJA$U)CS4`40I)292U M`U$2I23*VH$H-;>DQSJ!6`1X]D(98T>4Z:K*`X MW,GQ66F56DF*=2%%K:L.>OV#RM!)\2AI4JIL29//FB8K**TG5;8DQ8KJ@;9' M[8J+^)W2<\W$(-Z$!B"I*"-B.8EA4\)"$K88^\J;-8,E2#*HKAY'"T^)N%#X M)O[UHGVAF,QQ!#*2OX.Y8<9_+Z57M=M[(H<'8.+]";UY-O:R-,DP^U8&,9L3 MN[X2(+\`(%^V`+(^$Z,D(*L[M!F2_5-(+HW7&R'>D@/#B7T/-'UVE;\9;F3X M"T4?J8K>;@]4)9PRY<:;S0UWH1CF'Y'M,Q"QBL-[0BH3(`#E?NK#UOB!\M]> M,+=#PPE@`E^YF=J.Y3-7,5Q+^=6U'^$1.UPHWD2Y]Z)PJGQP/-^VC#1;Z8,7 MN1:5?%256]>\RK!7\NDK`$2`P%CPH#+W`10<,YS:00+7DQ$`E)[+6DBKRH31 M(Z^`EM'F(H@T5=/Y7\'4\`$_\(#IS68P9A`"RR'A1KC84'DU'%%Q8N5R;`3P M532'AQ`S+(#AC1"^FABVS]_@L+#\6.+YT#?UVXQ-]L6(NK=-KP MS`+6,0$&IM=]9C)['BKC16Y?8$)C/O<]F#[^Z<.[:Q``CO<$/$U?!(:30#:Q M_2",464!!CTK,L/\7@,N?2:V._1`=L+VPTZ"T$#@8:)7NL`E_(HO\N$\OW!% M[P`M\!PV#S6!]``H8"/%-<+(9RK?.6,&FQ_BO%@)%%:*\@JP'Q"U&6/;`=JY M4KYF8'RR'0=6&7C*F*U""[)I83B2GG]Y;SX_/(^8\YV0TBZQ.S;--0E8\?;Y3+](O7),61):*` M9(?)_-``P63Q5%+D-69.7<_Q'FSB)(=$(3`@J`$767(.4G&-%%\6UK%N":>^ M%SU,:=ZLG$>M@:-RV$`&^'/)F)(QC\*8YMD,L$]D!W4T,K^&>95,=`0<8KM8 M'SOA'N/!9PS3N@]@UPCP8*)*G#*LQ3W#>FDPPMQS%H^VNT`M:WI3#]2GO_`> MF+.K92:J?!.G=]MEK2Y=[:VQNTS'"]"RR4VQO\%%D"=H)(L"S2G;8D&"5#L( M(L/EL^4MH7Y^00F0\;[-`*<(;+P?0!)@-X)MFMN#283&$#=*"H$$ZG@']M]L M#,:@()!1GD```7.'T7@9BP^-+F[Q96P?8=N0(3R#C4D?2J!3P!8GNQ.-LQ@Y MA9!=HXT&2X^<%2,RH+W,H4O;O/]+YF26'@98$:)=#$*88QU-IY7!!XT@`L3" M9&!99@'A%B>J'M/'*?A.PVJ],3"RP6EF@^$JU8]4/T=1/];9_?^>FO+.JOM_ M'ZN+MS8I$S,@VW$WV9!X>/9**PAD1#,"<0#2BO@XB.9SQX8_2%X"7P93>PZ3 MSD%X$@?#,[^[WE-KZCVIL6(,WLR9/P/.55$+@$)SL0`H/1NF14#Q3SN]..7' MH0C\WDJO3%7.ZV*S_@7+M">+,C>65@EJYR:+AP.Q`\UW^KL0_?LTDL(58;8! MB,*^S\G6R>A+I*4ED>^"(C,-WU^@MA7Q!(KZ)'W(B+16"6Y-WQ$,1AA(CAA( M"5:ZD-1Y2\5%N(N\2MA-\`\/DOO;CQ7$-/UAY?=WS]&AA7_QQ/C.C3W'VGX4 M9'J(?H!*ORA[K)$HY5I=AEQ=^U8^WZR43W_3>.?]RZ692FJ7U%Y`[=<9;?)L M"5Y`NO?M>F2)<]RN+VY85GYS_P\L186YN*[",X^,L[YY[T]R^_M$'%OV>D=3 M.?H]MT2/Q,QGWO*CE+&L%WNOV5;R'[8=O+_4JC3E,X6.4@-64T>=^K08WY5Y M#FFOTA36Z4BVJ1Z$BOBGT^FIH_:HL?SS,I1/5W)0C3E(4WN#YK:3?@D:J"?Y MI[;\H^L]X*%!8_GG96B@ON2@VG)06^^JPVZGL1Q4>4'.1C#55\P[H>3M"EA+ MEH(\`HB5L&=/[7<[ZDBK,D3Q;,JET'%7U:=;>S&,K%-R_EM]21[&$5FE@;?Z M-B5W)"AJ7DY?MR=S^BJZTY?D%.V!J32SJC"E*LYO7J2GFZZSR`\4BNM7\84MNJV6S\PZ.'NNZ/./;Z*@]6`8\Q]NDX2N:\KG>F<'F"`> M^>PKX/`MR=`%ORIH^O=?C<%>_WH M1X=6T_2MT&IZ=]39"=H[8S&C?$P@B6N>+`J$8$[Q\!/T2[/&K M7SWQ8O+>M6LE;Q5@76MKH5<._]W^8)1!?[DIS[@X+5FJ!+67!^H=FWN! M+9*./>)/Q\-+MLR?B7S20L;DHNDP":*W1[U1;XDGEP<^/J1E\*EU.UV]+*1< MS#FI<%F&Z]8U<4<8*";Z]]:E5S[/F6_@I8R,7#I,1HQ&`RVK6$I/>YJU["02 M^NWA\+"UP#O>C"F7'[T@>,WOB]YX>`LF0BM!O.JY`1@`8$8PDH#A0OG$PJEG M*;?N(PM"DD)TG1^'^FI\1R7V_GOH&V`OV"[>-K@-V4QH-AC=]QP'A[^EZV[! MBC3E(R%('P"@%)X4G+<$#7^.)OQDNYX/D,5#@@C,C$!YW!GP#Z,EEI:>]3I M]_3<'IP*=+F'Z_9P)QYJ=3K=0:]_YCU\QR;,QYLW7!P7FW_Q0U_@MQOXUPYO M]M48=KASX6A"4TS*X0WF0N&>+-H;A:QR7>D`5R-?Q`@2WDUQ)?+X/. MWR9SX,[P/_OW(7I49!G<,?\>WRF#YDYV$;>_?+CXJ7W5;F_YXB7W0EH@)K;]UYA\?]<@P%F#V`!CINZGG M6,P/_AQ+].LP].UQQ`-)X,3`;A3P:/95\>(>X@-]QWY_F`%W==P305M"E&C: M<-3O]7N50RLXE%Y1_O&)8BK_W'<-WXAS4#'PI_`BI>>BGKC^;@??,GS&)]J\ MYD&WTQY4ON#K]';UG6%;+6"*&X-*0AU[^>G,./&M*Z8MA8K.L#_LM[N58R/O MOQX;`SF!4&;=K26GMRH:,,UH%O%[FJ"6;=,.C[WT+PP+*S#KO>&[8(H%I58/ M]H.N=;K]RA%PSWSTW:Z5.S^VBDY"`'S>ZV36TH10/0U4)?A(U50L^(9:9]00 MP5=F^8<(OEZO-^P=`1O5";XR&'BF@J_,TO<3?!U-ZXY&PT8(OC)8.++@2\,> MBKC]I5R^92[L<+ABZR=>OWA2/'=8(*F]''U8&?^HL.X4,-D!UI1*R)7ZB_(* M/K[];RHJ9"G)]TFA(4OQHC`(#3K'7#F'R1'(W@<8 MF246C%COY97PADHNCW/V+8?L7>1CN`\<>MNSQ$&-*IC_\YS'%]]_Q]I3`;-V ML`[X\'QT/C@-3;^)<9-AM_%8M6:$-M"7A,"%+L=`>YGG1,J(KSZ##ER/JH,/+"-@-$X,WU6)X>/AOK0<7MZ%:C8`M]X6)[YH M)R?5.DW$V^4O7L@432\\!1.O7;O63>ZEGA*C8 MFE\+$4A*7O$4*(^G$P-8UZ+Z:2[)\*;X`#<>0+P/\(FW,R\?<.BL#?7>('L, ML\-\]5ADF%5!25T!5UDDF5?G">*UFI@#O/F(A M91@:XK]X:%X"@(J"R,"40"8`X/!EPUOGL)W)*NJ`NNIEP MZ;%7>H;]KME>OOC]V%GQGWO'3N"N/<-M+F5/UWQK=XR@/>\-+>G=UWQ+#PD& M/,--W2744/.=/3`R<;+-O:,F0E9RFH76/$^QY[<)UIKQXD7Q'EC5F2L(!_@H MG<&@F[V"46*:\ZRE3-Y;O]O/7DC;92T[,!V-_W=^()` MWA^1QT)2[19Z%-.W"GHYE0U[(/XJLRFKP-EQC<,#,56AL58%KHYM=1V(K:JM MH"I0=@)S)H^U.VP8PZR`WZAB(AZ-[4:>#`SYK]ZMC-_`"S^_\6?22/]!LKFC MZ_U!)ZO'U\]TJ@7LFS14"G9^(`#TF$F&*7FVO>'6:-Q M!8R-*]O][*>2559RH+/30BO:PB.<%%+2<&_4K]$6GNQ,;NU"/S'_@?FPTNNT MZ2,_ZGIG!W3UG+Y(JW$$RC^P((="%3E6EBR&RPX&+DAVJ,Q(26&/K9+SIZ5" M.B?M@75HMP$$V*#&97^]F'A>Z'HAZW[+--G\YDV^W;]-*^(8^*E;V(GM>)^N ME]KT%K>'VU8GZ9CMLQJW[T7X+H>_@K*'I^WDENU3JO,"0&U5>6)+_6M=Y3KM MN`HRX\XQB'JX&%`N+ZC!&_\C>?+BM?)DAU,%91B8!@SD*>_1KOPWH!,-/][% MFB(K[A?`71)DR-UDAV=X-T+OR069LX%J`9#57RY>JXJ!S6_PU>ZOX)2PD\,C^D9GKWS(P0!-B3F1T$'D",20Z`1P3XU4!M#P=JC[]* M*=$J=@C'CHLNNA)C7&`\>@JO%_GY!K&7/9T2I\E4G=KF%-;O,[X'N)+`]+VG MI*S5//)!?Y!=&R!\B`QJYPN\,7-M\%YXGD[:\S5`Q&%=,AJNB`J+FP@GJ1H4 MBPML2]0#`#Y98(6LN@6+*EU!KDQ7 MD)(!KZZUIJ6QN0XB;,-L8[05J&61Z["K=MM==0#(I;Z8`>P#<$B,A\"<,BN" M)8R9`RC&UHB&'=\Z!P0#:&X+D%<(T&]LJ3_Q<.*FT@3Z+69X6MZ7B M6IV;59Y=9=VZ7,1Q>E@2:\OB3!&5$9('2)]%<]Q/K4"`94CLST%>E"'+:5?P M=%*F`7L0X==(CUB1,>TFSAQFQKR"?_.[2ND$*3P$Y5\4H,?+,0U6]+J`2(TG M"R*@'IH1R&FUQ7H*X.8571)ASH%AN43#1S]_O7G[%L'Q7)K*-01!4%:`CX`4`3P/>IEE(+N" M-9UY0F^3E`280ON1.L>3YK2,A9!$"WP=CP0!)_DKY782 MTP8"*!:1>K5/-NAG6('Q:-A.?'T._@Y@-Q7>:);4-:`HF!BY'3.P![+)^[AZ MKA6[6X`;%N)RP"P",+^@?-:ZW2OE:PE2)N!))9%5RIBK7&K#UPH`'$ZY)D+! MA21.E6L0K3#FG/HRN]%,$<29-34`.ZYISY,&ZUG%AP9%_$X.<4@>*SRUID-\ MG@(1`Z``'FU+M'`WQMXC*[=\)(1`6"U`K$9,D8MTP4+U8>D>!UDHPKBHC^(_ M!.;A93%CF^*NH!UUVF\:!_>QVW#2Q!CK@X>>2D8H`J`B%H`3G"@`"@3-+#I9 M8[]C=7W7[6J%;($8?39R_FN&;*9`-WF-OXU:B+AXLB;1.;7R\56EA'8=S:CG&<<6Z7YL>36 M@P/4,K8GD2_L5YP9K;$6M\9F=(+`O2O!+P7S@X&',C"V)*X4,-*0)Q+3`IC0 M9ZT833",39%>HE`8AY03,T!:3VS7`*Y'H1Y'I!(-0OP-0AV%74FFS,B3*_P: MG;[XBW)*FGP"<6^27$8#Q*Q+IQ4`9`$NIL8CM0TG80V0Z\+% M2L$#"-+F\9_R9#%><(Y? M,$=U_[@3GJZ4ZRUKH.*_[#MH7WAQRH1A`B:U9>7!SA#8!?`A/-8".-GB0DF8 M([Z2`0/X&R/1^`C MIF,$@3VQF0A_):XT%\OK-?O:Z0]7Z<7C`G6CTDGB)F`O(M%=W]\HW6$;CT3P MO<@.ICAMMN(KG<:*6AA/:""279JJ5]`[H1]QO4[GYN2[8.AT.=JGV9QG7Y(_``HBQ#!G3L-EX`2D\O@+.$MH'S<%( M`3$&R`GQ"Y?#R#TCC#)ZR+`(?097Q9J4K_W/2\N1G+XKIQO<10).`FD,R,G$`4^&K!7F!P3[AY&:-&;%)!C#`31>1*PP+#U41^1",%*-`#M@EC M(U"8'F.;QR"XW%@/,E"R9_+6"8'PSH,?#N_W`2^-?>5-F>8A^5;H::\-'@;8 MJ>?'\+"6'X>VPQ/M9CA=S9AE1S-P/K#[1[95D'@J].;YAVK?[.OO,0&OG&'$ MQ5LHUM?)Q*"J;;BW8VOXS8@^:^.]S;"=IQGY9IB2HZTZ=.A;"VK\@R#=\KM> M95>_4F*@]MQ^$ZLP9&L1YY#],VO:/[/#Y7&=>+,J%CRF+FX&$_HB\9=[X<^8*5XC48NC.Z$S`.)>O5E?6&NCH8U*(9NU2&52K# M[8EXDB?KRI-QR.`Y$_%*9,5L";LD-\73O$)Z=8%?)WM;M=>U6\ MK<=\[=G^*Z70Y\\Z\B<.1Q`!LN?]^7O>]]6NWE5'E9K[ST37^02="!]&L M4IHRI&5[#,MV$PS--VU?M,/)RP(E.LQ:.1>7;"?9K@D>Y9F93AON9$8:[@/% M>'C_=LETDNFDKMN'[?3!+FR'1QJMB<^8/&*LU!^KG`G[`TT=#F4@]9GQ'R\1 M9H@JF2Z3YXMUU8*=8>\Y,M_1`YIU.,?8C2?36[`PGRCB@LGS<[R<(,\SZ@EB M-><9NCKL]U_,84:]XYE2UYU-UPVZ/57K:%+?U=_CI31FQH_;T9YNV]MP4X&Z<>!]AL2G)B0WA M1+VK/5<^?,GZL*B>F.3!FO)@3^UUI#9\EGSXE'PN7+C2]:)MVYKCBUB`JP?%C`J>DQE7]@CU!:BF/_$=F6Y,Z:N MPOS/E3M?MJXLQY]4CDNR9UW9L_=<>?,%7$;($7>V.!B]&T]6*["6ARP/SNKI;=33J=DM? M^=GS+"R7+@VY>H)8T>D[EG(:=E]P'F:U?-[0DA+B'NY=?`_W"$PORTC(,A*G M8?N@*NN[EL\_3B?@W2KH_Y:_74A1&2]S]XDW:<'&0;PW+"^+G_2- MVUJ;?O>E'K$=V/F+VN^H2YJD')8HJ?8)S*#C89\-.8]EF+\^B44QSYS-J5_!>]!.7#%338)VN M#CK#QC+22]`_U[Q?7*!\82:S'\EAD=Q43V[2AAJVYFDL/SU_Q202$"0SU9^9 M.MW:Y.Q)Y;0V_0[;B'O^0G)1;;EHH&KM*D]MI$HZDH$W-Q84DL0HK&&:/K9Q M9-*!JC=_76JC/C!8+:IR$$"OCZJ=FI^M\(Y-F(_M:GPFJDB9<1T`B\V]0&:D MUA;$:ABVTU=[G2J#AT?8ZY),W$3E*"NA/F^%6*.2J$=.X4&\LZ[Q0)RM_FGOI>F[+Y''!U]+CJB>(%:5=]%5M M=,S;J6?UN/9TLBHWX*2+TTP7I]JV>&=R;\K?SA;0[GO/>)."60)T.Q`%.O&T ME[J_3NG*]MAVJ96"\F0$F$Z(.8:@)R<>7NY6C*23NC*.`K`8@R#W$CQBL0E\ M;RGCA?+A^OZM\M6;VZ8R;/>4EO(V?NXRN`J^830&`XLV8@/Z?`*>3+Y MW+=-IH0>?2LNG1OF'Y&-.AV3LQS;&-N.'=I8-#`(HAE\CRL:&W0C'2!U%<3S MG!&RD:@C/I7/\&10\<:A$:\C`A@E*>U&2HA0CGN`"=`(>V4O]ZM2#)\I033^ M%S-#?,"8X9GLOVD?UE+%ZBA4;2"=*%MJ`.C@$:`@ZLT,CH2$M0E6.V8=B-*7 M4H<@U@&A-U]QIZN_Z+XA1%0`@-[>[H$(9.[*))M=D/8N//(>!,7,0-$:!6P2 M;8H9Y^R_;:Y:%B$;_;026#I[>8CE#G M)+%(V8+`[=X_ZT42BY0L^[=X:CS!E#5W$+B)[0*E2&FT[]7LJCH72:*34JU" MDBO1C$=2G!1SI;-L=^THTWCBZI2C%7E\LE?,.ZYFKYC@[]D!V//BS()])\E6 M?()!U>Z\1_`5\4<;`;N)CF;P ML@:=:N!!S`--"B+7MB+#468LG'K6VA,28S[W#3N`!\52M@%GN_08V*AN8)AK M8_H)A'8`^Q?$ATWV#'#CD^Q?>ZC4Z;5!,:1!P@#^2H9#N#ZCSE@YNQG[RILB M^HX___@F"EH/AC'_X1/S'Y@?7..2`IM<^6O7>@$$$6/P*Q/<6 MJ>RG__P/1?GQOUJM^V@]*#PEANM18[P* M0JFK]$?8\-D8N-RJ7,^?&0Y_\+.K7(/H=Y1.6U60@542DC<>B#MW`3(PP/(] MNMKOZ&IOT%>"J0&BA>X#>;,92.4@1(E``I_D/XIE[SL=)3D+Y17VVZ"^B"1$ MP99V6UX4A:"V]JM:RAD5^(TG.K&L@7N.!_1*AP`$*IJG)P`C^_'- MRIO)3'$1B0^@2D#D_!^JH_>`X7>@5[/SBN?X8_@4/(3/;`>AU=+T5D?C0*P; M)H'GG6=&M'`@>QN!I7"8!)#WH$A!W?S&'*>%AUFN M/0[1QF&7(_NXY$3B,/CB2M@.J M:!6>Y`G^P*YP++V^/'],.5\HS1!5^7UHA%$!'.+)Y$'^W'9P_H\%67B*AUD& MBX!5;F`K'SQ_L0H,_1[_O!V&>^!R'#!=I3`(LY#EQEP&Z`M[L`.,'83*+^`; MKD*4/H"_;P?IT^VG]^_^G_+SE\^_WJG*[2\W5UE8\J.M;!H@T`<^OP6+\[OR M/ZP`0>(1>@(>V`X/V.A:9]#O=$:YWR-A: M2U;D$I#=3GNSU!ZV!]U^?Z#G@-XPQZJ(RLK,#_!E4"2D4E%'CY034WD!M33$ M6D"$R-P""G^J)##_JQ6!DAEB%9BOBWFAM,;OMT^HM5O_FY\2WTOMZ2EP(:_4 MDKB$<69]?WA!_[D5W@2#2ET.3[&SY6Q9I9MY`YXH[K>^?'-ML&/#*JF MZ=6#^GX%/C4IQ@L6UB?[$[.^<\VN[K>TX=M ML812TYQI,27VXY#%I(6)G%PU%>X\QN&/N>'C*I>]YMSR:"0D`RS+\GER0\/\ M!J-\X8/8^MZW=%@,!*+W6?2NJZ]S$[W0:6BRVQO]J@W6N/3K/:3?)LV]052/'1L%-V6]?( ML+,OLPS#@L#J';;,7V!I\5+%N\KGB9)Y6[EGKNWY\(\9X7'RG>_-["!`]Q,# M\H'RJYO2]KLBVH8Y-D#'AQ>CIX/3V)FA#^%R<*=&VB@V82H%YQDAL@3!Z7J_ MHW5[QT:D>1@>!:TKMT5"\@:#CGXTQ%%Z M"H_$M_BI*/;,9F[`SU/%J6?KVK+HE`MC%89MM<`=NQ&=M__QB`PX'9 M8@RTVZ-$1Y:`=%=D58R(\R[FGOF84G4-'!,7K.'^])GVG<-SG4!#P)39]?;Q M<)0-B9X++YD`Z)FQ\=5G1A"!8#TK/F(HZH`1$+X1)IF$E"LRL4UPA\^$EB^, MUY2(SZC/C)E#%[]3MH36'O3Z^RR&$S)/JU#>13Z>6_!(NJK\'3-$5.7]=^:; M=D`!C]\,'T]Q@A)R(9.OPB=P+S8+SM:FV< M%(L'&!X=#;S6_GEP>CQ\;5DS.$Z#SGG6O)OM?%'N'F`%'0"`_LJ]:B_)13ZU&E[,54(UV^J/-R%L':GJL0K==\5P9 ML^AFAFL\$(1_#I2Y8[C%USKX<4;\YK5K?4K>N[_#MU[P_8[.-R=&S-*UCF/> MZBCZM&UKSWD'KG$[7-.3"WS7=ROA$MY7%U8.ERQQ3PUJ]GM'6-;J>@>RMO4RJ!T&S.D9'[6L<=&,2@GMI6$2%H$CB2QD!YLPH:U)W"I))`W96-"#=)_C:R$R`X^O&! M'Q1TV&VSXDU>T[/G,.4ES-Y;%R_OV\!W=\_")%BMQ_AL;N%_S:E?5`?8`WIM M))1,O!](O`J=]+/O17,5M_Q*N19U@_5VNU]("LHEOGE!O^/?%Z_5[%@T"/PX M2$;B@V1>S4PQ$$/PPDY+$`F`9OS*(S[Q!70(*;?,$+V-$_3B"9ZF-M@LH-P? M;2O5+P_H\Z!6`IT+ZM>Q)S8IJWC!."GV24A_XXK;FY,^5<6?:#6`!R;*03\9 MOL65&QY\^K89)N^)W_"*XFSN>`N&/JAEP\NAY\-'O(@9.:$1ET8SK$<[@%^N M%*H-+49>*B"LQ*HU,*?,BJAN*-@4(:XRG**1P0P3_P4"YE4/C`>@$-2%?-SD M(BXH-)>#%Z%+[(()A%A*]IH,`.-WP%\41KY`GP#.I8M+9$,)]`LD@:]JB5H/ M*QM#BURA!\7+I.N#:9.W-[G]!\]W!KW$O,/19P88;M$L`\F:B\2<%DR8:,SB MV\2_C"9H:-)_9-7L2-AP4&S#!:;5/>I&7@%<'ZP;\&V%+]5Z26D5KFK`+Z MX<%G#\9J2>DF+>(6A)OM!K;9Y$50,E;=+M=-]?EW=#P2AFO;N;;73Z:B]8:=")CP>6EXHI93OJ5P] M@5QI5;83/SG'G)`8LD;7%FBJ[R$J]TCNT>$@'=3%I\'6R\^8W<"V-'QZH4>-7R/7FZ4)3Z.EI9*72V5 M2VV@U\I0>2W)X_SV2?MJ-*H-14C=UV#=)_>H_GM4911E6RYV[4V6#YX_83;> MB_%\O(B!J?#,>L.^S[&+9@5V3+5'?LNSDB:$HH<,W0K3O_:1CZ'&Y@7(#SQ0]6H:\VS3[ M[/.F"[A',,^Z]3'/`!3%\J*QP^IKGZV#L9IC$UWM:8.*PU4GWO`&$>%)<%6I MK=:MQ%:K,O0EJ:NVN#HKF0VN^I+*G@N5U4Z&J;U.U>DGI]S.L@')[2>D%<=R MR]>">'['474XK6Q25%W2AJ0-21N2-B1M2-JH9RRP26&_O[-`G,EBNQR3%UNF M\H)'B0)*5CL&J_75SD!71Z/Z9)L=[.4^/T(Y[^6]*J,BDC2>H0SI734C,_&% MDL@YI8?:Z6FURF4N8\>]H0JLR5\-J21_]JJ]6-?9CJN+X'Y&U"@):_;&U7I9 M?/E`L7B')?R15R#G#1L47KY[N6?(DQ$L-]O0^^JPW995EJC(Q8MP&; MHFSR@BI?YTHJY^II4PL0VC2J2KQBV&^ML[QIK8F+,_:5-SOPVT$5DRNICIP1 M9(Q:^T]J'5KKJ=AE:[^BS$02:[9[,7+ZFN*JKK'TIT M^K#A1/<^U3F-(+J=MSL7-EP7)#QB#;[N7@'& M.QIIA*RJGC2;JC!%6X/=;-AZ+<%KF*Z7+/6\64K6]:['$F1=[_HLXR77]9;Z M1.H3J4^:KT_R[IL4#><4#2]4%#P#;^W9!\F:PD)2NTKM6J,EO`3M6C[MMD%9 M-LCY^\S=ONHU(,/FY69@59JDI^W9/KDW[#4C$TO2R5GI1*_T&K2DD3KJF3U) M0^J9>M-&+>1'K]M1V[IL!E5C.I$RY,CE#FJY87L[%_V>TE)>:5?2>*PS4]=" M^.OJ8#10>Y)2)*5LO30VE#127QHYKXDPD+118]JHA?S0U;[64T>:I)0:4XJ4 M(M65#VG2ENWI:H"+T>6NQE`:D#5FZUHH@*':&W:EJR$I93NER/H4=::1>5(EV]_K3QG,XT-F:?[>E]Z%?=8U;G M/G)5@U)L7X]*"\^ZT=W>\?!>^\CEX24!UMM*V8B;_4_;)44UD**.IQSWS@J4 MRK%VFD*LJ8I1=J!8 M+86Q6X>#ZVQ3`VPM$81&&`7Q7S?>;&ZXBS\'2N0^\N9E^$_3ZK2M@1-#R@B5OQENA":Y[`1\HC3G/7LU=M5.IZ.VA[+Z4XT)Y8R] M/-M7@V>4Y/S<)"Z9!,R2TK6FTE57>Z..K+]8;T(YJW3M#^I/&B_7HKTQ7(R] M,NL-^SZW?2EI:RMI+_7.0.T-ZU.`\+4DCUK(URIO0C3`>CW"^[?*810 M@9RM1U[ULT[LWU=6][I=M3NJ4E8?8;/W%>#UH+N3H.AH2?[[!RNJ+/Y4SQS_ M?;1`MVE:(!M*_F3XYE3I5!=)KD=2UC//#-R3A?NJ!LJAKRX/:\M<:E_'WU0L-1(M=GIO?@PO.8N#&;,S>"A\J7=WL&+SL+Y158J]TAAG$5P[5@;QU' M&3/%G`)P?/!XOG#J>]'#5/E;!*_!<+VKBC%:@+-GD\?Y=D6)`N!,^OXMJJ[6O3GU'!:T M/C$_A!?X^*VY;V-JI3+S+.;`TP:^",LR@B":)4FB/NVRB7,]>D!6MF.'"S7] M$M!J`]JL(/-=R/R92D2#,/AV\'MKXC.FV)B2`;`K/H![E=FJY-/[E;ELA,AG MRM@(^'*G-M`R@`Z[_Q-7V]>`^ZN"Y2P MLA!8P`-S85X'&)IC/IH+4HO'CV`#5K&V=L*4"G#S<89D1_'M7Z_NKY2O/C." MR%\H"YLY(-LB_Q&)1@%7`/""4@L?1662TCJN`;^=`\(]*P9F:5_]5:@-W*/` M].TQLXXJKO3!LQ-760D1X2;"'@$_FA&RHR#W8I&VCV1"[@\8[70XQ:EH>,I> MI\'0(&AL%ONHJBSVS7'U?K_RP+I2VKZM+K9_4&IK?]OA@ZXW-%7UZQ3EZ@R> MGX(2`:"LU+S;'#@X_9G`88F%VXEM4_2*N.!$1%^OG.X7FL.]/7)6DRCI/OLK M":_6A*<]3\([2E9,OPG!^57?="'S8FJ:%],;7M4G)^9/DC3J1!J#J[[24N"? M^G3,6::0(R1V-TO$.O:$*9?@ZR^8X0>OI9RM*3/)^S.20)I.(-*B30YQ>."] M5M*V0L_XG%<[#<.K!:=>#"?7`FB4T2VUGC&L_>Y/Y2?#I?*QU0`QZL`\.) M-*YA??U621KG)`WM:M3_D])2]"NM6UL2D87_JLC`>(J+$\7903P9AM+`,ID7 MF!RSG)QD17Z<@Q%N.#>FM,"BK$"\O-NX_#Z.6_P5!$T(/YFGV<+R)T:_&3YN MT$KML[IC]LR,$"=%$G4'F$H'Y"RR79\$2BD]R7-=\'4Q2_;)#J<*^R/"M,$` MZ\TI\PB(WL#;P?8_YV%?)@XORZ'9QB9)UK:;A#B MU?$2X$Y!<"ECQES%#H((H*0\/D`A%3"=((XI]-LX25,I"#`9,D,\VV9;:86U M"O7QAR1QSH9=SM:03?;&BT+<1R+ME4QQGFF'0\<0[I@U=QPT[0/$08E[6OO( MF7N%Y_SG3%YJ0N)((Y-%GD7EUG7VRS&S7NJ58R7Y0U9B?=:56-]_9[YI!ZS1 M)5COR(R=LV87DA725@I;*6RE,5)0P`R>!)(!6)X#ETN;2K*YM*FD357;13P/ MFRI5&DU>Q?.S#(]3A[7$7<^SYV;\MB8B*[L,-.-`?J1VAD-UJ#6@V/'+)90S MUFG5KF2)]#J31AUD2$_5NSVU.ZQ/1H\DE#K)D/956ZL_:1RC4TD3++A;GMQ0 MD'LQ]^U'S-8",$PVPTB5-\FE54BKKJ8265/[`UT==.MSP5A*9"F1)6DT289< MUD^(R,X=4G:<\\9LP^TY)'@RX7QFV2'_+J[#.S=\62NFMK*XH_=DK[IZDXF4 MR)(T:BQ!+NLF0J0M)R7'&2)S&[NP-<&\2PY$I(49CL= MYZAZ=Z`.NE7&WB0-OE1A5G$0M_9=U55/Z,*%VJHTDZ)O? M>+M0N%1/JB2=K&I2PFBA-\^Z:OE):,>*/*\JZF=M=H7R@(S6P+&ZASO08_$% MPJG!\=Q8Q$G06'-O MYD7P!_LC2HOHB?)D"4>)@G2SR`GMN6.G?9+=N()!\@H5MPN`'=&YC6O<67\! M3MR`E485*I7<*KGU8&YECDAHRW,J-7H'EG$?6(X1+[$&IN?STI53YC-O\EKA M[9BQ`&7"A8+[!F> MU]1<-P3!NN"P`6UY,.1VZ+8.NU(OLZD2K62T]+36W=[/ME:L,`(/HMUD6*'0:X2*U6B#6&68,)\JM=L M!`'#,*W/"Z8"B3\:ODW\LVI^F.^K@)/N,B++M=%G/`B/$3 MN1!P`Q[-%64^702V"<(-=BATQ&4NL'!`30($4]&_7/RBQIS+ZW+'\H;+6I6D M@B`;7E^8UQKF8YE&,,T,)?=YEWV^=ASJ1!_Y>08V'6`M>X(&I)$PH4%EB)>* MH>/>O&,F(VX3WVJK`K?@\X]O9M;WAQ_>T^!?`0=O<;$__>=_*,J/_]5JW:<* M+TDN_U?D9K++43X8)KP>V#'5W$>P3*2ZM[;G>/`Q4)6/'V]:+3XL3<@'YDGK MM^Y-.NIO,.AM&%RG0WZ>Q`,FXWUT3(0$]^P+FX`]B>MMPW]#CSYU.MJ%$KDV M__77=AO^M)AISPPG0&ORIY[>:\-_Q.H/!B;!%[P+O!C:*/S>L7&HB+3\6U?) M#*)\+D*2`@/E<)09#,>*X=L=-7J">5-?H2:KJ=02_!S+X@U!PA&VEE&2%: MCE8.QLA;YK*);=I48QW'"A`!$V:$$?`\[XX07\_@==<3!%J(0,&+XAK'@^%; ML>EZSUP;)/(],V$D2[D#/P@>]OR%\HL7LB"'RA2*FP2(#QR&OR,(7S@$7[W" M]2)??*&YOWI\5C%I.B=->2`E#KH#@?73@)N*/:H>+TCU'6]+<<=\V[,4FDZY M`7WGL"!0DBI90,%QA`V(GBY+\U'^\8G$\C_SX@]_XN/SX?GH-'@\=CSTYTD2 MNMN"SF_W(6`!%3"7YV@B>"[\&5Q_MX-O'"R:FL.TA>X[_5@^[@5M5=B\3IL2 MW!FV!4H:7N!=#.J#VQ1(A!&4"(>P#)Y;=4'T/3P*/'L-DH.A<0^#U(V$.8C7 M"8"EB;E="PQ_]9D11""0ZX;7&+"&X?/:-*-9Q'7E.U(088V0^H6%ANTRZ[WA MNS!ET!R\'A]UY\:"<&R.I,?YZ.=2Y,O.#N@7O;M%Q6R#N#*`$)'/!&<'*^3M#%<,G8ZGP\?GM[.WD[.R%T,?YT>CH9_W9W^Q0L80Q& M""<,X``.!YS^/,D>WI(`L$S#'?;U"XUR`6?CHBTMA?AKE).-Q*/1Y-/H;'*R M3L*A5%&\=F@D)U_7Z*5-D\^?/X^SMP4I%X0,H@NSN?<&@ZW_*(G@(YP/Q.]O MC[.".T8Q#-$ M:Y-)9IL5O!@F*%Y%,'^VI'!^,8S#]8([9_+I]&SKFN^:2!]_A/;W*P$Z'O[D M&P9IB/CK#[%#V4YK%EV"2,3W:0DA^P!#=.)W]0]`%*119N(M_[O4-%PSR,46 M"@E#6C$P:S_7(")!J=5(=&Q"RQ;+1K/^,0?)2]9)>&)9`+#BG64R&<.()?D3 MX9O)Z'0B>_)W\O'OMPB\H`@Q!),IYG$FP1]+$H4\4]W\)T5LD[<9@1<870Q= MR1EBPC%V\K$'ANMMU)O3H>;W;`GICBH_$QRDE/+>63'$3BCM,A&6S=SI&U-: MMAC0(!?+_UGJ&/4\+BG&21K'F;01[P5QSC^G)%;'@32P:D?7\\$.PX"1@4D( MH1R@3TOBR>\W@.+1?(CC#=UD.R7I*)9J- M>*0+''F\B_$^MIK"[2A/1OY3&Y%O/4M=*?NXGJ">LZ[4??J(YO#BEZ2\BI#N MYV,"?T)3&%KMW(-3.J`1IQ<]H6H'.<1\7;>0U*)W-!+>9G9L!U37<`ZY+B:Y@`&@R@9^C./0I_"9_(((U%8/P!JK(:<:',( MF&F]A4$#$UV@8!8GX?!/?^#`YUFOD.O)D]@U?-&D`3.1](Z.R-?(.QGE$'*= M'!GK?WU@3?RT))2-GB&-:]5:)8(.E-)B(Z6OL70WSR&@1F$RJM];HNK!A&#O M,D?XP%#&>#26[72]6X(7(F0_$P;SJDR?Q4S4]72FIO8NX,WL,T7?*LEQ'.O( M*>9E-F):KM)Y12FRTE%\+/2MJY/6]4BO5B`?(0,(PU`D9H07"9]TI7&:55N\ M"$&[D!NAG5C8TMH5^/;1:9_L'^F$"0IW60V_0*BM#H6Z`FD M:U0$OL;=:HQ#G%4R5&M[HVX#.PWY[)J;`:('@,(9O@(KQ$!47?DR4^6K7#HJ M7^/L9I9#L+6"?"SQXIA@;3_6O2Z*N.IK7V-K,<0AJ'4)/:_2K*5)XV)-)=&_ M#8QIDD!6W6$M/\PSF'S8[;[J5@OSEJJ.9G1FJ@X";) MOYRDB;[&>#^CV"Q2M6AX5!0]4+*"E&T>(H`9'^W$6+829\TXG"H1='<4@6H=_8OG.3Y5WSD1RH>80#1JUAGYGW1?++%1%HYRJ(F M]1`-#6PSP\`LR+\20QSVYF`5OT0V?@61.#P]95>`T@TOCY33_R8\^9J`&X^' MT-C'6C-&'"7Z5P'-\"O7E-!-O>)1O2IF'KNO/(RP07=S(,N,'B[\U(NXA@-< MEM*48YCNA,67<=7*6_[WT;Y:L'T`TE77X0B98:XZO"5)=95)^4[&I/*NPZXO ME'@&:UG@7$(,Y[6-/PM5D1`T5-UU%'4(B*M%I9Y3DK5-$QH9JG*PXZV>=\V_ MY6C;?6X(4V#QDH\A5C%45WO;8+R!`7/Y7RP1&US-:] M5=KY-_'\BC#`0:;FUD:9'"N8M)%)A^O)_N?0Z>BQ+B&J5]'#PP]F?)J=_'\T M^@M"'?;.;-CSJ"[MHEIRJ76/I)=E.C[G0I^+?0]0(J$4P-Q$`U>P^UO MI_4^,ZMQV4_'VEF.%VNT7,4'2EX1C_GEYAN/Y0P7I=0T8.A5]0E^<\;W>;TS M8Y=N:7_1XLCILVEXB-FT:O9S%"]28T6L?R7Y-5Q1&*#,N$JT5:^*KU!W7_4M MU@;##@AU6:I_NS[3F%"&_LSTNY]7C\=4]_VEH#"2Y"5 MVK&8N*E&*S-1\Q.?8O*F>5];\F!I6_XVL,1!P#,K36) ML,]>+1U7%<]/C-17$IQHM:`JT?8?37K36X51J9E\/G[J-8#D,=/\\B/E<5,K MLIH(T4+.34C_L;B'LUH%J5O[.7H].TNBR=NF"]R9VE_S"T.J+E<;W>6@XQC]8RZHIG M*;TPLTE2M')J`6?@[#_N7-W2*OP,C>8HM*V:'-/7>VWOD@/V/DO.;M*ZW$5S M;M6_+3:-]MM3#7ML-!L8S1O-2L;N/E0$F^R@Q#.9!AP$%-Z!8(DPI)O=KT0K M+FG&E'^NZ,CD7>HS19KLZ0R7K*=H-_O#CQA[E:WZ=^A!HWVQ_]ET M[#4PFL=>)6.7UUH$$(;92/@!Q:Z^ MI@1CI5,@IN<)QM7DEM"B3C#6@J@CK!@N%;>1*9#BRS7BAP/%]7KQ_7%BOW:\ MZRG%]_2)UZ_W<^6%V^X,BBI&Q]`W$#5V0DMUC:ZM-D^0M8^K M[-K2^U7VS=+-&M(`)?7U`%=Z!:HT]'T&E8L+6L*4IBG_CIGM*OTKH!1@ENM; MG6>ZD"J`5"?M,X8LAK<$GWHK$CG__N_=F+&O5WS$XI"R5FV36;3'7+9#C/9PD"V[=N.L`^@KBQ12=Z0?U])V"P87V1A M@[,OB;&/SNW[="3+LM^]7P6D]16XP(S>M'MGY^T64(_YF,YOVJ'H(.%AW'[_ M^X\_O/NIT_D#*'`DP6]-7UI/"Q8(1EMC"*52T.I['A#5I*.%":9?KO6?*1+0 M4D:HN%X)?-->2+F\[G:?GY_/GB_/&)]W+\[/>]U_/CY.O`4$J(.ID(AZT&XI M^6MA3CXR#TGCX5;SU9236,%E=V,K4T+_ZL1B'7VJT[OH7/;.5L)O1R[JRQ9& M8O'5GGP44^_JZJIKKFY$E2*QOA;<&WYIZDW`JX+\0J'SXJOX(9A?GE^L\O=G7T77PY(Y1R9$G0T3N6!!@&;CZDZ7)Q:N!(GX` M3V@%3J[L-'>Q__!?B.6+B^FXI1L60<#H1#+ORX@@#PZ`(E61BT_W,)4N+JS; MN6&O>M\<3PGTA0`I^M0?LQ=$Y$M_SL'$XL8)"[4N_HXX6P)7:JBOP5^Z.IBN MQRV#NB`PCEU[SU9S%_M]3_DOL!XFAK-)R.?80^06,\+4D7@DGHM7%DI=?'W$ M2JV/3=H_(HKFA@D3U6VH4_+R];EX.,%SBFSZ..A&,EU$+%B1<5<6WVSI MF\6WQEVCK0*OU+&"2<78\6&&0F(Q=[/V,45WM1ZS`&$+L%T3B`K]3=6^[;4B":9FAONH?NX8AI4$54\VE4B[ MZU@9ZK#H7.Q.X$#.T%&K-Z6&YZ-YDC<%,O[$'A'F[;A!]$(@XZE]P?2#&1)3 MTQE"T9DCM%2=HM?K`I$B/J/'GU[GO!>M_+V)3G_>^*=BAX$ZW,QF"9H"N6EG M"RBVZVRD"71/%AR0@'M8_Q_0_:2/&2$?&']&W$_$ZM@Z2D3IUKM9^D;# M/M_-ERJ9L:FH>CH.!#/.@EQ$V:$Y^!;$=6O?3DNR5FG]C*L+T2+]R7BU[^-> M-\D2V'23?8%&$J`PDF*,TU1$,%Z<%L:%&I#$,)3ZJ8-^VI-$,>MZ#.+^]69B M6!"'!83[&B($+T^*8-__-Q3KQQU/K._[)@A$1@C[`WJ'EE@B8GS7#ZS42!PL MU9!LAO\QK!FZ]3\1EBI.VTH'%FSU94D1:UM MJLIKIXEE#@ZL)SE$N3I>,='/U`D(9[Y8*K$H+GE*7A-[RF7DL&*39R9>)#P_ M8M4YE$VV6FRJT/?"IY(Y.;`JV3#*==W9H3Q]8+SO>5Q?PAP\I?(#0)G2E*_` MHBQE*7A-%++/Q&'E*,M$3!S7E6Z74G0(YJ5J(CS3%U7->4JZ'.GR#7KX0\,I&L0*G7HE0D MKC42YCS_BZ%,M([A.O6J<.3J$YJ2Y,.!](O)?1_1Q3H1V]K.:%?=<_RV*=R[ MS6.DS.JJ[%U[C$I8R0=BA&[:`N;;+Y"<$L7UTW;]$()173/Z*YRYH2=/-HEQ MNFR=D.?L#TQ08!=D5B["5#88C3M,2-?4B*TI"=?N=_:I1ICGRD29R)"IM1!G M[*Y-`)P+([.++A7G-,4:]@R%KQONSQ>-`GQW`W@5B.\%>#CF6F4S-BZ!?D6P M/U(J@7.]K53=6WS9(GFG_E=V56)KQM]%/5F@*?IZX1_7WK M_>)4O#.O1VE(N=Y4;(M"L4(T14DC>G#&O5LJIE:RFUOG7-FF8ETF1"O<"Q0V M8O/BD][Q'/*7[-Z<(Q$E(U6BJ2@7AV.%;:J:`W?058/H&*3R$?P'Q"FF2G-:HRF_F=D:H,%']1I;I02GY9_4$L#!!0````( M`&V`KD#R[^-T!C\``&U;`P`5`!P`;61X9RTR,#$R,#,S,5]L86(N>&UL550) M``,.9;%/#F6Q3W5X"P`!!"4.```$.0$``.U]:W/CN+7M]UMU_P-NGU2EITJ> MMMSSZDFB4VI;G;CBMGPLSTQ24ZD4+4$V$YI02,IMGU]_`?`A$L23``FZ>S[, MM"SN!T2L!6R\-O[XWT\/$7B$21JB^$^OIE\?OP(P7J--&-_]Z=4^/0K2=1B^ M^N_9__T_?_Q_1T=_AC%,@@QNP.TSN+E'#RF*P37<9]@`F*_7,,(J1T0X"N-_ M_TC^=QND$&`G`/G[ M2U`$K^$6D']_NCX7:K][0R3>Q#"["&YAA%U2]>QY!__T*@T?=A$LO[M/X)9O M)TJ2R@QY.^_(VYE^1][.?QTLO[$IWAV!S@W*@LA-.:F]=EE;;NP+?>GJU]%]PUI6KPJ^R(!D`*FUG]C^@_U)SBAJ1 MKR[PIX9?^)3!>`,WI6=B6])V4M>TL:66*]MHW;`:D5X$)=R?0PUN@_266L6] MV%T0[+#UZ?0-C+*T_.:(?'-T/"VZC?\JOOXG[OO0/L[2:[B&X6-P&T%,YM-] MDL`X*_W1G_JG5SJB69B1'RP7?=/\L<1ZX^ZQ=]E1X_=O$_2@6X.8]Q"'07XM+-TQ1F*2[U_F$?D:9C_H"2+/Q?&@4R@.YNH'B770Q8 MDL_0?)C'C=)>)6@'D^SY"D,VP\\6_]F'NP=NA^S4[*'S M=F36OJ-W4A#'08'+,BD""'>N9N5C$,0;`,MGS29K4W/C/0AQ"VW4+ZQ:P8T3 M#TP@Y+#4WIK"J^"9E"*]0?,U+E("W^_3,(:X\4YQ8+?C%3M6RV3)QI-TVR$6^SA>K@7M8*&9N;D6_`+@@W8(L2W+[@9VE(,$D'-P!M MP9I(!+D.^?MW;]].OOWAK=\FIQ.\D'VU-YL.$ROUYL'<^\`HG[KJ@;LX=@GP M*>Y+"Q52`<4C<-":@,LJ7!>ZI7W1/?0;[FPUM[8+H"K>!Y_%IL`NS M(&)C=[E4&8J+I&PC:[Y=IX&RU(4T[I5HS@X/:1=S%,:X-Z'//0>LBOI$1B^? M"2?Y"HWH4&;3'Q5J`>ERBX?M0;P.X[M3E.*1>KPY"]-\V@;<9V!0R=#"Y@5N8D`9[6YH":V++,R%-083L M*IBAK*:%!H>-O'HC=7WTR1"$]ZAX+\U'E@2L&W-),HY=&9%:XK.ST4R@<*L" MJ5]A$\9UJ3I4V]HCZ6/8^6!ISR(2YO8G;6&GO0AKOK^^0^!)O\?@&FCU$R&[ M.C*F[D!8\\).0%8_LJ:?U1,W^'P/_IKY/;Q!UY!..%X%N)QXJ(5?+W=G@)9L MV1'(96U[!IEUIUV%AB-IWZ'4GYVB^!'B)X1"N`B0SISA."O,P*-BX9',YY=A&IEC^_:;=Y/OOW]'0[;???/=Y'O\'[:1[N`Z"Q]A MA$WLHGU*%@22/5;&!(;X<:'\P^3=VVFA>S+Y_H31]=S9:>$/=8`)TQW*U!K] MH]J^-V*O,EPJ,IM2Q9AXT(CR&=KY;9HEP9KEMXE*\<;T5"S9KN/$)>D-_,FX MKVUF=KJ\7"TOSL_F-XLS\'Y^,;\\78#57Q:+FQ7XM13]AU_R&8$#=:^\)A5U MM.N,U/?FC9CU2
I8V1<&4T2293JW%':]DN9>$/^(0O8$W,*[,([)+#8>^.3%_=RQ*5BM[0^< M[?79WM!Y8H[.UCF>CM@\<87-DQ*;,-Y\.:@\&1J5)QXCF?-BMH4LWS*0YSTJ M7DGSD26EZL9<1ADET=RKH)G0 M^+DX!:[L*<0JPIZ"I^*?.B7R!LW>NS33(K0#RW$O6!)ET*5LH4J M@_EO+#'K3(>CR;BZW^6.Y!@F1_;RT[>"W=3FBL)N5JSHO/D0N>IWZD+AU:R1 MD!JKM0N;>KM`]ZGAM[6/B"8@=`3K>^P4]ZCX\>OBV`7<;N$:PQI_K&4\^>K' ML34;2JA)FPH=$*A:!Y$->8L@]^QO`RIZ>`@SFIN";#%!,2DBC-=X>$#.ZT8H MW2?P!CYE[W$A_LWN1.VD7&Y)-52VW6]EY,ZT47B$R2UBTSXSNZZZ%$"Z^\K< M(#F215&W#R)0T_>\$ZL;C)"+RF6V9AG9:>S1ZE""P1'M+#+NYMHMF,E^UX,2 M#7<;:N"@!WXEFH"J>CYLY`/KHMVQ`X+=9YQ+2HOB58:+LKH/,*GF^^P>)>2` M*:<_4TC6.B^AI`->"VP[/3NA=*/BJTQ[E@N`E$A,0$IE0%`)@=>S!AVD1DP=7M7+^".H(@6):EI2)K6LCX%.W).O@L=MVC@ZS\H8 M[(D>VJ=4>2H-&OP!_.[KX^,IR:@"'HG('\#T^'ARG/_7CL+^`+[_83)]^V[R M[;OOR@Z'#*3PM\<_Y-_6"45.K^":.\EEOIF\/?YN\L.[;QN:WTQ.OLV_Y6A. M1\-#\>DN29T+^=8^LL6UXI%752:>,W@KN!Y)+E1QC"]DS32>6;=\DWB0LTZH MV,AP1/-*EBF-,!1X><.%N8W>'4^FWWZ7IR>:?G\\^?;XG4%NHW>3']X6RM^\ MF[R=?CNFW$8*6"$3$+`$Y,DW:2BV.`8R7J#X[@8F#YO*E MW?&49[\GPDI<:3)7:*%!X16,0]Q1K>!Z3]+!7F'\XJX-)<^`ZJEI?#(YQ@2< MOCO.R7@R.?GN[63ZS;?Z7/[NA\FWTQ]R]>\GW[\]&2F5I5CD8H" MEHM]>*1[FBVW?T9HDZY0U)XRX3ZMZ,P\M:9OPYY;NO),R^G9UIB1+VF&@`1M M]F0].L6/?*.>7T5(Z[VRJ&X(-E',L>$-M;4SE_QH42Q0_&*>@"5\VR9-$9RU MKT!NPECH0H9D@=*,WH1<;5:,#E)^`2VI.J3[LINP;LO6D2VRU`L:G*UQBLV; M0V'Z:E9[,`'%HY<+`\&28A<<^%P:;)=(L.5-+2AL]9QM:1.;[F&WBM*9&0F8 MK*#M%M'S/C.-^I5R0KV/3*PCIXATGYA;"/78=+)NNJ-G^KG#1[MI-<>/SZ:6 MS+^H=Q0JI*J[.`12UM=R<.WVT+S*/)L\;"+T#.$^6+HT2V1`NN:6'G>T'-2 M>GG-(I-Z8!+/<^4;J>8E%KWQH;I.K,PS49RI8M"I$BO>A5C,DA4BPST^7;DK8(+,J;E).I%$GG=QJCZAT%KNHG'0%Y+2.R/)Y M>!_/BXN;U9@^0$LKQ;7\YMS+#":&W94M8R,JJ1U/I.GP!S&%-OT3)"; MX$D]*Z(CVJ"*2-0)7_C&>Y@DT7"G)I!$?99+@"QX\AU_:-5PBR;JFN!QA:_5 M)HS,>L]`YZVK')3:S!4/FMZ\ M\5G`60$OG7&O#WX9<*C)D_(OOY"6P58-31[\1@(Q^6RD?!+2]=QC_U..YC.- MW`G&:A*GF%^D3;?W-E9K>ECP_Y+!B_@6+9=78UG<=V6RD]QLRV1][_@8]XSS$*EU:93@)BC5]4Z6 ME=K'KD;#;8SM+>`OJ3+5&Q(EM3F2W=WS>$,/8]^C:`.3E%RCF3V+FQRI>+L= M$HB[PS'709\MELRA)NC%)MIM&YV,26O2OZ>)V*T$<$GC[+6A(3B:@I8 M)O$R``#[:%VESFS1UVR'*?`6GS'4U(VW$ZR-N9E7'^G14M-L]OLX[B-UY'(4 M9>C3AHO-_0P7Y_/WYQ?G-^>+%9A?DBT-R].__F5Y<;:X7OT>+/[GI_.;OX^; MH)H'/K2KTHROBK,@&EZ]T1>/0LG]V%<)>@PWIY4!`[BPC-W;I#\#2',-$`I0JX?0:OB18(XZ\.>S/!_`M$ MLR"L'`+./D--_9(*@L[N!HS[+F>!J+E+ER%I9^]N&@-FVZU&E^;Y*+(%PCJU M!NK8U=Q6M\9AW/$L675)LP[QK$11WB9P%?MI"SBNAHIGQ:X[-``B8]QX-BR% MQQ[/RA"DYKRB;K6XSK&AP7&AYT%!W'<\*W'K#L'J>+92''L\VPN:S>)9IW`> M83S+*:E9/*MAP+COZCN>E;@<()Y5>W?3&,CC65Z7-LYX5@=AG5J#SO&LQ%:W MQF'<\6QUGZ%I/"M1E+<)7,5^V@*.JZ'B6;'K#@V`R!@WGD6E\-CC61F"U)Q7 MU*T6USDV-#@N]#PHB/N.9R5NW2%8'<]6BF./9WM!LUD\ZQ3.(XQG.24UBVE=CJUCB,)Y[-SR!? MH)03LK:?'9A=?V9/VH,UQWQL&590C9&G/6N$__).%$Y=((U7V(+W08Q!+JOO MNE*-8BV=$4/;O%'=DK!I<0,NEJO52ZM<<42C6;OMN,2Z>D^,JA!2)C!(X1G,_V6@UD6UO"O&2-7V(AD#9\YG3CHXE]Y#8VHNGSVYQ_8@37:( M%3W?4-,%-P2N=-BA$0./=`/-:T)R/5` MJ0A>EZJ^;\\=&-V"2&,H>'N=/T%Q-63.^]/BY+IHND17OAQ#J>5M8S25!Z=C M+4UGTB!.R\9L>?.7Q34XOSQ=?ER`UXN_72TN5XNO1G!671\"J&,M,2&@2K41 M%NKY\<:W9;-PG!D)B43Q7K@2EBSBV'3)&[%Y&5-$6C,RG`4?KI9Q_>E-@""X?1+:P%\#LMQF;SY/.]]D]2LB%*TR+HR=<5(9* MV++5DYMW.:30\B1KCS0,S"J9/%?-)+]#*@5!)0=>AW'QK>=9,TT8H"Z5U62R M7*_.2QT/HR+9>9KNM0C6%)20JQ3L@5BYZ;Y)U?!B2JB:LI!,(949-Y&8ZE:0 MJ%TQ:@+E.BKRU"V/BCC+?99F.-X*XSL-]G"D)11J2/?`HYK]OLG4=F7**-:" MD%;H(#AN;O'`H""8H,;4+*LIJJC6\C$2OET%R3*AT>OFYR#:PRN8T`)+::=2 MXK)/K.24A"(W_7%1X5&?DE)#;6;N@@0\$CE*R`V*HB!)R8:=G)RCXJ82,4** MZM2GC*DB?3%AY1X]\A:M(=RD'_#K)1TW'GA"7,X@@LLM-R&IOD+%5[6"-5=5 M+MSR5-.;G*-:1F:E7+YU/,7/R031&CT\H#BG+)U!^A0D24!FB<@?C:?TJM,$ MWH5D;9%.,"7AW7UQ,XUO,FM#"76M;);$*MTF@?4\C8*\%V&,XX'M*6YO0G9' MA%*.0U5&SB%#&Y:-]^&I-JRJ/.F2LJW+<)$($"[F$B7/\AN><"?J.W>KNLX% MG!)6CYA*#141@SAV^P25LW4(I9?.B)KR()4>,/6Y`$@PV6Z/(+_3WX>"T0!O MN2.]:[IX@LDZ3#D3=)KRG+98(.^0/EP/?05-,F>Z9!+;8#@%BX>$5GE$A'*M M\;!+#@!C"K5L!043U(*9'74/$CK;5'J'3 M2^O*<](5-:VV]3/$C4:[V@4X8VE53U'\B&/M$!?K#-[*(EB!)*=M;4DZY`AC MN^<6EN]-ERX\[68[6Y,`1*1:O,(H"M9XV).&_@\8Z8!`0"9);8GIQ"B)&,6U MW2_2>FF0!7XL0-9JEEF8?4YXTFB?NP/*;RN=!3@6WRR")`[CNW1^F-4]@]MP MS9ENT%6HVFRU@C6A5"YZ.&VJ[53.,2TCLWECLIT^\$TO;1B@KA7%P1==U9P\ZVK[G@J"4!*_K0"R$/6\4[1.)PF;?/11]=@)DHUMZ#1]A MO(>74+2LHY`J7I%0RI)I`KLN%V[D+F2,DFG.KA<_+RY_6JP\9_Y551\R>M=- M0@@4ZBR0VAP%\O^,T"9M[RN0B7`P?Q!Q"/C2:%]H9^SK0KVA1M,2DFW+GO?; M2.M+`'+>^Q4CO)06P;MIS1NVR9TN,;;]K$YFHR-:O`^YJ"7F9<9[".$UW,FH MH%2?E1+>+W_0JF!D7A%-DLBTZF116^\91\X"/-?/,0QL5QG<R:@&4R0324RM-32;S#4P.-@ M"'4V_C%SZ0:LPJLR5N-R26PT^D/OV1$L6 M&J)E+R(5M66FQ+C3N$SM1\I!E?KL='FY6EZ>:*=TJ,D_A1T9$5+/[GI_.;OX^1DAJH MX7-3KU*%)!6K"]BJ\N>1MMI7;)\_*9Y:LH6.<)^,=&1!5:I+S4J$@52P4FY*25 M^AT2KCWV"0JOSI#:ZC&*_(5$99Q[`H8#L79?XQK%7GNB_6X7T<8JB,J9A/-X MBY*'_)81P1C`3*OLA72U;$FMY\?IJ-W(I93.!I9F=6&P.="7)'LEE^)NL3(( M#]J^(T-#V""K.F5HK&>@06(3GQZW9I)+$F^")W):-V03"`J>5ALPF:?6>^4: M]EPRC&]:OA^NK9%?&KW#?P)T<6QX M@^X\36&6GNZ3!'.,@13W6?$[F6>6H&U8,X5LAG#C(!N4\*S+4-N6G]T0'V"= M?P4"*N`7K?S*01KOM(G4AE@=IQQ]U[7L+)KG6C:J8AR5Y]]-0/'M2ZM>0>RL M7[\^8^!&8001KU2&URPYBV:Y5EWVK#('VC!F5I0:;97GJ%->=2)4JR-*KK@0 MY".)%F\2&.`APK-X\ZE$HOC]7`E+E'-LNL2XV+P,X2*M6?E@5%M)916'M-]T M$^,QQ(%I<64CS M_3;1W!*M8UE@9WR9DM7+1%U45?F3^U@L,G'6PWI1!_>=\BP+5XWX*9='FF=9 M<\J]:YUJ9E]6S+N;>Q\8PBXOF#%V[!*]TP-\)X`J4117:N-<31H:W>)+;`:! MM]]L8"G$-7*/BWD&'V&$:$'Y!U.U9*L<8%)9ZR1,$NLN(S<=1_+$2RK]62E" MB;DY"(WD@*E>I:,.=<-F6)*H-9,K*>U[GJ/B3DIQ9Z$<33OU-!VN/;M4GP`? MS\2W>/)(-5O4GAYR.+G=PZRV_G1V8QY[_)4DG;#FUY+/SO0\SO#K)XD^\_+H MI.'1UJ@6@S4TK!>(E3YZR9BM::O84#I,-&/MC\'>)PV`%DT<*,*'V=-MMI-=^A,2^S4)";@(//YX$C0!+L`TBB2 M"-QP;GKB/V3/,-\XN=6I::Z74\DWFEC]9P*T9WCGAUOL4 M'`B^82_4X5GP/(`DW=GD>$M3?WN9C#KQP4"["-:4W`58-:F>RE466M:S6L3:5ZXTJ>`/IH M+"ULN\IXK2SW)0M:VDJ6V]HREKR!6II(09H\P7'"A/[RE1AG1.!E02A.(8XE ML8CZU+INI@/QX?11)?^X*JZ4ND%S2YOLC,8,M,J=Q?I*ED MNRU#RXTV#_3OXC-R+-V/H6]H=H7?Q'V0YI<$CV4?D1DZD$W=,9LKM/0;VRH, M/`X&3'<[A8Q'7W0A#BKYYEZASQ^IHGU`/4+5YXQ(8U_XST&T M9^D@%N"=,2@$7!XQH"9[:/^%3K3/&1R4#L<,4KHI^_6WQY/CXV.0W@?XIX(@ M`VN4^KXR35*3HD,'K7@&'LS98;-X<%U/V_,D$T&" MUK$+$/QNTEB3,L$SF/]['K?3@%RC*/J`DD]!PCFIWT7[<)+?3-O^I+^)/^-] M9-B(8DM'%_^*=`'&%F>E$GA=JGT%PKB1,Z;*L?,KT0:%NO>E]FY@0TX0T$I7 M8&*(26=@7H;AD>]PYT@GWXYA/_T-]QWKWR?PO6])R9<;Y+M11#+UC2AM&1=[ M"%BK+N=(90Z4^P:X>K,SN$-I6&PM1/G6$Q3?`=QQ/HQBI[2\.MDM`[*WS]DL MP(JW]@GP[?E;!RBN:[Z"R8H,WD0K`@JQ,2%D5%;E$":\GG/H8Q2G",>A[C@`6FY"QK MTTH>PGZ$V3W:D'M8TXQ.>[=;@J$]-S(G#N3925;&0-Z\VV*^6D';!U72T3,EV7^K9GS0)TOL9WS.3EZ5MRW?(T+ M4`5N5$UDS*=6?E8T#G#$=QO$I=JT$IO7WL-5TV(V]TW*77V$-?G' M,6WL8^I0M*.K_=(E.[IR8>&6KKJM$5W4QV!/+""\>J^'2\N<3[L)79C=1%9/ MWY5R;JKT?3Q-6'?2.\1DQ]-86?FE8$ZF6/AFC69"S''`0GGP$(3MR!X*0G M$+QU%0*)S9O7_5O!593S+$O"VWU6IE+`0;#W4;H-/MZZP\=;[XN\-\%3D0_U M/8SA-F3GJ!12[+5SK)2KZ^>:=GO()"7WI'4K'4>SG'0?TWUT@HKDW4LG?NN" M^^F:"MQ[ZG@V^T.)X^4CH8^.`#DLR^#'H,Q@_+J0\#Q>=(,8Z2I$5\CXG-V_ M2HK)5>%92(E$=2D'1\+ZXH*639>3)6+S\DL(^%JSZD$^C/P#^-W7Q\?3PV3C M'\"WY&ADXWCD/KM'2?B_6(?LD:Z^#]-T7WR']EF:X0]A?.?[6@(Q!)!VG;%W M#+2$FU<)"&SYSP"4!SRGZ&&'8K)`-W\*A=3*V1DDYMW^.%-ED0QG!3GJ?@$DDN5%UAPQ>ROKN& M9]8E9Z0>Y+?5"!5G\_5Z_["/R"HGV:X0KG%[@P]X#(R:)3*-++;M62<)+ECK+K/=<=WH$YYQ].;L7$6^#5_.HH, M>*)*;"7"D[QS7CX\1KR=%H]KS^\B\#D=-I[M$TS&*[I.0L=,]-ER1WQC&#BT7E^CZXE4*Y#&-N"W5% M%;MDT;6B.0L:)J9:ZQWFY?`!C0=JB, MBCO(\6QFM("9NIW0K'BM=D)B2Z.A4);$"_+[[C$UW+N'/>DSB<31;4#JAHQ8 M8)S2HTE@GB3869Z-__89U.6*_*U@3M(R3=%)UIRE)HY47X,MEC%G7VBME M?':NIRC-4I+6M[BN69`U2"56'701B5F?;N$;=GND1>I#?HY%HCI;7BVNYS?G MEW\&I\O5S0K,+\_`XF]7B\O58O6C[[,JBGI%9G7`GDKA:S2/HLBL>CT6%N9G M-W'A\K.A=S!>MS,%:4C6CH$))1T<_Q+8=GWL2^Y&==Q+ICVK"=#-$^NZ"'A] MB3((IB_?-O4N;-D-KLU(!['(-&DP%N0Z`1:3MN2'J@")D7;U, MLZ%OI-$:F/H>%LK.IL(Z^'6(XFD-QE09V582`LFL(;!M,\I MJT9G+-C,1V??N4+:#_@\@@* ME\4Z(Z@Y_:WUZ17RGW?SX_F8[0[_EF*E"H?(M6M@^%,E!AJ'8[AJ#?MCN2H? M/4R)Z'M5G-[5LC(K!*O9CMHE1N6%/F.XPL@$(:AS%;9.[:J4F5.\>KZ&@:6[ M.ZOU_3E`Y/0`R3*I`D%D?I=)+CV2:8Q^(2FZI;H73(Y]FH*6NL-\0T//8.*@ MT!L@@J>>O`SEZYYMP^J#K=E9F-(9,H"'T;X]:(2"U:#85DHM;!IMBXVQQ%2C_RX%*A/BLE M\ATGL'9,HNQG?$>3&A6.S"N_%6LVX467=WS$GNDE\>4@7Q2!7^+P\I-1^ M;GL2@[5H2@S=E+\"/](#%5R=,M/KB`X%"6L-:;YHYGP"*]HX?L"WTP<,.J1^ M5N7\%;DQAL'TL\*!Z*"*,1`26R;@R`D^+<5(J#S[&DW^L. M`%'R9V,`M%,_#]>[?83)'1XGS]?Y1#\Y`S6/-WA03:^8)W^2`7:$4CR"3F_@ M4_8>%^;?#`[MC!2OKZL12^YT<]O#/+Q50614M#`\JRF1T'6U3^["-1Y,O@]1 MA/!'S.2+BU._#+9$'W*)A693T,U>O;VP*9$W8CB;2;$K0C^`SRYYY#4&6](L,J8")2D4HC,I7;[1,X[G)$ MJ+QTQLR4`YH1->KN$"0:U5I#R&<#2R[\C;'MYT/K+SB[JB%9W6,BD;2^I4)H MV^4.`E4AYM@KOXG"+Q]5D[ULE"W:%\&C( MHU'=[6-3BHKA'I+BZ'#.1`DMCR:0%]!&)28(XYU11F38)6$4/DP",88L[3!L M)/105JLD!E-30Z0A"\!&0HO3:B_6; MOT?#DSR%C]+`K+XFD>^/RT)R>G<#;[/&2?0PSB!6IMC*+^L=SX*=)CY0EUID M<_W(])KI?M0>QI"FE>4:[U$[M:JCZVE[8`W'KF:RQX(1>5IC>HL8W1N'O M?;RFRQUTOR?9!QJ\@#40;DWR^MT+`PHU_2KF.3?TW[B0V*HB!)P0XF M>9_ANW>-BS''/%MS!RSVY@@9W;^P& M!CD!+:T4[[:S%4O"=O3KDLAV19`1W,:R@/BC"!!M(8>AHL-YJ6)7) M6VMRB>LK2._)G&=*TZ[%FP]A',1K_/D\@P^BJ1)CO>)]&^A9MA':GERV"J9. M9>V`F:W9:K_;132].0Z!-]74-8F,8Q0?Y:D62_TRO^*SY^R*YC!"EC7THA?"BZWT&]J+_`X8\BN*8#$4D%HN-OQB4),_2#Z.PR2!29%D+'H M4(F5"Q-",0M4BHRZ`JC"O@BK4K59F20B?PS(<[`@6V6QA.>5!%55(OW7SJP< M"#1*E,LM#@3X,[3>$Z9=E8?`.&B7RA2_62!C@7.N15<@EQD7(5RL,RL?E?G4 MQ@%M>;TAS=?<`W+L<_3Z?$??4, MY`_'@'91M2'-M\Q#-R/>1#77UJ!H+N*I:[A#"9E;6&5!MN>#6B[:P+9(U!KB M?,-ND2[U(0>\1+7$?1G45S(@%QH#_A4UC,QJ@L<&OE:3%#++@W*#DO(41V-W M*'GF4H(KT6`"(V%-@(8]M[CGF9;#O:U1HIP^`>6C,6";7U5(Z]WRD-P0;@*8 M8V=0W%[#NY#,/<;99?#`0DDFTD`N*V(-W:9!M]CEVI:#EZ-2HO?P")!G8X"O MH,*0W@OF`;@IW40PS]*P80GN`)(@.H\W\.FOD-_X"F2:@0@K8Q^!-"TZ#CVX MQA4Q!T>G"C;R9X`^!/CI&*`LJC>D^9JY<453G`DH>+:&A3-=HZOM;Q;G1--7 M:`)=JF"/>HEYQQ10>U+P066@(D>^<$HEBPL@TO$D5S+``>I24UP627092BF] M##P5?U@0^("_80>P"BEF.KXEY6!"GK'I>DJ>;UXU*<_3.DS+UY>=Z/-Q3,R+ MZA!IOW#^Y#RCP$[/<^UY`7F^4*"&.4>."_2&G#.HUZSV`_:V`SVXLWHMP!?+ M4:.#/*\^N:`7O'H9[&LJ?."W;`X,_1ML5H#V^B,&X/DC!Y@FAES#N&93A=Q* M]`!6\M4XT-EX_TC^WO@8)%(L[`Z:'9#VL'FZ(V@Z.7Y;8(E\\\_5/4JRHQN8 M/)"]7$;TG72%6XDV125R+`$@$0$[0_8\SS_X1`_PA3*U@#J?F99Q[I1 M:F5)JCM=7UV!=')HN.@R5'Z`N0VHJJ4ZC\''\"/"^<;D]I?0(<\W6I8NUJK'I7A0?I',3VMEX=TXW'/A=5(R(5+?<3EII M`;]@.@@"12]\L`PCN[IU&E7:%,(Y+\AT6:U_T&#&/@X>2(Q)[I3>%!=1?\'L M$,2B7MCA(5(MH5!>2=XI5A49,8I6VT;Z;RE8GYXB5D$Q+!L+KM79#0Y0:Q/K M[;:`!)_-:+39J+R(R%*(2+/F0H:/+NT%:\^PQ>`7QP]-AHPQ1?Y[((AQG/DB M^](>Z6$5;?;`CT$B3IYC#S&GJ!@]\,0\[GR)([(>>6(5=_;`$Z>Q9[&"?Y7' M&;@@G>&)'$"FV5R86JH:BFY%&)HG;H+,KIZ=,F3*W=?$(GM\`:47L`N" MR$'1;ADX=G'I-&3L6@"GJ&?"Q!SBXYN!]`)R000X*,@'C?JDJ^+=E#4C/IIN[AVBG!OX?>&0[ACP.8.TTV#O$L62 M$JQ@'*)D!7$W#3=7^'6':8J2YTN4P?2G0_@OF/_KQ796W;+CTK9-&^&T*,X# MS3Y*)VQ@W#MS-R$9'T[*"#KLE)8/_T,+"'95";$N+J+GN+0?-J&^0=QL))VZ MJ=K0'@H_J@;!37F2%4=CT, M6G>CF+9](;05#W?&S%O[ M88Z[LK@>XK@MV3#\-1W:C&N%Y85053R<&3-5G0YCZ!W*-*'XT?L@A9M3]+"# M<4JCY,43^*U:&C:MCX8#Y\,%?9_"!D/7Q.SF'H?.,((T#6T"=_A= MX$\IC?+Q2)M@%V9!1,Q]]3681QC8,1F;X.^)2$HL1OL-I-8_H623@E>- MWT/3YW!^SBO/PPH38J!NR&VV4QK*50ND[6@`'KH)S`VC$*,7$+)0DP#3S:XO#DB\>A(&+K`8=.HRR:DHS> MG[LYHWUNGMS_9S)CMWB"R3I,X7+[2Y"0"\#8.R:Z*9?)T@V5K1(1&_ER'I%U MUUA,I2T/QL3: M/3!7Y&RH<$SAWY2\4G,TYU6\?[C%0R82E>473GY.89D2>`K6ZZ!!B_4B0RK: MRPLP,/Y[C MAW'1YG_UQ:':+&;K`]5.H[;W01JFR^U5OO)%8X[Y;9HEP9K=/ZDA6;P2J:0- M(26&W?4R&DZ$'%/JSJ@$(5-=!OQ:2OW#+Y]TZA@95D:3)Q*MBA-JRPYS^H;_ MV8>;,'N>QYN/01S'2OCW*=@1\=$0R`@;J&O=,0D.-=0/Z0SU?0U#LAOXE+V/VE?9&>EH MT*RFTQ?/*A?.A_PF7COQK6F$#N_QLS"!]#A/A-)]0D/`!O7(3I0TI7M3\*/M M/MZ0L5`,X2:E/`W6:W+9'89>D<1T&ZS+6_$('LGN^760W@.T@PG][4%4J!=[ M8,B5+8`D#O:=(ML(C#J\YF)%G]>5NA:Q&6>#X+__CJ;ESA[Y6ET-T0!49<2= MC0-4=NAN+&!IFU5:UX_;)-(F7NWA>:*&YV>-2%&&YWX0Z72#4&>C:TTW;CKDLP=BGDG:&E64V>!#RE!JA4 M)N#BXG0T8Q%SZ""K6FV24MM&14Q3K^[(>8Y#[_B.G!B8D\W5*6X9KM%S$.$V MXBZ!M'T0T+.#9O&:C#1M*&K@R!U).S@5TM38UNR@D>^6SX8^*']M\9$.JNB5WK.%9%=*B+3PC7XT& MU-QZ0*KWUX1E7:S"'4?78<9E>I,T797!$>&:HE@T$:PE6^93ELM:)<:4F7:8 MYE7'C3C?I5I[ELOD2VG@(#4:1.O5-S*N%B9YI4SOD*M2P[H[5BSH23?15*W@ M:?&S6D^M;KUO&G,^TVS%'?&9/[U%?AT'Z[OZZ<9-S`)'[&]1YAG M%REF8,F!Q#OR)9EIO4<1%J,?J4T"M!VNA7M6)7!%VD MQEN3M8Q@Q5.N`<<,<-.^"PR;8!^WX05(QS-)VJ&&!0VS015;3F9R+#J=MA38 M-ZGJD[*J7USM"B81#6K7Z<3@.3WF?1,\05&8*9&HYA(X$G9S!BV#+N<&A,8E M/J% M;MC,-W*>Q]CYO_;QFH3PY*K0<^Q8-;G-P->9O?*$C+T]JZW4MN[=GZ)Q5"+Q M?FLG#MB3-O7SSW@@M3Z8S:\(#LG`4&^=*LRS4I(-.-LP#N(UV;V#N1$^TJ&> M[W,YS@B`^L`@L_O;UO1A/[B;0GKGJJ,3/ZZ*TB]+R:F@QA$X.V;^1CP9H$;- M/-L31R[*X'2JP%F)^F7@B0X#:>8UO;YQ/">W2V/U;1`F1<;X,ET\C.$V7(>XED\=G"("LVU=/K6(MVBS94";P+D@WA@GZ3Y?NJ5EM8(X<0:TT8=+)8GTJP M*)(OOCF;V;(J02],FS9S.--M+\6!_/.XOO.0Y&5O\P5@,[^Q13*_YH\NMG?$ M6KAV>UNL94%ZH0T.DM]+^Z*\VRKW)Q3=3_V.$B<]U6_4$]Y;ZY-Z;M,*5#@[ MK6#V(4<9S4=UG6/L!G%+3&+\:XJL&R3+X.,$DPAC$_R&GQH`_]V4T58ZRQ0Q:WA$T M4E/C(-(@@%2T5+\U5,,PX@MIJ=R>2"JBF7F\6<3X!3Z?QUN4/,@R:IFHE">8 MM%2L3C9I>'!XXLG`F_@DE+:162E*-\_GPJ`F/9K-5$;00%VKCCELI:%^.(2E M[VN8VQY.@_0^@FGG3,.:1C1N?Y`9Z2MCN-BG^XU3-L7HE$)<8=7\=HAU8?`% MY2/6A:=.,G(]L.CG)!?;T\I-KBJ.'\[T?YV$VG\/;)$F,,YOEP"EA4,:X^7( MTQ@/QXX.MT[T2H\>;Z&0.Q[H-@IU(7H@";DC5M9%?.$*SK46`X>9*J=#Q9F:Y>B6!ET5:7:\]N(%QIO:2-5*I>XPXE09U,NL[B'F MU'$\P#T9[J-./;NRL+/8NOORXLXA6=+E.HU^:=+G]1J^@T_=4O1!%E7X.:+= MZ?YIT>4^CGYI,=@%MQ]0,E^O$_(H3.`:F_P`6YMBNAO0F.H4&>AK2,KW-^@4 MI[0(G<:B$HNUJ4U%K$G2"`6Y%;`IS(`M]+Z[PP)^.@-5-2#TQZA\6UKC4UDQ MAN="_U.7&`L``00E#@``!#D!``#M75MSX[:2 M?M^J_0_>R;/'XV3W;&8JLZ=\&9]R'8_MLIR3W:<434$23BA"`4F/?7[]`KQ( MO.#2`$D1T/@EXXB-!KKQH=$`&HU?_OJRCHZ>$4TPB3^_.WW_X=T1BD,RQ_'R M\[LL.0Z2$.-W?_V??_^W7_[C^/AO*$8T2-'\Z.GUZ'%%U@F)CQY0EC(&1V=A MB")6Y)@31SC^XQ/_SU.0H"-629Q\>DGPYW>K--U\.CGY]NW;^V\_O2=T>?+C MAP^G)__[]686KM`Z.,9QD@9QB-X=,?I/2?[C#0F#-&]AK?C+$XTJ!C^=;.N2 M4O#_.Z[(COE/QZ<_'O]T^OXEF;\KF\@_`RJIR%\Z]*5,IQ\_?CS)OVY)&2.L M8+T5FVGOZ*C0'R41>D"+(_[OKP_7TM(?3SC%28S2F^`)1:S*O'CZND&?WR5X MO8E0]=N*HH683T3IE@W7SD>NG=._<.W\L.-\TJ=Y2PZ=1Y(&T3#MS/EUV]JI MIG^C;X=2K:K)MT-JF8U(M`\7=50C9^E`=T#5+J5 M]1=@_%8;-'6-UVC^\CXDZX+Q+'M*T)\9BM,OS^P_B;Z=Z_G+DK7C],1; M757CRC6N*".U/I^Q5B2:,S^\F$A_C8.,C28T'T4>97VC M2'BWX3L.#-?)N)()ZQE,HO,@XHO[V0JQB71;P3A#"537R)*-+(RE9T;"C/8"4]?K^,%H6MKXZOF5V_AIF:?;]@/CHN7YXF*'R_ M),\GR#CP[G$B"GK@/D(J-(:"A,1H?ITD&:)"PZ*A M;1@8*:TW\#&1N8_!D=90`NDG/X#T#Q)E3`/T]0I';&$F!)"$I@&<#HUG@%'+ MV`U=\X9N)<:(F;3HR$E+/4`.2N)=;(ZF@Q-!_ M^8&A'/D7;)I=$BIV?H44#<2T*#P#BDJ^/OAH\2UA\1<_8%$[.9NMF,*3NRSE MD2P\@DAL8``%FF9&6<`S#!E(W\OD**LI$?;?KB.LDGGGZ5^Q7]KSEH:JM=G4 MH?(&0#`Y[5`CY5U"Y6>_H%*$Q^C!(J`3PJ5!YRE@Y+(.`9D&]Q(T'WT!S2-C M*\%)_5,+&L4G[]`@D*@?``J&U5:=\YNY9ZS-\QRX4=#V4(3?2B6UOGG3[RJ9 M[#J^Q;'J>>=W:2OYMK&?@BU:)4W+`+1HO$$$1,9^)J'%N4)(WWW97TXZJKUA M/XQRT&IR&MT/OHL@>XPC%K&683 M,2E"OB3'M"9%2BC`BO0**/U86O?5Q8A'*;2*E)!*:AD`=FLGD MXM%/S&3P?WBPT',0L78E9^E%0.DK6XG^(XBRSAF929GJP`Q69C(#K>X[8B=T MTT(+J\@/RV"LISZ*[S%XBHC,Y`&%B(GW%*%;E):*:(\A`&DUE)2D[B+)0$0@ M@-0I3];M^_F>HDV`YU]> M-MR=8Z;P+ETAVA"[U?T&)4J5@DJX"Q9S@8$8`C&V/VM_1O2)M.X?3NV^J=PV ME;OF,CX&0(*XSRV.S]/.O=[)-*95E<1-%ZE,JJL=#W]=M.JB%K_3D]9O:W6G M7@CIUNBJ2!W$AH%L.HBH6?GKE/V-D/DW'$4M5+1_+K6T^]G!WI:T6=>SNV+^ MNESMFZ,,E%]>PBCCI\^2'C8ILG7%(44<1(:%K#K4P%A.'=5HCZB:WWA+XE#H M:BEI2CU*:!P$"40:'2HD/*:.7>SK:0M=;*%O[63/"ML+\PG[Q`PZX3@;'3\0 MS?Y]4V<0UCM-'H);?8.#)QPQ`1'/S="]FBLY23`M5FH;7LP%A:@/4_2$7:'= M.5:I=F3O@U>^'/H@DIH@B4%3W_7^I<9>B0/ M*`J*[`1<=*EO#Z*MH*.F=1T^!I(:04C-U]_-A@L2,QN8\K4O3Z$E-CMJHBJ, M0$+D.&)`LIE`1<9PBNT#28**V8K0]/@1T?67@,;'=UE:B=2^F@2@K.*<5)2. M8P`NI0D0E%SM=Q$<<5FTWK+6'?30]QW4Q55XLKYN4!@OCH4Z!6U80*L2:WJ( M#8S>`U%BG3O6HEP#7<=?\RC;7-;68#,J4]T/A)7Q"DPV>K#'%;`V^T6&([:^ MYM+>MAY_5R3YL4M-%^H3*R5A M_=A*0N@5NL`2VP-+587WH68UN>3.JMQ+]0PM>M$ MMY$4%+O0[R[%A.?KD)&AEZI]M*X:`T)N_IZJUU*G".^G23[7S&?SL^-8T,AC M`H0N*W\/I\[F\SQR)(CN`SR_CB^"#4Z#=M2BAJHZ.Y=1.0X-F'0F")%R]'>Q M]TA1D&3T56HPY`2E`D4$CB-#*Y,)*$3,+!9JPL>L)H/%`TH#'*,YWV!C+F%R M%H;9.LM/7R_1`H>X[4G!"Y0JAA1P'$;&,IO`"L+<^S.LK@JT#KK6,7<>-EJ9 M3&`B8O8=GF&!%W+V:V55%?8Y+QT9B#I%R'?KE.3`V%O/P&8H_2";?9**[%-A M.C'43>/I+6._[2+MX94-M$YT-#]4\^FEMV11DU\@\CM95-V/97AF&N;*97]' M*-=R/#];\T3C_\I_E]X4;@L_,-O=O8&!V+IXDVLB#).CF)28FX63_#*G%29E3(Q0V65R$+C4Z&9X9'8KG#"V M68+-4KA[WE02,U&:][%TJ+0M7D4P&!=W'(D]]6%T<\ZX*ON#[ZG0IYRE[0H# MD>?9S-Q+%T.B3C(;#QP%[<^9@U^7M`:_.WM+8@5B9BC&A,Y0F+$&WC-UXR3A M28#YW8Q?XT`S]XS"N^R8@7E[A=XQ]6H/^(%;Y9XGMKL[8BJ@>IHPV-H5HTH8OX=IO`^C8!6V[>T7S+=I['--XCFK_$V1+9K)#PSH&\ MD.-Q7%:RV]],D%?@[PYY4\+BJ=>S+%T1RJ=6)=9DQ$*,=8F]PI9&5GM,=1G[ M>^5!)-EUDF0@'#4)%1BJ"#W$CU#&OMBIF/I[`T(DE?P1<""U`D%N//]M#R/H MB]_F6!(]\NUALN_:/3*@%V50HGM/SUO_R5QJR]M\6L_)PU3B-?$T;A.`L@LJ M[QPFN)26()*Z2A[>C^^()?23-%0RT'CB(<&DZP66EF]D<3O$.:#('2,(J0PR M/KE$!G+V`H_(&;*XYC$U@AJW8PO)6L!14(AN&%<4CL-$+Y7U'>.*6PF*G_V+ M,O7WAM]0RQ&'0WK?[EB->L=JJYGD;G&W032O9W?9:K+[5=#7`R M!KLUE5-05$G=110N`T,O$A@30E;^AD#+0@8X+N=M//T8)05-`]!B\H^8IC0G'Z6J&,N7--+L5IPU>4K@C[\LQ(\BUZ MX>[W7FMN[*COJ6:7A\QT70`>?'MMHN=/P&QU4-JG<[9T77222VNH&F-$0.4^ MGG6B&6)/P,X^6,V16UBW*)4N5H7?JK5'\YO+6%")`9_ZFTSL8\^R(-61U1[<%),Y(^!YD."0;Q/C*$L[(9E`:HFX'>K)!H.VOXBIK,WQ(>-? MO1FJY'O09[[`D0(V-W)^_L8L:A"2O]#(K_U'),FH]%"X)Q?8&)9SF4Q[OR&\ M7/&4F,QQ");H-EL_(7JWZ$2UJBU=3RZE]JRY.&,935%#AE*=VJ`"F\4MA'5S MOBL[;&<=K,TTN+J!@HR="KOLAIE.'WY9"Y@UR#=A4*:;X-[)+!3;]CT*'C87 M?VQ+]BAZMGP*$0JE7I#UAL0<>64 M(30$[/P-4)&\M"D$!XA6_9:I/Z`Q$=800!K6_H:W-&[/"2&DH!#=0?0'+GK! M#$$B9.CO67+[E4TA.M1$DO=,_<$(2#Q#F,AX^IMPHR7I)5DS`=M;?BJ::D-/ M3.,^3"#"&:)$PG+@Q!I3*+.Y0"5F"SV)%G.>Q3UE)2]_EP%;P6Z8[;AF?TJ7 MRQV"]AJY1C!E<`.?+=$E*OZ]CKM;+@\DBJX(_1;0]@ZX9>E=,(19:8?2JW8Z MW:)2'IH^"#+*2&,# M(&EN&HM-!H?P8U?GXV#9H:&Z2$C_`V5T5OA(*JM-\LZ@FR`=W5(K/?94;9#%@, MIGP$Y=_N-GF,]Y<71$.<=`);K,O7G5VS\CZBMZ^:AG&5S1K0(Q;?8607+E\/ M:`,8J+&M9'!`X(8K:BQT*UM@ORTWCG>@&J%5L^\6OP64!MVK7':%`3985/B` M,`I3T*C65U1[CVL.^\1F,;YLP:DK#;&B!PY/H(K&M9\*@%I$P^_?>%X$R2I" MB35.@4P`QE3%Y(!0:Z:P48VKJA7VL<`3&-F^((9R@1C=[P3&ABH;UP@#@/S1 M<2#G`Y+)6SZI>(DI"AG+*]3)H6[/`&"$90P."+EP18UJ?&4MJ(Y8+,[H)K"\ M?1`+X0"QN-\!9@U4-:ZEU:'6XF30B?TPR'E+ON-M<;C7*&=P2E>6\Q'&MFK9 MR[E967$%V?V?@+TER>@)+Z/D&:80$B?5./7Z#,LLY.KW'[^;H*N.J&.&79U: MG!85<3-?XLD3'QI'7751=*!Q5R-@2!YY97$BHX;0%!'3-YV(7M(W!E821[VM MJ4R895:#?;BDW/2[%:'>[0G#L/0:@X%O($ZA*-#E>B+5K.9U+-V+9$V>`X7V M.Y6-@6_4747D6^)"[H5M8_0I%Z2DW4P+`M(IEPB\.?>4/&/6A^>OO[*^N8ZW M&^;K*PYM+C3T&'E@; MASA"#?$>2;]Q-V85HAVHP:J8K%,N$0-1B'.$MI0I^E0JH?EILH$[:G<3I0:: M(WN,AO"QWVR`QT-_36B*_Y7+<;>X9GJ+EYAY:V=)@CJ'S3#B:CAJB`\6FT9: MV@]:=4WR.-5*0[+M,QW5LT<\*QS)NF$3IL6$F%85^T[0#=;<%#A7-<[??#!5 M!L3F!171WJ64J+Y]*2`Z6.R"M+(?I,J:,D4RFK?[:Q/AL>\EM['`:7(3SL-D M.-U=\ZT^R@-U^?OQA@6E^2SD!1U2RUE83)<,6@@_"U*:FA21JD)4Q*%C-&T7 M"T]ZM'K0':G)JA4?^XBJ.X"7Z=IB\L>#8E8;[D3D@6BE$&S0>H\]N>3#@JY1 MSS@OWDV*MGN*-@&>7Y;"5(_0Q47"<>$.23\F4GS"F'@/7`M=#8MH6`,LUHZN M0[V:/^Z#5SYY\,>WBZ#8&QP\X2CW$,%S/X2)UAM0,_$>ZA:Z&L=C4#?`W]RH MHNFJ>)ZPE)@MDP`^A*R(PI7H%O$>K5H]#.U8=*L[J.4FGTVV*C$QL=J2\@6G MO*3W\(1J95B4*FKU-P?LV%M>UELH^]GY,FF>OYW<+ZQF#Z$<0T3GC--,?T]* MX5JT#IFS#I7S=BQ8ZV:@^#-PY3V2(TI?TITFGED>N6K4'R#+HZK6K`6 MBLP*E6J!%G+-R$(ZGECJ!&1@%0W@PQM:L?QI+:.KD`!FJ+HF0PG>=`28C0/+EB""Y3E%4YR]HF%D):>09* M4M?,**1KB9'\(,.IJ#:?^975^;L*KL-IA=@S[6LW<,!T#Q/=W\4JC-S M>SA7/*!-Z5ZSJ9.P^9"F_%;-)7IJ3PH`RNU+G`I*3X$'EWX(R"EK\SYVISZ@ M;OA*C@G)1,"=C20=G<#@\11M4\J'-6ZLNSU^*J8\B%RH'L%$-WPH=9*-:69V_>0#RD[MXSO_AYO"9&48>SI^G MQFR',;9LB$W1LD?,BCJ/T!Z:,,.F644]UHY2^S`Y-,_8Z*3TE0U$T:/21F64 M8.R4\12%:MF'@%^G!OM+%@Z]ACX:^CIID;\K_&F20@^+P,&30N\S04^VV42Y M*H*H4L5UO"!T7?2Y)#>K6:DJA0^TU(2WGZJ[7+A],B?ZM+V_5/\TW0`R[!2B M%*HU8&"\BULI=9[^'MT6-R\>@Q>^LR2`@_#K[D9;\ZM?H%")U@,7+;8'D;!< M.579F4FSJ0I\2YW\G M6)`.$4!9=^EEE*YMBP+C=^'2#Q&PJZQM8-_%P0G*G^!<#QW(6Q*'3-J==/%\ MN[N;O]DBLXNFY2IS""_W]I[N5+;1N&^'?TD7W(:>;^B^/:&K1ZFC3^@."5/K MQW.'P"GLV5PO@,IG3O5C[Q"PZKE``*OB<,%U7[(VF%.1>R_X;3U0-:!I01S%","9VAD!6= M,V=QC9.$T-<\R*N%]?U66O;VOBKU:R1-TA4]!MZ^VNMO5L*W5]D'&AK#O,=N MA&[SE]@MSM&=B/W?C=[RB<]BZBR&Z6E[;PU$7&VO:8C]`J&1Z#V0IZMGX$QT M^W[+78PKT:>N(^T=9A1B#>/RGDX3%BU;?]60RJPDB?^9Q2$7D,_VUVE2VQUF MV,[HDI\VG6,2$?97SBT9CE*8SAB1B\EH'" M9?89OW$>)#BY6]S7&%K$9LCVF[K,)0=J`,IJ9T=%.9G?>4>705P^%+F+A.%M MB^?UIFX?D0RB79`,?T8R(DE&T2/KNW/6S#]:ZAF+??5JWN#L)[,=$""1T17: MM#"*-N6OXPW>%OO3/=$,L$]S-,/+&"_8G!:GY8,B?+N=:23D]]PFVV7K-$5B MQO2$U3Z:@G"ZQ;-*^3+39%:H6B4!"TWW;(&^(XFE[*V'!Z05Y2L:8`7^#O@; MS/S9.4YY!MRO01PL<[,VNX^"V&:\2QP152V2H6Q2I.Q96)'AEH:J^F3#U:@, M0"X7!JM15Q$['31'+:1&/GZ!-?D[?/7+T<'0KJU*.B<;EMM.T>!RD\W87Q%= M(EK?V"J?I=^0\G]W_J'4)/1C4FK+ELF$,[PI+,A`JFH[`,!V<'MB6[^_!J;^ M)NQTU\R*-KSNE"NQ-0#*[?4S!>6$%^HZK9)9#0BI7%87+`"DLXB1H,V1K>!? M7+93\?5WQ-Y3LD$T;3YI,6&:KKPQW.-*ZRV2#&`P_2Y)EXY^RA1EXK;I![=- M49U&W!K\\(XFO=31-`G:6LM$90:U^6LHKAF7>,D/N(J'L)FH#^0UB)CI6%*$ M+.V&9/4`J$PZIQN7W"4=@)><,J%"HY60J1]<0J()MVR!30\3&S6T_0-PM672 M!GUU_EJ#/)WV8,.=F@IK-QD(Q+6K\1>"V/PYUG%9QE(U#RM=$J%T:31'E$)T%SD#2Y\%'1*>TO]FMYIH9&L[9W"%R^=C)2,>&%PP@``,)-```1`!P`;61X9RTR,#$R,#,S M,2YX2$[B_?ENRC0TV_D5N MEDSQ-++5_:F[OY8LBB)"$DYNVYUSSHM1)C-'Y`P]DD`!`.K9-G%!Q=+"*WDE[27Q,%)8 M+(BZQQZ1/K;)=6NIE'_5;GO4(\[JS.9>^[S3/>]<7'1A;)=XA*D[+KQ;,L>! MJZY;OP?8I7-*G!8"8YF\6LD-R//S\]GSQ1D7"P#I=-O__C2:F&%C6<]9+8J' M#.7`;K7V28(\QW)F<.,>K=*U.ETK47(I^VW+E-5,N+$Q%VW=/<.2;.S.R$>F M=R\O+]NF=R,*0+0`FC*I,+-)6MY1&X6T\-MVV!F+4O9$Y(ZH)/;9@C^UP[X< M3UG@Y5OC*-'6X6F#!!'4WBAP5D&',VM'SR$TWS3H2-L%.8:0SC+,&%=80?J: M5]%+WZ=LSJ,W\$[']BKFXY',D8GVE;;BNB6IY[LZE.;=4I#Y=4OGC14GR:^^ M(&=@7RPBN$L*R-'=;5"1D,G&LE$R<`R!A9U!R60#@'"?"$4A^Y)D:K^86S9V MZ[H%*G;@'K57#IG7]0I4**/'[)2+9W6=`A7B_G_]T3A3\`#IQN?'8=Y*:VRY MY7:@%_8>PO04GLFC%J+.=:M08C-L/'!"V(<.K/N=#K)0C)!N8N:@ M$`ZE\-ZW=T%V\0-)G#'[8-J[,SG2CD2*-'QA0T9:;/F4,8 M0$-##6]V:C$?#V]X4'FYZH]Y]?X`F'P>#Z01]'\0C_'"BLA&5#UA`')9$47"L M-J_;VB4D=P\G&7V_->*)]#+2-]&6X_G8UUMV,*721"[3+"3[O/J,GDSAGT^# M>R!Z?(?&#X/'WG0(`J>YW9#FB>+V;TON.G`4&_P>P!>O+MU%"(6T7S2E?3(= M]__Q<3RZ'3Q.OD.#?WX>3O]S2H"&"=#'Y$OI#<-TW)[?#`KB0"'0;9X@,ECP]$V9*)8I(23 M\RPG*3R$-X#(CQ!/["3LC"AL-.!COX9C_R?,\,*L0),'.'5$Y!1*E'!SD>5F M`V>N!KP-X'<2^1KR1$Y"3L^&6$DS%NP.`['0B_L-Y2Z'EARY=LA0N5@)36^R M-*4P]>(6HZ(-[(]H-.J?R$K(&K(G<(Z+S:J6?E%"P-LL`2GM4Y23*#^$MZ)Z M,=)')%\O'6&XD85AC]K%<>YV MLG$.%4]A3:_OT"13O$HV,LF+D@#G')!#;:2T^BG,6Q=12F!;!=C5$C=3P0S"?L\<'#PE#"0>5L2^YR3;@*!0HQO..KOVSM% M/^&+[=(@71A$/9\+A5BF&BU=[K7`V-^J@0HKV4;<-F#;]4FYBFWB*AF_L1*H MLY5TXBJ*0G.*2I\*S=G5T8V##<@I"ZMB0THM:A]LB;E,$^O:IJ3UXH?#C0F$ M(,QN8$U:K? MBJ/&"GK@M\T\S:_OK3)^6O,^5#QX!F0KE.M9TMR,XA+RYIL*@_4R*U14"PJF MVLHB*_T3"%96Z]8LD_F8&`N7%).5Y1_+>Z/.%L8"F&'3\;SOA'_0M7RD;@XK"Q4 MZYYM@QW.D"D"AQ"5BD8S]6\K.![,`OH_XNC#GM[(U@Y/%N!8`N2065%\^F:C MK!ZT_?JWQCZ'0P6T87!]0UP4F?JJWTA,]DZENHK'$H^R273/68%K$\(H%Q," M9RZ8#H)[5$KX4MUS1721:T$&O3#NL82S)+W`:[N9U_LS[P4QCR6*94DY5DLB M)DLLB'6#3?V>YQ,FS;8*-DRZIB\5H$K27]MU)Q!1\5J]##(;E*&4P-MM('1A ME0']%W8#,E@185,)GZHO6`B\N?T,MWLU%8\F(&7)L,A)MRLU!JRR6E@_`"+H7/33PJ*D_+<:V:^"OR<4I6ZL;=/K-4 ME`^]#/]0^$K%[__6 M=.0X42)W9%Z%A0]YRT>FYQ@7BE110NX4R>D],@+R?^3/S:MBP2/S*]P-A;ND M(0/C_QLP6ZOHBY`A&%ZMJCFZ1;]]SAW!"LXE)H#2'2A-N6YL0BOW!98@$#1>3:]Y_U*`[X:!HK^/XB\+W@E M\6-;J@J.N/I/^5PB&QT(2P%>3184GG@/"5$YPK$MW$5I;0M_FH6G/P!02P$"'@,4````"`!M@*Y`OBRZ M*>>&``"9%@<`$0`8```````!````I($`````;61X9RTR,#$R,#,S,2YX;6Q5 M5`4``PYEL4]U>`L``00E#@``!#D!``!02P$"'@,4````"`!M@*Y`?-KM".,) M``#R?```%0`8```````!````I($RAP``;61X9RTR,#$R,#,S,5]C86PN>&UL M550%``,.9;%/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`;8"N0$Y.VO&, M!P``3$X``!4`&````````0```*2!9)$``&UD>&`Q0````(`&V`KD#R[^-T M!C\``&U;`P`5`!@```````$```"D@3^9``!M9'AG+3(P,3(P,S,Q7VQA8BYX M;6Q55`4``PYEL4]U>`L``00E#@``!#D!``!02P$"'@,4````"`!M@*Y`QQB, MX(0<``!4RP$`%0`8```````!````I(&4V```;61X9RTR,#$R,#,S,5]P&UL550%``,.9;%/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`;8"N0'(- MX87#"```PDT``!$`&````````0```*2!9_4``&UD>&'-D M550%``,.9;%/=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``'7^```` !```` ` end XML 20 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Cash flows from investing activities:

Acquisition, cash acquired $ 33,583

Supplemental disclosure of non-cash financing activity:

Common stock issued for accrued Director fees 184,653

Common stock issued for accrued Director fees (in shares) 167,086

Cashless exercise of warrants (in shares) 136,246

Beneficial conversion feature value related to convertible debt issued with regard to the Senior Secured Promissory Notes 4,747

Discount on beneficial conversion feature recognized on vested contingent warrants on the line of credit with related party 514,456

Outstanding convertible debt and accrued interest to equity (in shares) 406,664

Stock valued in conjunction with the acquisition of Surgical Biologics, LLC 7,087,500

Shares issued in conjunction with the acquisition of Surgical Biologics, LLC (in shares) 5,250,000

Beneficial conversion feature value related to the convertible debt issued with regard to the acquisition of Surgical Biologics, LLC $ 437,500 $ 1,250,000

X

- Definition

The fair value of the beneficial conversion feature of debt issued with regard to the Senior Secured Promissory Notes.

+ References

No definition available.

+ Details

Name: mdxg_BeneficialConversionFeatureValueRelatedToConvertibleDebtIssuedWithRegardToSeniorSecuredPromissoryNotes

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The fair value of the beneficial conversion feature of debt issued with regard to the acquisition of Surgical Biologics, LLC.

+ References

No definition available.

+ Details

Name: mdxg_ConvertibleDebtIssuedInAcquisitionOfSurgicalBiologicsLlc

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of stock issued in conjunction with its acquisition of Surgical Biologics, LLC in noncash financing activities.

+ References

No definition available.

+ Details

Name: mdxg_SharesIssuedInConjunctionWithItsAcquisitionOfSurgicalBiologicsLlc

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period upon the cashless exercise of warrants.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period for accrued director fees.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodSharesForAccruedDirectorFees

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of shares issued during the period for accrued director fees.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodValueForAccruedDirectorFees

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents increases or decreases in additional paid in capital not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The fair value of stock issued in noncash financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 21 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)

Mar. 31, 2012

Dec. 31, 2011

ASSETS

Property and equipment, accumulated depreciation $ 1,924,861 $ 1,814,473

Intangible assets, accumulated amortization 3,802,492 3,468,515

Current liabilities:

Convertible line of credit with related party, unamortized discount 549,779 46,746

Convertible line of credit with related party, accrued interest 58,931 42,726

Convertible debt, unamortized discount 90,156 170,509

Convertible debt, accrued interest 59,836 49,315

Convertible Senior Secured Promissory Notes, unamortized discount 2,049,190 2,263,145

Convertible Senior Secured Promissory Notes, accrued interest $ 68,518 $ 7,732

Stockholders' equity:

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 100,000,000 100,000,000

Common stock, shares issued (in shares) 78,139,596 74,306,895

Common stock, shares outstanding (in shares) 78,089,596 74,256,895

Treasury stock, shares (in shares) 50,000 50,000

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on the current portion of convertible debt that has been incurred and is unpaid.

+ References

No definition available.

+ Details

Name: mdxg_CurrentPortionOfConvertibleDebtAccruedInterest

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of amortized discount on the current portion of convertible debt.

+ References

No definition available.

+ Details

Name: mdxg_CurrentPortionOfConvertibleDebtAmortizedDiscount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable to related party on long-term convertible debt that has been incurred and is unpaid.

+ References

No definition available.

+ Details

Name: mdxg_Long-TermLineOfCreditWithRelatedPartyAccruedInterest

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The portion of amortized discount on related party line of credit.

+ References

No definition available.

+ Details

Name: mdxg_Long-TermLineOfCreditWithRelatedPartyAmortizedDiscount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on noncurrent portion of convertible senior secured promissory notes that has been incurred and is unpaid.

+ References

No definition available.

+ Details

Name: mdxg_NoncurrentPortionOfConvertibleSeniorSecuredPromissoryNotesAccruedInterest

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of amortized discount on the noncurrent portion of convertible senior secured promissory notes.

+ References

No definition available.

+ Details

Name: mdxg_NonCurrentPortionOfConvertibleSeniorSecuredPromissoryNotesUnamortizedDiscount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 22 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Equity
3 Months Ended

Mar. 31, 2012

Equity [Abstract]

Equity
10.         Equity

   Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the "2006 Plan"), the MiMedx Inc. 2007 Assumed Stock Plan (the "Assumed 2007 Plan") and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the "Assumed 2005 Plan") which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2012 totaled 375,000 and the maximum number of shares of common stock which can be issued under the 2006 Plan is 12,500,000 at March 31, 2012.

Activity with respect to the stock options is summarized as follows:

Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term
(in years)

Aggregate
Intrinsic
Value

Outstanding at January 1, 2012
10,333,583 $ 1.17
Granted
2,593,000 $ 1.25
Exercised
(172,000 ) $ 0.99
Forfeited or cancelled/expired
(237,583 ) $ 1.17
Outstanding at March 31, 2012
12,517,000 $ 1.19 7.6 $ 1,533,000

Vested or expected to vest at March 31, 2012
6,372,990 $ 1.16 5.9 $ 1,351,000

The intrinsic value of the options exercised during the three months ended March 31, 2012, was approximately $26,800.

Following is a summary of stock options outstanding and exercisable at March 31, 2012:

Options Outstanding

Options Exercisable

Range of Exercise Prices

Number
outstanding

Weighted-
Average
Remaining
Contractual
Term
(in years)

Weighted-
Average
Exercise Price

Number
Exercisable

Weighted-
Average
Exercise Price

$ 0.50 585,000 2.6 $ 0.50 543,023 $ 0.50
$ 0.65 - $1.00 2,797,500 5.8 $ 0.78 2,615,918 $ 0.78
$ 1.04 - $1.80 8,584,500 8.9 $ 1.29 2,664,049 $ 1.42
$ 2.40 550,000 0.5 $ 2.40 550,000 $ 2.40
12,517,000 7.6 $ 1.19 6,372,990 $ 1.16

A summary of the status of the Company's unvested stock options follows:

Unvested Stock Options

Number of
Shares

Weighted-
Average
Grant Date Fair
Value

Unvested at January 1, 2012
4,333,086 $ 0.72
Granted
2,593,000 $ 0.67
Cancelled/expired
(237,583 ) $ 0.65
Vested
(544,493 ) $ 0.78
Unvested at March 31, 2012
6,144,010 $ 0.70

Total unrecognized compensation expense related to granted stock options at March 31, 2012, was approximately $4,448,000 and will be charged to expense through July 2015.

The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the "simplified method" which computes expected term as the average of the sum of the vesting term plus the contract term.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Three months ended March 31,

2012

2011

Expected volatility
58.3 % 57.6 - 57.8 %
Expected life (in years)
6 6
Expected dividend yield
- -
Risk-free interest rate
0.88 % 1.96% - 2.14 %

The weighted-average grant date fair value for options granted during the three months ended March 31, 2012 was approximately $0.67.

Warrants

The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors.  The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants have been issued for terms of five years.

Following is a summary of warrants outstanding at March 31, 2012:

Number of
Warrants

Weighted-
Average
Exercise
Price per
Warrant

Number of
Contingent
Warrants

Weighted-
Average
Exercise
Price per
Contingent
Warrant

Warrants outstanding at January 1, 2012
9,388,817 $ 1.00 5,245,484 $ 0.01
Issued in connection with private placement of common stock
1,672,743 $ 0.01 (1,672,743 ) $ 0.01
Issued in connection with line of credit with related party
325,000 $ 0.01 (325,000 ) $ 0.01
Warrants exercised
(3,494,993 ) $ 0.09 - -
Warrants outstanding at March 31, 2012
7,891,567 $ 1.15 3,247,741 $ 0.01

Warrants may be exercised in whole or in part by:

·
notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or

·
election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.

These warrants are not mandatorily redeemable, do not obligate the Company to repurchase its equity shares by transferring assets or issue a variable number of shares.

The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.

All of our warrants are classified as equity as of March 31, 2012 and December 31, 2011.

X

- Definition

The disclosure for compensation-related costs for equity-based compensation as well as "Equity warrants and rights outstanding" which represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.

+ References

No definition available.

+ Details

Name: mdxg_EquityTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2012

Apr. 30, 2012

Document and Entity Information [Abstract]

Entity Registrant Name MIMEDX GROUP, INC.

Entity Central Index Key 0001376339

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 80,746,672

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q1

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2012

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mdxg_DocumentAndEntityInformationAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income taxes
3 Months Ended

Mar. 31, 2012

Income taxes [Abstract]

Income taxes
11.
Income taxes

The Company has incurred net losses since its inception and, therefore, no current income tax liabilities have been incurred for the periods presented.  Due to the Company's losses, management has established a valuation allowance equal to the amount of net deferred tax assets since management cannot determine that realization of these benefits is more likely than not.

X

- Details

Name: mdxg_IncomeTaxesAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

REVENUES:

Net sales $ 3,705,808 $ 1,043,487

OPERATING COSTS AND EXPENSES:

Cost of products sold 958,855 710,117

Research and development expenses 407,072 962,224

Selling, general and administrative expenses 2,971,246 2,627,492

LOSS FROM OPERATIONS (631,365) (3,256,346)

OTHER INCOME (EXPENSE), net

Financing expense associated with the debt discount recognized in connection with the senior secured promissory notes (218,701) 0

Interest expense, net (243,586) (91,216)

LOSS BEFORE INCOME TAXES (1,093,652) (3,347,562)

Income taxes 0 0

NET LOSS $ (1,093,652) $ (3,347,562)

Net loss per common share

Basic and diluted (in dollars per share) $ (0.01) $ (0.05)

Shares used in computing net loss per common share

Basic and diluted (in shares) 74,872,122 70,333,476

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 2

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents interest incurred for borrowed money which was used to produce goods or render services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 2

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_FinancingInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph h

-Subparagraph 1(i)

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Chapter V

-Section 563c.102

-Paragraph 9

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 4

-Paragraph 5A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 26 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventories
3 Months Ended

Mar. 31, 2012

Inventories [Abstract]

Inventories
5.
Inventories

Inventories consisted of the following items as of March 31, 2012, and December 31, 2011:

March 31, 2012

December 31, 2011

Raw materials
$ 82,703 $ 95,288
Work in process
443,072 308,763
Finished goods
323,165 361,007
$ 848,940 $ 765,058
Reserve for obsolescence
(53,424 ) (52,456 )
Inventory, net
$ 795,516 $ 712,602

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Acquisition of Surgical Biologics, LLC
3 Months Ended

Mar. 31, 2012

Acquisition of Surgical Biologics, LLC [Abstract]

Acquisition of Surgical Biologics, LLC
4.           Acquisition of Surgical Biologics, LLC

On December 21, 2010, we entered into an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC, the owners of Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia.  This transaction closed on January 5, 2011 and as a result we acquired all of the outstanding shares of Surgical Biologics in exchange for $500,000 cash, a total of $1,250,000 in 4% Convertible Secured Promissory Notes, and $7,087,500 in stock, represented by 5,250,000 shares of our common stock (525,000 of which were held in escrow for the purpose of securing the indemnification obligations outlined in the Merger Agreement).  Contingent consideration may be payable in a formula determined by sales and certain expenses for the years 2011 and 2012.  The contingent consideration was initially valued at $7,404,700 and is shown in the schedule below as fair value of earn-out.  We completed the acquisition of Surgical Biologics in an effort to extend our biomaterials product lines.  As of December 31, 2011, the Company evaluated the contingent liability based on operating results for the year, and adjusted the earn-out liability to $7,410,503.  No additional adjustment was required as of March 31, 2012.

In total, the 4% Convertible Promissory Notes are convertible into up to 1,250,000 shares of the Company's common stock at $1.00 per share (a) at any time upon the election of the holder of the Convertible Notes; or (b) at the election of the Company, at any such time as the closing price per share of the Company's common stock (as reported by the OTCBB or on any national securities exchange on which the Company's shares may be listed, as the case may be) closes at no less than $1.75 per share for not less than 20 consecutive trading days in any period prior to the maturity date. If converted, the Common Stock will be available to be sold following satisfaction of the applicable conditions as set forth in Rule 144. The 4% Convertible Promissory Notes mature in eighteen (18) months and earn interest at 4% per annum on the outstanding principal amount payable in cash on the maturity date or convertible into shares of common stock of the Company as provided for above. The 4% Convertible Promissory Notes are secured by a security interest in the Intellectual Property, including the Patents and know-how and trade secrets related thereto, owned by, or exclusively licensed to, Surgical Biologics, LLC.

The Company has evaluated the 4% Convertible Promissory Notes for accounting purposes under GAAP and has determined that the conversion feature meets the conventional-convertible exemption and, accordingly, bifurcation and fair-value measurement of the conversion feature is not required. We are required to re-evaluate this conclusion upon each financial statement closing date while the 4% Convertible Promissory Notes are outstanding. Notwithstanding, the 4% Convertible Promissory Notes were issued with a beneficial conversion feature having an intrinsic value of $437,500. The intrinsic value of the beneficial conversion feature was determined by comparing the contracted conversion price to the fair value of the common on the date the respective 4% Convertible Promissory Notes were issued. A beneficial conversion feature only exists when the embedded conversion feature is "in-the-money" at the commitment date.

As a result of the beneficial conversion feature, the 4% Convertible Promissory Notes were recorded net of a discount of $437,500 related to the beneficial conversion feature, the offset of which is recorded in paid-in capital, and the discount will be amortized through periodic charges to interest expense over the tem of the 4% Convertible Notes using the effective interest method.

The contingent consideration which was initially valued at $7,404,700 was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer's equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the Surgical Biologics acquisition, and direct costs associated with the combination. The actual purchase price was allocated as follows:

Value of 5,250,000 shares issued at $1.35 per share
$ 7,087,500
Cash paid at closing
350,000
Cash retained for working capital
150,000
Assumed Debt
182,777
Convertible Secured Promissory Note
1,250,000
Fair value of earn-out
7,404,700
Total fair value of purchase price
$ 16,424,977

Assets purchased:

Tangible assets:

Debt-free working capital
$ 671,880
Other assets, net
385
Property, plant and equipment
72,866
745,131
Intangible assets:

Customer relationships
3,520,000
Supplier relationships
241,000
Patents and know-how
5,530,000
Trade names and trademarks
1,008,000
In-process research and development - liquid
2,160,000
In-process research and development - other
25,000
Licenses and permits
13,000
12,497,000

Goodwill
3,182,846
Total Assets Purchased
$ 16,424,977

Working capital and other assets were composed of the following:

Working capital:

Cash
$ 33,583
Prepaid Expenses
2,738
Accounts Receivable
181,087
License Receivable
340,000
Inventory
347,106
Accounts payable and accrued expenses
(196,101 )
Deferred rent and customer deposits
(36,533 )
Debt-free working capital
671,880

Current portion of debt
(62,590 )
Long-term debt
(21,187 )
Line of credit
(99,000 )
Net working capital
$ 489,103

Deposits
$ 16,582
Deferred rent (non-current)
(16,197 )
$ 385

The combination was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.  The allocation of the purchase price to the assets acquired and liabilities assumed was based on an independent valuation report obtained by us.

The values assigned to intangible assets are subject to amortization.  The intangible assets were assigned the following lives for amortization purposes:

Estimated useful
Intangible asset:
     life (in years)
Customer relationships
14
Supplier relationships
14
Patents and know-how
14
Trade names and trademarks
    indefinite
In-process research and development - liquid
    indefinite
In-process research and development - other
    indefinite
Licenses and permits
3

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.  Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction.  Goodwill is tested for impairment as defined by FASB Topic 350 - Intangibles - Goodwill and Other.

X

- Details

Name: mdxg_AcquisitionOfSurgicalBiologicsLlcAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.

+ References

No definition available.

+ Details

Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Contractual Commitments
3 Months Ended

Mar. 31, 2012

Contractual Commitments [Abstract]

Contractual Commitments
12.        Contractual Commitments

The Company has entered into operating lease agreements for facility space and equipment, and employment agreements with some key employees acquired with Surgical Biologics.  In addition, the Company has minimum royalty payments due in conjunction with one of its licenses.  The estimated annual lease, royalty, and employment agreement expense are as follows:

12-month period ended March 31,

2013
$ 848,000
2014
231,000
Thereafter
93,000
$ 1,172,000

X

- Details

Name: mdxg_ContractualCommitmentsAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Debt
3 Months Ended

Mar. 31, 2012

Debt [Abstract]

Debt
8.
Debt

The following disclosures reflect a summary of our outstanding convertible securities, as well as activity related to financing transactions.  The table below summarizes the Company's financing, and further details regarding each transaction are provided following the table:

Convertible Line
of Credit with
Related Party

Convertible
Senior Secured
Promissory Note

Total

Face Value of Note
$ 1,300,000 $ 5,000,000 $ 6,300,000
Due date
(a)
12/31/2012
(b)
12/31/2013

Annual Interest rate
5 % 5 %

Contingent warrants issued at inception (c):

First Contingent Warrants
(d) 325,000 (e) 1,250,000 1,575,000
Second Contingent Warrants
(f) 325,000
(f)
1,250,000 1,575,000
Total Contingent Warrants
650,000 2,500,000 3,150,000

Vested Warrants as of March 31, 2012:

First Contingent Warrants
(d) (325,000 )
(e)
(1,250,000 ) (1,575,000 )
Second Contingent Warrants
- - -

Contingent Warrants Outstanding as of March 31, 2012 (g)

First Contingent Warrants
- - -
Second Contingent Warrants
325,000 1,250,000 1,575,000
Total Contingent Warrants Outstanding as of March 31, 2012
325,000 1,250,000 1,575,000
Weighted average exercise price of warrants
$ 0.01 $ 0.01

(a)
The initial termination date of the Credit Agreement is December 31, 2012 and the Company may elect to extend the termination date until December 31, 2013 upon payment of an extension fee of 5% of the outstanding principle balance or $65,000.

(b)
Unless the Company has repaid the applicable lender's Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender's Notes as of December 31, 2012.

(c)
The Contingent Warrants have a term of five years from the date of issuance; however each is subject to automatic terminations as defined in the First Contingent Warrant and Second Contingent Warrant terms. The shares of Common Stock issuable upon exercise of the Contingent Warrants do not carry registration rights and may be exercised on a "cashless" basis. In the event of a change in control transaction on or prior to the First Measurement Date, then the Contingent Warrants shall be exercisable immediately prior to the closing of such change in control transaction. In the event (i) of a change in control transaction after the First Measurement Date and on or prior to the Second Measurement Date and (ii) the per share value of the consideration received by the holders of Common Stock in such change in control transaction is at least $1.75, the Second Contingent Warrant shall be null and void. If the value of the per share consideration received by the holders of Common Stock in such transaction is less than $1.75, the Second Contingent Warrant shall be exercisable immediately prior to the closing of such change in control transaction.

(d)
The First Contingent Warrant, (the "First Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "First Measurement Date") the closing trading price of the Stock is at least $1.50 per share for ten or more consecutive trading days.  During the three months ended March 31, 2012, the First Contingent Warrants vested due to the Company's Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.

(e)
The First Contingent Warrant, (the "First Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000. During the three months ended December 31, 2011, the First Contingent warrants vested due to the Company's Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.

(f)
The Second Contingent Warrant, (the "Second Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "Second Measurement Date") the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days.

(g)
The contingent warrants have not been included in our earnings per share calculation per the guidance in ASC 260-10-45-13 Earnings per share: Treatment of Contingently Issuable Shares in Weighted-Average Shares Outstanding which states that shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) shall be considered outstanding common shares and included in the computation of basic EPS as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).

Convertible Line of Credit with related party

On March 31, 2011, the Company and its Chairman of the Board and CEO ("the Lender") entered into a Subscription Agreement for a 5% Convertible Senior Secured Promissory Note ("Subscription Agreement") and, in connection therewith, agreed to issue a 5% Convertible Senior Secured Promissory Note ("Note") in the amount borrowed by the Company, and a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.

The Lender agreed to issue a Revolving Secured Line of Credit Agreement ("Credit Agreement") to the Company of $1,300,000, after reductions for funds raised through other financing activities, to fund its working capital needs.  The first borrowing in the amount of $800,000 was on March 31, 2011, resulting in the issuance of 400,000 contingent warrants at an exercise price of $0.01 per warrant.  Additional borrowings in the amount of $500,000 were drawn during the three months ended June 30, 2011, resulting in the issuance of 250,000 contingent warrants at an exercise price of $0.01 per warrant.

The Company may repay and reborrow, provided there is no event of default, as needed. Collateral for the Credit Agreement includes (i) all of the Company's intellectual property with the exception of intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, as more particularly set forth in the Security and Intercreditor Agreement.

At the option of the Lender, the Note is convertible into the number of shares of common stock of the Company equal to the quotient of the outstanding principal amount and accrued interest of the Note as of the date of such election divided by $1.00 per share.

On February 28, 2012, 325,000 First Contingent Warrants vested to the Lender at an exercise price of $0.01 per share. The vesting of the shares resulted in an additional beneficial conversion feature which requires recognition. According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The amount of the warrants and beneficial conversion feature totaled approximately $550,000  net of previously recognized interest expense which has been recorded as a debt discount that will be charged to interest expense over the life of the convertible note.

The issuance of the aforementioned securities was not registered in reliance on Section 4(2) of the Securities Act of 1933, as amended.

Senior Secured Promissory Notes

From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the "Notes") to individual accredited investors for aggregate proceeds of $5,000,000 and issued a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.

The aggregate proceeds included $500,000 of Notes sold to the Company's Chairman of the Board and CEO, who had committed to lend the Company up to $1,500,000, to the extent other lenders did not subscribe to the Company's debt offering.  The terms of those advances were subject to amendment as authorized by the Company's Board of Directors to be consistent with the final terms of the Company's debt offering.

In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company ("Common Stock") at $1.00 per share at any time upon the election of the holder of the note. The Notes mature on December 31, 2013, and bear interest at 5% per annum on the outstanding principal amount payable in cash on a quarterly basis, with all unpaid interest being due and payable on maturity.  Unless the Company has repaid the applicable lender's Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender's Notes as of December 31, 2012.  At the election of the holder, unpaid interest is convertible into shares of Common Stock at $1.00 per share.  Common Stock issued upon conversion of the Notes is available to be sold following satisfaction of the applicable conditions set forth in Rule 144.

The Notes are secured by a first priority lien in all of the patents and other intellectual property owned by the Company and its subsidiaries, provided that until the Convertible Secured Promissory Notes in the principal sum of $1,250,000 issued January 5, 2011, in connection with the acquisition of Surgical Biologics, LLC, are paid in full, (i) the patents and other intellectual property owned by Surgical Biologics, LLC, and (ii) all accessions to, substitutions for and replacements, products and proceeds thereof, are excluded from the collateral.  The maturity of the Notes may be accelerated upon the occurrence of certain Events of Default as set forth in the Notes. The lien is at an equal rate for all note holders in payment and lien priority with the notes outstanding under the Company's Line of Credit with Related Party Agreement dated March 31, 2011, (the "Prior Notes"), all of which are held by the Company's Chairman & CEO.  In order to effectuate that, to conform the description of the collateral and Events of Default in the Prior Notes to the description of the collateral and Events of Default in the Notes, and to clarify certain adjustments that would be applicable in the event of a stock split, stock dividend or similar event,  the Amended and Restated Security and Intercreditor Agreement executed  by the Company's Chairman & CEO in connection with the Notes on December 27, 2011,  superseded  the Security and Intercreditor Agreement that was originally executed in connection with the Prior Notes and, on January 3, 2012, the parties also executed an amendment to certain of the other documents executed in connection with the Prior Notes.

Under the terms of the sale of the Convertible Senior Secured Promissory notes, each lender received a warrant (the "Conversion Warrant") to purchase that number of shares of Common Stock equal to the number of shares of Common Stock that would be issuable upon conversion of the principal of such lender's Note, at an exercise price of $1.00 per share, provided that such Conversion Warrant shall only be exercisable for the number of shares of Common Stock that would have been issued upon conversion of any portion of the principal of the lender's Note that is, in fact, prepaid prior to maturity of the Notes. The maximum number of shares of Common Stock issuable upon exercise of the Conversion Warrants is 5,000,000 shares. The Conversion Warrant expires on December 31, 2013. The shares of Common Stock issuable upon exercise of the Conversion Warrant do not carry registration rights.  The Conversion Warrant must be exercised for cash.

According to GAAP, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.  The amount of the warrants (i.e. the exercisable First Contingent Warrants) and beneficial conversion feature totaled $2,278,052 which has been recorded as a debt discount that will be charged to interest expense using the effective interest rate over the life of the convertible note.

In conjunction with the sale of the Convertible Senior Secured Promissory notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share.  The warrants expire in five years.  The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique.  The total direct costs of approximately $47,800 are recorded as deferred financing costs and are being amortized over the term of the Senior Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders' equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.

X

- Details

Name: mdxg_DebtAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property and equipment
3 Months Ended

Mar. 31, 2012

Property and equipment [Abstract]

Property and equipment
6.
Property and equipment

Property and equipment consist of the following as of March 31, 2012, and December 31, 2011:

March 31, 2012

December 31, 2011

Leasehold improvements
$ 925,086 $ 925,086
Lab and clean room equipment (a)
1,470,852 1,463,144
Furniture and office equipment (a)
334,740 295,654
2,730,678 2,683,884
Less accumulated depreciation
(1,924,861 ) (1,814,473 )
$ 805,817 $ 869,411

(a)
The table above includes reclassifications of production equipment previously included in the furniture and office equipment category.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Intangible assets and royalty agreement
3 Months Ended

Mar. 31, 2012

Intangible assets and royalty agreement [Abstract]

Intangible assets and royalty agreement
7.
Intangible assets and royalty agreement

Intangible assets activity is summarized as follows:

March 31, 2012

December 31, 2011

Weighted

Average

Gross

Net

Gross

Net

Amortization

Carrying

Accumulated

Carrying

Carrying

Accumulated

Carrying

Lives

Value

Amortization

Value

Value

Amortization

Value

Intangible assets subject to amortization:

License-Shriners Hsp for Children & USF Research (a)
10 years
$ 996,000 $ (512,933 ) $ 483,067 $ 996,000 $ (488,033 ) $ 507,967
License - SaluMedica LLC Spine Repair (b)
10 years
2,399,000 (1,387,577 ) 1,011,423 2,399,000 (1,313,573 ) 1,085,427
License - Polyvinyl Alcohol Cryogel (c)
10 years
2,667,000 (1,067,011 ) 1,599,989 2,667,000 (998,932 ) 1,668,068
Customer Relationships (d)
14 years
3,520,000 (314,286 ) 3,205,714 3,520,000 (251,429 ) 3,268,571
Supplier Relationships (d)
14 years
241,000 (21,518 ) 219,482 241,000 (17,215 ) 223,785
Patents & Know-How (d)
14 years
5,530,000 (493,750 ) 5,036,250 5,530,000 (395,000 ) 5,135,000
Licenses/Permits (d)
3 years
13,000 (5,417 ) 7,583 13,000 (4,333 ) 8,667

15,366,000 (3,802,492 ) 11,563,508 15,366,000 (3,468,515 ) 11,897,485
Intangible assets not subject to amortization:

Trade Names/Trademarks (d)
indefinite
1,008,000 - 1,008,000 1,008,000 - 1,008,000
In-process Research & Development-Liquid (d)
indefinite
2,160,000 - 2,160,000 2,160,000 - 2,160,000
In-process Research & Development-Other (d)
indefinite
25,000 - 25,000 25,000 - 25,000
$ 18,559,000 $ (3,802,492 ) $ 14,756,508 $ 18,559,000 $ (3,468,515 ) $ 15,090,485

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.  The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date).  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.

(b)
License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair.  This license was acquired through the acquisition of SpineMedica Corp.

(c)
On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel.  The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date).  The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales.  On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement.  As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000.  At March 31, 2012 and 2011, there are no additional amounts accrued for this obligation due to its contingent nature.

(d)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.

Estimated future amortization expense related to the March 31, 2012 net carrying amount of $11,563,508 for intangible assets subject to amortization is as follows:

Estimated

Amortization

Year ending  December 31,

Expense

2012 (a)
$ 1,001,932
2013
1,335,909
2014
1,331,575
2015
1,225,337
2016
1,024,843
Thereafter
5,643,912
$ 11,563,508

(a)
Estimated amortization expense for the year ending December 31, 2012 includes only amortization to be recorded after March 31, 2012.

X

- Details

Name: mdxg_IntangibleAssetsAndRoyaltyAgreementAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44, 45, 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock Placements
3 Months Ended

Mar. 31, 2012

Common Stock Placements [Abstract]

Common Stock Placements
9.
Common Stock Placements

October 2010 Private Placement

In October 2010, the Company commenced a private placement to sell common stock and warrants. From October 30, 2010, through December 31, 2010, the Company sold 2,405,000 shares of common stock at a price of $1.00 per share and received proceeds of $2,337,020 net of $67,980 in offering costs.  For the nine months ended September 30, 2011, the Company sold an additional 3,778,321 shares of Common Stock and issued an additional 1,889,161 warrants and received net cash proceeds of $3,730,587 net of $47,733 in offering costs.  Under the terms of the offering, for each share purchased, the investor received one 5-year warrant to purchase the common stock of the Company at an exercise price of $1.50 per share. The terms of the warrant, (the "Callable Warrant") are that for every two shares of common stock purchased, the holder is issued a 5-year warrant to purchase one share of the Company's Common Stock at an exercise price of $1.50 per share. The Callable Warrant does not carry registration rights and is callable by the Company at any time after the issuance if the closing sale price of the Stock exceeds $1.75 for fifteen (15) or more consecutive trading days. Upon written notice, the Company may redeem the Callable Warrant at a price of $0.01 per share.  Additionally, the Company issued a First Contingent Warrant ("First Contingent Warrant") and a Second Contingent Warrant ("Second Contingent Warrant") to Purchase Common Stock.

The First Contingent Warrant, (the "First Contingent Warrant") vested during the period resulting in the issuance of 1,672,742 warrants at an exercise price of $0.01 per share.

The Second Contingent Warrant, (the "Second Contingent Warrant") is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company's Gross Revenue as reported in the Company's Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the "Second Measurement Date") the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days.

The contingent warrants have not been included in our earnings per share calculation per the guidance in ASC 260-10-45-13 Earnings per share: Treatment of Contingently Issuable Shares in Weighted-Average Shares Outstanding which states that shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) shall be considered outstanding common shares and included in the computation of basic EPS as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).

The warrants met all the requirements for equity classification under GAAP and are recorded in stockholders' equity.

The Company's Chairman and CEO invested $1,006,664 in the October 2010 Private Placement including  the investment of principal and accrued interest from the October 2010 Bridge note converted under the same terms as the Private Placement, receiving 503,332 warrants with an exercise price of $1.50, 251,666 First Contingent warrants at an exercise price of $0.01 and 251,666 Second Contingent warrants at an exercise price of $0.01 as per the aforementioned terms of the offering.

In connection with the October 2010 Private Placement, the Company entered into a registration rights agreement that provides "Piggy-Back" registration rights to each investor.

X

- Details

Name: mdxg_CommonStockPlacementsAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) (USD $)

Series A Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Treasury Stock [Member]

Accumulated Deficit [Member]

Total

Balance at Dec. 31, 2011 $ 0 $ 74,307 $ 73,868,604 $ (25,000) $ (62,021,346) $ 11,896,565

Balance (in shares) at Dec. 31, 2011 0 74,306,895

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Employee share-based compensation expense 0 0 400,049 0 0 400,049

Other share-based compensation expense 0 0 100,936 0 0 100,936

Exercise of stock options 0 172 170,828 0 0 171,000

Exercise of stock options (in shares) 0 172,000

Exercise of warrants 0 3,357 319,316 0 0 322,673

Exercise of warrants (in shares) 3,357,369

Cashless exercise of warrants 0 136 (136) 0 0 0

Cashless exercise of warrants (in shares) 136,246 136,246

Common stock issued for accrued Director fees 0 167 184,486 0 0 184,653

Common stock issued for accrued Director fees (in shares) 167,086 167,086

Discount on beneficial conversion feature recognized on vested contingent warrants on the line of credit with related party 0 0 514,456 0 0 514,456

Net loss for the period 0 0 0 0 (1,093,652) (1,093,652)

Balance at Mar. 31, 2012 $ 0 $ 78,139 $ 75,558,539 $ (25,000) $ (63,114,998) $ 12,496,680

Balance (in shares) at Mar. 31, 2012 0 78,139,596

X

- Definition

This element represents the amount of recognized non-employee equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "non-employee stock-based compensation".

+ References

No definition available.

+ Details

Name: mdxg_OtherShare-BasedCompensationExpense

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of shares issued during the period upon the cashless exercise of warrants.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period upon the exercise of warrants.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period for accrued director fees.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodSharesForAccruedDirectorFees

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued during the period upon the cashless exercise of warrants.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued during the period upon the exercise of warrants.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodValueExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares issued during the period for accrued director fees.

+ References

No definition available.

+ Details

Name: mdxg_StockIssuedDuringPeriodValueForAccruedDirectorFees

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents increases or decreases in additional paid in capital not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value stock issued during the period as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 34 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Liquidity and management's plans
3 Months Ended

Mar. 31, 2012

Liquidity and management's plans [Abstract]

Liquidity and management's plans
3.           Liquidity and management's plans

As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents.  The Company reported total current assets of approximately $7,048,000 and current liabilities payable in cash of approximately $3,611,000 after adjusting for the short term earn-out liability payable in MiMedx common stock in the second quarter of 2012.  The Company believes that its anticipated cash from operations and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities and pay its debt when due for the next twelve months.

X

- Details

Name: mdxg_LiquidityAndManagementSPlansAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of management's assessment of funding needs and access to credit facilities to meet cash operational needs in the long term.

+ References

No definition available.

+ Details

Name: mdxg_LiquidityAndManagementSPlansTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 22 126 1 false 5 0 false 3 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 040100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R8.htm 060100 - Disclosure - Basis of Presentation Sheet http://mimedx.com/role/BasisOfPresentation Basis of Presentation false false R9.htm 060200 - Disclosure - Significant accounting policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant accounting policies false false R10.htm 060300 - Disclosure - Liquidity and management's plans Sheet http://mimedx.com/role/LiquidityAndManagementSPlans Liquidity and management's plans false false R11.htm 060400 - Disclosure - Acquisition of Surgical Biologics, LLC Sheet http://mimedx.com/role/AcquisitionOfSurgicalBiologicsLlc Acquisition of Surgical Biologics, LLC false false R12.htm 060500 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories false false R13.htm 060600 - Disclosure - Property and equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and equipment false false R14.htm 060700 - Disclosure - Intangible assets and royalty agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible assets and royalty agreement false false R15.htm 060800 - Disclosure - Debt Sheet http://mimedx.com/role/Debt Debt false false R16.htm 060900 - Disclosure - Common Stock Placements Sheet http://mimedx.com/role/CommonStockPlacements Common Stock Placements false false R17.htm 061000 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity false false R18.htm 061100 - Disclosure - Income taxes Sheet http://mimedx.com/role/IncomeTaxes Income taxes false false R19.htm 061200 - Disclosure - Contractual Commitments Sheet http://mimedx.com/role/ContractualCommitments Contractual Commitments false false R20.htm 061300 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Process Flow-Through: 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 040100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) mdxg-20120331.xml mdxg-20120331.xsd mdxg-20120331_cal.xml mdxg-20120331_def.xml mdxg-20120331_lab.xml mdxg-20120331_pre.xml true true XML 36 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
3 Months Ended

Mar. 31, 2012

Subsequent Events [Abstract]

Subsequent Events
13.         Subsequent Events

On April 30, 2012, the Company issued 2,632,576 shares of common stock valued at approximately $3,185,000 for earn-out consideration related to the acquisition of Surgical Biologics.  The consideration paid in the Company's common stock was based on a formula determined by sales and certain expenses for the year ended December 31, 2011.  For further discussion of the contingent consideration, see Note 4 - Acquisition of Surgical Biologics.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2012
Basis of Presentation [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included. Operating results for the three months ended March 31, 2012 and 2011, are not necessarily indicative of the results that may be expected for the fiscal year. The balance sheet at December 31, 2011, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2011 included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC") on March 30, 2012. The Company operates in one business segment, Biomaterials, which includes the design, manufacture, and marketing of products and amnion tissue processing for a variety of surgical applications using the Company's proprietary biomaterials-CollaFix™, HydroFix®, EpiFix® and AmnioFix®.

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Mar. 31, 2012	Dec. 31, 2011
ASSETS
Property and equipment, accumulated depreciation	$ 1,924,861	$ 1,814,473
Intangible assets, accumulated amortization	3,802,492	3,468,515
Current liabilities:
Convertible line of credit with related party, unamortized discount	549,779	46,746
Convertible line of credit with related party, accrued interest	58,931	42,726
Convertible debt, unamortized discount	90,156	170,509
Convertible debt, accrued interest	59,836	49,315
Convertible Senior Secured Promissory Notes, unamortized discount	2,049,190	2,263,145
Convertible Senior Secured Promissory Notes, accrued interest	$ 68,518	$ 7,732
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	78,139,596	74,306,895
Common stock, shares outstanding (in shares)	78,089,596	74,256,895
Treasury stock, shares (in shares)	50,000	50,000

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	Apr. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		80,746,672
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
REVENUES:
Net sales	$ 3,705,808	$ 1,043,487
OPERATING COSTS AND EXPENSES:
Cost of products sold	958,855	710,117
Research and development expenses	407,072	962,224
Selling, general and administrative expenses	2,971,246	2,627,492
LOSS FROM OPERATIONS	(631,365)	(3,256,346)
OTHER INCOME (EXPENSE), net
Financing expense associated with the debt discount recognized in connection with the senior secured promissory notes	(218,701)	0
Interest expense, net	(243,586)	(91,216)
LOSS BEFORE INCOME TAXES	(1,093,652)	(3,347,562)
Income taxes	0	0
NET LOSS	$ (1,093,652)	$ (3,347,562)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.01)	$ (0.05)
Shares used in computing net loss per common share
Basic and diluted (in shares)	74,872,122	70,333,476

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) (USD $)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2011	$ 0	$ 74,307	$ 73,868,604	$ (25,000)	$ (62,021,346)	$ 11,896,565
Balance (in shares) at Dec. 31, 2011	0	74,306,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee share-based compensation expense	0	0	400,049	0	0	400,049
Other share-based compensation expense	0	0	100,936	0	0	100,936
Exercise of stock options	0	172	170,828	0	0	171,000
Exercise of stock options (in shares)	0	172,000
Exercise of warrants	0	3,357	319,316	0	0	322,673
Exercise of warrants (in shares)		3,357,369
Cashless exercise of warrants	0	136	(136)	0	0	0
Cashless exercise of warrants (in shares)		136,246				136,246
Common stock issued for accrued Director fees	0	167	184,486	0	0	184,653
Common stock issued for accrued Director fees (in shares)		167,086				167,086
Discount on beneficial conversion feature recognized on vested contingent warrants on the line of credit with related party	0	0	514,456	0	0	514,456
Net loss for the period	0	0	0	0	(1,093,652)	(1,093,652)
Balance at Mar. 31, 2012	$ 0	$ 78,139	$ 75,558,539	$ (25,000)	$ (63,114,998)	$ 12,496,680
Balance (in shares) at Mar. 31, 2012	0	78,139,596

Liquidity and management's plans	3 Months Ended
Liquidity and management's plans	Mar. 31, 2012
Liquidity and management's plans [Abstract]
Liquidity and management's plans	3. Liquidity and management's plans As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents. The Company reported total current assets of approximately $7,048,000 and current liabilities payable in cash of approximately $3,611,000 after adjusting for the short term earn-out liability payable in MiMedx common stock in the second quarter of 2012. The Company believes that its anticipated cash from operations and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities and pay its debt when due for the next twelve months.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2012
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On April 30, 2012, the Company issued 2,632,576 shares of common stock valued at approximately $3,185,000 for earn-out consideration related to the acquisition of Surgical Biologics. The consideration paid in the Company's common stock was based on a formula determined by sales and certain expenses for the year ended December 31, 2011. For further discussion of the contingent consideration, see Note 4 - Acquisition of Surgical Biologics.